Mechanism of cell death in Burkitt lymphomas by Chumduri, Cindrilla
Mechanism of cell death in Burkitt 
lymphomas: apoptosis or mitotic catastrophe  
Dissertation 
zur Erlangung des Akademischen Grades 
doctor rerum naturalium 
(Dr. rer. nat.) 
im Fach Biologie 
 
eingereicht an der 
Mathematisch-Naturwissenschaftlichen Fakultät I 
Humboldt-Universität zu Berlin 
 
Von 
Cindrilla Chumduri (M.Sc. Biotechnology) 
geboren am 11.10.1980 in Davangere-KS, Indien 
Dekan der Mathematisch-Naturwissenschaftlichen Fakultät I 
Prof. Dr. Lutz-Helmut Schön 
Gutachter/innen: 
1) Prof. Dr. Wolfgang Uckert 
2) Prof. Dr. Peter T. Daniel 
3) Dr. Ingeborg Tinhofer 
























ZUSAMMENFASSUNG ................................................................................................................ 6 
ABSTRACT ................................................................................................................................... 8 
1 INTRODUCTION ................................................................................................................. 10 
1.1 Cell death .................................................................................................................... 10 
1.1.1 Apoptosis .............................................................................................................. 11 
1.1.1.1 Cellular and molecular basis of apoptosis ..................................................... 11 
1.1.1.2 Caspases ........................................................................................................ 12 
1.1.1.3 Apoptosis signalling pathways ....................................................................... 13 
1.1.1.3.1 Extrinsic apoptosis .................................................................................... 13 
1.1.1.3.2 Intrinsic apoptosis ..................................................................................... 14 
1.1.1.3.3 Cross-talk between the extrinsic and intrinsic pathways.......................... 16 
1.1.1.4 Regulation of apoptosis signalling ................................................................. 16 
1.1.1.4.1 Regulation of death receptor mediated extrinsic signalling ..................... 16 
1.1.1.4.2 Regulation of mitochondrially-mediated intrinsic apoptosis signalling by 
Bcl-2 family members ................................................................................................. 17 
1.1.1.4.3 Regulation of apoptosis by IAPs ................................................................ 21 
1.1.1.4.4 Regulation of apoptosis by p53 ................................................................ 21 
1.1.2 Non-apoptotic cell death ..................................................................................... 22 
1.1.2.1 Necrosis ......................................................................................................... 22 
1.1.2.2 Autophagy...................................................................................................... 23 
1.1.2.3 Mitotic catastrophe ....................................................................................... 23 
1.2 Apoptosis resistance in malignant disease ................................................................. 25 
1.2.1 Apoptosis resistance confers insensitivity to cancer therapy .............................. 25 
1.3 The Cell Cycle .............................................................................................................. 26 
1.3.1 The cell cycle phases ............................................................................................ 26 
1.3.2 Regulation of the cell cycle .................................................................................. 27 
1.3.3 Cyclin dependent kinases (Cdks) and cyclins ....................................................... 27 
1.3.4 Cell cycle checkpoints and their role in tumor formation ................................... 29 
1.3.4.1 Structural and functional aspects of PLK1 ..................................................... 30 
1.4 Burkitt lymphoma ....................................................................................................... 33 
1.5 Carcinogenesis ............................................................................................................ 35 
1.5.1 Treatment modalities ........................................................................................... 35 
2 
 
1.5.1.1 Chemotherapy ............................................................................................... 35 
1.5.1.1.1 Taxol .......................................................................................................... 36 
1.5.1.1.2 Vincristine and nocodazole ....................................................................... 36 
2 Aim of the study ................................................................................................................ 38 
3 Results ................................................................................................................................ 39 
3.1 Inverse relationship between apoptosis and polyploidy in various Burkitt 
lymphoma cells upon microtubule inhibitors treatment ..................................................... 39 
3.2 Vincristine treatment does not induce polyploidy implying different cell death 
mechanism compared to that of taxol and nocodazole ....................................................... 46 
3.3 Microtubule inhibitors induce endoreduplication during mitosis leading to 
enhanced ploidy in apoptosis resistant cell lines ................................................................. 46 
3.4 Mitotic catastrophe is not associated with immediate cell death ............................. 51 
3.5 Taxol induced loss of viability is irreversible............................................................... 51 
3.6 Taxol induced caspase activation ............................................................................... 52 
3.7 Taxol induced cell death is p53 independent ............................................................. 55 
3.8 Lack of Bax and Bak can be the cause of apoptosis resistance to taxol in Burkitt 
lymphomas ............................................................................................................................ 56 
3.9 Role of pro-apoptotic BH3-only proteins in taxol induced cell death ........................ 57 
3.10 Taxol induces downregulation of the anti-apoptotic Bcl-2 family protein Mcl-1 ... 59 
3.11 Taxol induced apoptosis is Bax and Bak dependent ............................................... 60 
3.12 Individual pro-apoptotic BH3-only proteins have no impact on taxol induced 
apoptosis in FDM cells .......................................................................................................... 63 
3.13 Apoptosis induced by the microtubule inhibitors is caspase dependent and 
inhibition of caspase activity leads to polyploidy ................................................................. 65 
3.14 Caspase-8 plays an important role in taxol induced apoptosis ............................... 70 
3.15 Induction of apoptosis upon deregulation of PLK1 function in Burkitt lymphomas72 
3.16 PLK1 deregulation leads to G2/M cell cycle arrest, while PLK1 overexpression 
promotes cell cycle progression ........................................................................................... 73 
3.17 PLK1 deregulation triggers G2 and mitotic arrest ................................................... 75 
3.18 Similar cell cycle characteristics observed in different Burkitt lymphomas: DG75 
and CA46 in response to PBD overexpression. ..................................................................... 77 
3 
 
3.19 PLK1 deregulation promotes polyploidy in Burkitt lymphomas lacking Bak/Bak 
expression ............................................................................................................................. 79 
3.20 Deregulation of PLK1 function has an antiproliferative effect followed by necrosis 
in Burkitt lymphomas ............................................................................................................ 80 
3.21 Deregulation of PLK1 and treatment with microtubule inhibitors failed to show 
an increase or inhibition of apoptosis induction .................................................................. 82 
3.22 Deregulation of PLK1 function induces apoptosis but lacks synergistic effect with 
microtubule inhibitors in HeLa cells ..................................................................................... 83 
3.23 PBD induces aberrant spindle formation and chromosomal congressional defects85 
3.24 PBD induced apoptosis in HeLa cells is caspase dependent ................................... 86 
4 Discussion .......................................................................................................................... 89 
5 Materials and methods ................................................................................................... 108 
5.1 Materials ................................................................................................................... 108 
5.1.1 Cell lines.............................................................................................................. 108 
5.1.2 Genetically modified cell lines ........................................................................... 109 
5.1.3 Cell culture media .............................................................................................. 109 
5.1.4 Buffers and solutions .......................................................................................... 109 
5.1.5 Fine chemicals .................................................................................................... 112 
5.1.6 Kits used in this study ......................................................................................... 112 
5.1.7 Antibodies .......................................................................................................... 112 
5.1.8 Primers ............................................................................................................... 113 
5.1.9 Plasmids and expression constructs .................................................................. 113 
5.1.10 Enzymes .......................................................................................................... 114 
5.2 Methods .................................................................................................................... 115 
5.2.1 Cell biology methods .......................................................................................... 115 
5.2.1.1 Culturing of mammalian cells ...................................................................... 115 
5.2.1.2 Freezing and thawing procedure ................................................................. 115 
5.2.1.3 Microtubule inhibitor treatment ................................................................. 115 
5.2.1.4 Transient transfection of BL cells ................................................................ 116 
5.2.1.5 Stable transfection and establishment of single cell clones ....................... 116 
5.2.1.6 Measurement of cell death ......................................................................... 116 
5.2.1.6.1 Propidium iodide uptake ......................................................................... 116 
4 
 
5.2.1.6.2 Trypan blue exclusion ............................................................................. 117 
5.2.1.7 XTT cell proliferation and viability assay ..................................................... 117 
5.2.1.8 DNA fragmentation and cell cycle analysis ................................................. 117 
5.2.1.9 Quantitative DNA cell cycle analysis and cell proliferation assays ............. 118 
5.2.1.10 Determination of the mitotic index............................................................. 118 
5.2.1.11 Caspase activation assay ............................................................................. 118 
5.2.1.12 Caspase inhibition assay .............................................................................. 119 
5.2.1.13 Transient Transfection ................................................................................. 119 
5.2.1.13.1 Electroporation ..................................................................................... 119 
5.2.1.13.2 Lipofection ............................................................................................ 119 
5.2.2 Molecular biology methods ............................................................................... 120 
5.2.2.1 Construction of shuttle vector pGEM-T_SfiI ............................................... 120 
5.2.2.2 Construction of pGEM T_SfiI+_PLK1 ........................................................... 120 
5.2.2.3 Construction of pRTS-1_PLK1, pRTS-1_PBD and pRTS-1_KD ...................... 121 
5.2.2.4 Bacterial Culture and storage conditions .................................................... 122 
5.2.2.5 Agarose gel electrophoresis ........................................................................ 123 
5.2.2.6 Mini-preparation of plasmid DNA ............................................................... 123 
5.2.2.7 Large-Scale preparation of plasmid DNA .................................................... 123 
5.2.2.8 Measurement of DNA concentration .......................................................... 123 
5.2.2.9 Enzymatic manipulation and analysis of DNA ............................................. 123 
5.2.2.10 Vector dephosphorylation........................................................................... 124 
5.2.2.11 DNA ligation ................................................................................................. 124 
5.2.2.12 Polymerase chain reaction (PCR) ................................................................ 124 
5.2.2.13 Purification of PCR-amplified DNA fragments ............................................. 124 
5.2.2.14 Transformation of E. coli ............................................................................. 124 
5.2.3 Immunoblotting ................................................................................................. 125 
5.2.3.1 Preparation of SDS PAGE gels ...................................................................... 125 
5.2.3.2 Composition of polyacrylamide gels ........................................................... 125 
5.2.3.3 Sample preparation for SDS PAGE ............................................................... 126 
5.2.3.4 Determination of protein concentration ..................................................... 126 
5.2.3.5 Electrophoresis and immunoblotting of proteins ....................................... 126 
5.2.3.6 Stripping of nitrocelulose membrane blots ................................................. 126 
5 
 
5.2.4 Immunofluorescence microscopy ...................................................................... 127 
6 References ....................................................................................................................... 128 
7 APPENDIX ......................................................................................................................... 111 
7.1 ABBREVIATIONS ........................................................................................................ 111 
7.2 Erklärung ................................................................................................................... 114 
7.3 Publications ............................................................................................................... 115 




Bei dem Burkitt-Lymphom handelt es sich um ein hochmalignes Non-Hodgkin-Lymphom, das 
sich aus reifen B-Lymphozyten entwickelt. Typischerweise ist es mit einer Epstein-Barr-
Virusinfektion oder einer chromosomalen Translokation assoziiert, welches zu einer 
deregulierten Aktivierung des c-myc Onkogens führt. Zur Behandlung wird eine 
Kombinationstherapie mit Vincristin verwendet, auf die jedoch nur rund 50% der Patienten 
ansprechen. Ursache hierfür könnte die genetische Instabilität des Tumors sein, die in der 
Selektion resistenter Subklone und somit zur Entwicklung von Therapieresistenz führt. 
Apoptoseresistenz wird hierbei als Hauptfaktor der Resistenzbildung beim Burkitt Lymphom 
angesehen. Um die molekularen Mechanismen der Apoptoseresistenz aufzuklären, wurde 
die Apoptoseinduktion in 15 Burkitt-Lymphom-Zelllinien nach Behandlung mit den 
Spindelgiften Taxol (Paclitaxel), Nocodazol und Vincristin untersucht. Interessanterweise 
entwickeln Zellen, die sich als resistent gegenüber Taxol- und Nocodazol-induzierter 
Apoptose erwiesen, eine Polyploidie (>4N DNA), was eine inverse Relation von Apoptose und 
Polyploidie nach Taxol und Nocodazol Behandlung aufzeigt. Die zugrunde liegenden 
Mechanismen wurden in drei resistenten und vier sensitiven Zelllinien näher charakterisiert. 
In den sensitiven Zelllinien war die Taxol -und Nocodazol-induzierte Apoptose von Caspase-
Aktivierung, Bid-Spaltung und Herunterregulation von Mcl-1 begleitet. Im Gegensatz dazu 
wiesen die meisten apoptoseresistenten Zellen einen Verlust von Bax und Bak auf und waren 
durch einen anhaltenden mitotischen Arrest mit Auftreten eines >4N DNA-Gehalts nach 
Behandlung charakterisiert. Die Inhibierung der Apoptose mittels Caspase-Inhibitoren führte 
in apoptosesensitiven Zelllinien zum Auftreten von Polyploidie und anschließendem Zelltod 
durch mitotische Katastrophe, was den inversen Zusammenhang von Apoptose und 
Polyploidie weiter bestätigt. 
Um weitere Einblick in den Mechanismus der Spindelgift-induzierten Apoptose zu erhalten, 
wurde die Rolle der mitotische Kinase PLK1 (polo-like kinase) näher untersucht. PLK1 hat 
eine Reihe von Funktionen während des Zellzyklus und ist in ca. 80 % der humanen Tumoren 
verschiedensten Ursprungs überexprimiert. Erhöhte PLK1 Expression korreliert bei vielen 
Tumorarten mit einer schlechten Prognose, so auch bei Non-Hodgkin-Lymphomen. In dieser 
Studie konnten wir zeigen, dass Verlust der PLK-1 Funktion in Burkitt-Lymphomen die 
Zellzyklus-Transitionskontrolle beim Eintritt der Zelle aus der G2-Phase in die Mitose 
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aktiviert. Hemmung von PLK1 interferiert allerdings nicht mit der Apoptose-Induktion durch 
Spindelgifte, was darauf hindeutet, dass der ausgelöste Zelltod durch Mikrotubuli-
destabilisierende Agenzien keinen geordneten Ablauf der Mitose voraussetzt. Des Weiteren 
induzierte eine dominant-negative PLK1-Mutante Apoptose. Die zusätzliche Behandlung mit 
Spindelgiften zeigte hier keinen synergistischen Effekt, was darauf schließen lässt, dass 
sowohl Inhibierung von PLK1 als auch Mikrotubuli-destabilisierende Agenzien den gleichen 
Stress-Signalweg aktivieren. Tatsächlich führt die Hemmung der Caspaseaktivität in Burkitt-
Lymphomen und in der Zervixkarzinom-Zelllinie HeLa zur Polyploidie. Andererseits 
unterstützt Überexpression von Wildtyp-PLK1 in Taxol behandelten Zellen die Zellzyklus-
Progression. Dies deutet auf eine Verbindung zwischen Zelltodresistenz und genetischer 
Instabilität (Aneuplodie) hin. 
Anders als Taxol und Nocodazole induziert Vincristine keine Polyploidie. Da sich die 
Entwicklung von polyploiden Tumorzellen aus der chromosomalen Instabilität als Folge der 
Störung der mitotischen Spindel darstellt, kann dies als kritisches Ereignis bei der Entstehung 
von Tumorzellen angesehen werden. Die Tatsache, dass Vincristin nicht in der Lage ist, ein 
solches unerwünschtes Ereignis zu induzieren, könnte erklären warum sich Vincristin besser 
zur Behandlung von Lymphomen eignet als Taxane. Medikamente, welche die Caspase-
Aktivierung unabhängig von Bax und Bak induzieren, könnten eine weitere Möglichkeit zur 




 Burkitt lymphoma is a fast-growing Non-Hodgkin's Lymphoma that originates from 
mature B cells. It is generally associated with chromosomal translocations or/and Epstein–
Barr virus infection leading to deregulated activation of the c-myc oncogene. Combination 
chemotherapy with a vincristine-containing regimen is the treatment of choice in Burkitt 
lymphoma, however, only 50% of the patients respond to treatment due to the high genetic 
instability, selection of resistant tumor cell subclones and development of clinical resistance 
to therapy. Apoptosis resistance is considered as the major cause of resistance in Burkitt 
lymphomas. To elucidate molecular abnormalities that are responsible for resistance, 15 
Burkitt lymphoma cell lines were investigated for apoptosis induction upon treatment with 
the microtubule inhibitors taxol (paclitaxel), nocodazole and vincristine. Interestingly, cell 
lines, which are highly resistant to apoptosis induction showed development of polyploidy 
(>4N cellular DNA content) and vice versa, displaying an inverse relationship between 
apoptosis and polyploidy induction upon treatment with taxol or nocodazole. The underlying 
mechanism was characterized in three resistant and four sensitive prototypic cell lines. In 
sensitive cell lines, taxol- and nocodazole-induced apoptosis was accompanied by caspase 
activation, Bid cleavage and Mcl-1 downregulation. In contrast, most apoptotic resistant cell 
lines exhibited a loss of Bax/Bak and showed prolonged mitotic arrest with >4N DNA content 
upon treatment. Interestingly, inhibition of apoptosis in sensitive cells by caspase inhibition 
promoted polyploidy and subsequent death by a mitotic catastrophe confirming the inverse 
relationship between apoptosis and polyploidisation. To gain mechanistic insights into 
microtubule inhibitor-induced cell death, the role of the mitotic kinase PLK1 was addressed. 
PLK1 has multiple functions during the cell cycle and is known to be overexpressed in 80% of 
human tumors of diverse origins. Elevated levels of PLK1 correlate with poor prognosis for a 
wide range of human cancers, including Non-Hodgkin Lymphoma. Here, abrogation of PLK1 
function in Burkitt lymphomas induces cell cycle checkpoint activation at G2 and M phase. 
Blocking the function of PLK1, however, did not interfere with cell death induced by the 
spindle toxins indicating that cell death induced by microtubule disrupting agents does not 
require coordinated transition through mitosis. Moreover, a dominant negative PLK1 mutant 
induced apoptosis. Additional treatment with microtubule inhibitors failed to show 
synergism in induction of apoptosis indicating that PLK1 inhibition and spindle toxins might 
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trigger a similar mitotic stress pathway. Infact, lack of caspase activity promotes polyploidy 
in Burkitt lymphomas and cervical carinoma (HeLa cells). Conversely, overexpression of 
wildtype PLK1 promoted cell cycle progression in cells treated with taxol. This indicates a link 
between cell death resistance and genomic instability (aneuploidy) of Burkitt lymphomas. 
Unlike taxol or nocodazole, vincristine treatment failed to induce polyploidy. Since 
polyploidy development of tumor cells occurs in consequence of chromosomal imbalances 
following disruption of the mitotic spindle machinery this might be a critical event leading to 
chromosomal imbalances in tumor cells. The failure of vincristine to induce such an 
undesirable event may explain why vincristine is a better treatment option as compared to 
taxanes in lymphoma therapy. Furthermore, drugs inducing caspase activation 






1.1 Cell death 
Cell death is a highly controlled event, which plays an essential role in developmental 
biology and tissue homeostasis. Apart from biochemical processes taking place in the dying 
cell, execution ultimately also involves the orderly removal of dying cells and cellular 
debris. Processes of cell death and cell proliferation act to keep appropriate cell numbers 
or eliminate cells that are functionally redundant or potentially detrimental to the 
organism (Ullrich, et al., 2008). For instance induction of cell death is important for the 
removal of cells when there is organelle dysfunction (mitochondria, endoplasmic 
reticulum), DNA damage, abnormal protein folding/accumulation or oncogene activation 
when cells are exposed to harmful viral infection (Twomey and McCarthy, 2005). 
 
Table 1: Cell death-some historical aspects. Scientific discoveries, which made great impact on the 
development of the very field of cell death 
Year Scientist name Discovery 
1858 Rudolf Virchow necrosis: degeneration, softening, advanced tissue 
breakdown (i.e., gangrene) 
1885 Walter Flemming spontaneous cell death, “chromatolysis” in ovarian 
follicles 
1886 Nissen Chromatolysis in lactating mammary glands 
1910 Von Recklinghausen Proposed the therm oncosis (swelling precisely to 
mean cell death with swelling) 
1955 Christian de Duve discovery of lysosomes, concept of cell suicide 
1964 Lockshin and Williams “programmed cell death” 
1971 Kerr, Wyllie and Currie apoptosis: apo= away from, ptosis= falling 
1984 Wyllie et al. Demonstrated discrete inter-nucleosomal DNA 
fragmentation in apoptosis (as a biochemical 




Cell death is classified according to its morphological appearance (which may be 
apoptotic (Type I cell death), necrotic, autophagic (Type II cell death) or associated with 
mitosis i.e mitotic catastrophe), enzymological criteria (with and without the involvement 
of nucleases or of distinct classes of proteases, such as caspases, calpains, cathepsins and 
transglutaminases), functional aspects (programmed or accidental, physiological or 
pathological) or immunological characteristics (immunogenic or non-immunogenic). 
According to the NCCD (The Nomenclature Committee on Cell Death), cell death is 
characterized if one of the following molecular or morphological criteria is met: (1) the cell 
has lost the integrity of its plasma membrane, as defined by the incorporation of vital dyes 
[e.g., Propidium Iodide (PI)] in vitro; (2) the cell, including its nucleus, has undergone 
complete fragmentation into discrete bodies (which are frequently referred to as 
'apoptotic bodies'); and/or (3) its corpse (or its fragments) has been engulfed by an 
adjacent cell in vivo. In particular, cells that are arrested in the cell cycle, which alludes to 
the loss of clonogenic potential, are considered as alive (Kroemer, et al., 2005). 
Pathological conditions, such as cancer and autoimmunity, are very often associated with 
deregulation of apoptosis signalling pathways and defects in the cell death machinery. 
1.1.1 Apoptosis 
Apoptosis refers to a special type of programmed cell death (PCD) characterized by 
unique features such as rounding-up of the cell, cell shrinkage, chromatin condensation, 
membrane blebbing, fragmentation of the nucleus and the break down of DNA into 
oligonucleosomes. The disassembled cell is packed into membrane enclosed apoptotic 
bodies which express special markers like the phosphotidyl serine (PS) groups to be 
recognised and phagocytosed by the neighbouring cells or the macrophages (Savill and 
Fadok, 2000). 
1.1.1.1 Cellular and molecular basis of apoptosis 
Apoptosis is a genetically and evolutionarily conserved and tightly controlled 
process. Apoptosis is induced by specific interaction of cell surface receptors with their 
ligands or by intracellular signalling pathways with extra- or intracellular inducers of 
apoptosis followed by serial activation of proteolytic caspases. The caspase activation 
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leads to cleavage of various cytoplasmic proteins, DNA repair enzymes followed by 
prevention of DNA repair, DNA fragmentation, and disruption of the cellular structure. The 
process of apoptosis can proceed through two major pathways, namely, intrinsic and 
extrinsic pathways to activate terminal caspase-3, -6 and -7. These pathways are not 
essentially exclusive as there are several caspase independent apoptosis-like PCDs 
recognised (Jaattela and Tschopp, 2003; Lockshin and Zakeri, 2002). 
1.1.1.2 Caspases 
In mammalian cells, apoptosis is executed by activation of multiple caspases 
(cysteinyl aspartate-specific proteases), which belong to a family of cysteine proteases. 
They recognise tetra-peptide motifs and specifically cleave after the aspartate residues in 
their plethora of substrates (Dixit, 1996; Earnshaw, et al., 1999) and this cleavage 
irreversibly modify their target protein function (Thornberry and Lazebnik, 1998). Currently 
13 mammalian caspases have been identified and based on their function and length of 
the pro-domains they are classified in to three groups: inflammatory caspases, apoptotic 
initiator caspases and apoptotic effector caspases (Philchenkov, 2004). 
 Caspases are expressed as inactive zymogens (procaspases) that become activated by 
dimerization and/or autocatalytic cleavage. This activation is achieved by scaffolding 
proteins that either concentrate the zymogens sufficiently for autocatalysis (‘induced 
proximity’ model (Salvesen and Dixit, 1999)) or allosterically activate the zymogen without 
processing it (Rodriguez and Lazebnik, 1999). Inflammatory caspases include Caspase-1, -4, 
and -5, which are predominantly involved in the maturation of proinflammatory cytokines. 
The initiator caspases (including caspase-2, -8, -9 and -10) function as sensors and 
transducers of various apoptotic stimuli. They contain either a death effector domain (DED) 
or a caspase activation and recruitment domain (CARD), which are important for 
interactions with upstream adaptor molecules (Adams and Cory, 2002). Oligomerization of 
the initiator caspases through binding of adaptor molecules results in their activation. The 
activated initiator caspases subsequently cleave and activate the effector caspases 
(including caspase-3, -6 and -7), which in turn cleave multiple cellular substrates leading to 
the execution of apoptosis (Boatright, et al., 2003; Fischer, et al., 2003). In some cases, 
effector caspases can also function as initiator caspases; this activity helps to amplify a 
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suicide signal in the cell whose death pathways have been only weakly initiated. 
Furthermore, the activation of effector caspases can also be achieved by non-caspase 
proteases, including cathepsins, calpains, and granzymes (Johnson, 2000).  
1.1.1.3 Apoptosis signalling pathways 
Depending on the type of stimuli, apoptosis can be induced through two distinct 
pathways namely the "extrinsic" or receptor-mediated and the "intrinsic" or mitochondria-
mediated pathways (Roy and Nicholson, 2000).  
1.1.1.3.1 Extrinsic apoptosis 
 Death receptors situated on the plasma membrane are responsible for the induction 
of the extrinsic apoptotic-signalling pathway. Activation of the receptors by ligand binding 
induces a signalling cascade that culminates in degradation of the cell. There are eight death 
receptors characterized to date all of which belong to the tumor necrosis factor (TNF) 
receptor super family. These death receptors include TNF-R1 (DR1/CD120a/p55/p60), Fas 
(APO-1/CD95), death receptor (DR)3 (APO-3/LARD/TRAMP), TNF related apoptosis inducing 
ligand (TRAIL)-R1 (DR4/APO-2), TRAIL-R2 (DR5/KILLER/TRICK2), DR6, ectodysplasin A 
receptor (EDAR) and nerve growth factor (NGFR) (Bhardwaj and Aggarwal, 2003; Lavrik, et 
al., 2005). Members of this family contain one to five cysteine rich repeats in their extra 
cellular domain, and a death domain in their cytoplasmic tail (Krammer, 2000; Nagata, 1996; 
Nagata, 1996; Peter and Krammer, 2003). 
1.1.1.3.1.1 Fas/CD95 signaling pathway 
 CD95 or Fas is one of the well-characterized members of the TNF receptor super 
family (Ashkenazi and Dixit, 1999; Lavrik, et al., 2005). Upon binding to the Fas (APO1) 
Ligand, the receptor trimerizes and recruits the adaptor protein FADD (Fas-Associated Death 
Domain) through their respective death domains (DD). Besides the DD, FADD also contains 
a DED (Death Effector Domain) that can bind to the DD found in caspase-8. Thus, binding of 
FADD to the Fas receptor will recruit and induce dimerization of caspase-8 resulting in DISC 
formation (Death-Inducing Signaling Complex), further leading to caspase-8 activation 
(Boatright, et al., 2003; Curtin and Cotter, 2003; Donepudi, et al., 2003). The proteolytically 
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active caspase-8 in turn activates down-stream effector caspases (caspase-3, -6 and -7), 
which subsequently execute the apoptotic program (Fischer, et al., 2003) (Figure 1). 
 Procaspase-10 can also bind to the DISC and become activated similar to caspase-8 
activation upon Fas ligation. However, the importance of caspase-10 for apoptosis 
induction in the absence of caspase-8 is still controversial and needs to be elucidated 
(Sprick, et al., 2002). 
1.1.1.3.1.2 TRAIL- and TNF-receptor signalling 
 TRAIL induced signalling via TRAIL-R1 and TRAIL-R2 is very similar to Fas signalling. 
However, TRAIL is also involved in non-apoptotic signalling, which proceeds via NF-kappaB, 
PKB/Akt and the MAPK signalling pathways (Falschlehner, et al., 2007). Whereas, the TNF-
receptor signalling is more complex. The pleiotropic actions of TNF range from proliferative 
responses such as cell growth and differentiation, to inflammatory effects and the 
mediation of immune responses, to destructive cellular outcomes such as apoptotic and 
necrotic cell death mechanisms (MacEwan, 2002). Apoptosis induced by TNF-receptor 1 
(TNF-R1) involves a two-step activation cascade. First, the membrane bound TNF- R1, the 
adaptor TRADD, TRAF2 and the kinase RIP1 ( complex I)  activates NF-kappa B and/or 
JNK. In a second step, TRADD and RIP1 associate with FADD and caspase-8, forming a 
cytoplasmic complex (complex II). Activated NF-kappa B mediates transcription of a 
caspase-8 inhibitory protein, cFLIP, which interferes with the apoptosis signalling pathway 
from TNF-R1 and assures survival of the cell. Thus, TNF-R1 signalling harbours a 
checkpoint were a decision between survival and death can be made (Micheau and 
Tschopp, 2003). cFLIP is also active in the CD95 / Fas and the TRAIL pathways. 
1.1.1.3.2 Intrinsic apoptosis 
 The intrinsic apoptotic pathway is initiated within the cell and involves 
permeabilization of the mitochondria (Figure 1). This pathway is triggered by various stress 
signals, such as DNA damage mediated by ionising irradiation or chemotherapeutic agents. 
Stress signals elicit various signalling cascade reaching on to mitochondria to induce 
mitochondrial outer membrane permeabilization (MOMP). The local regulation and 
execution of MOMP involves proteins from the Bcl-2 family (Bax, Bak, and, in some cases, 
Bim, tBid and Puma) (Green and Kroemer, 2004). MOMP, in turn, causes apoptosis via the 
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release of apoptogenic molecules like cytochrome c from the mitochondria into the 
cytoplasm. Cytochrome c, which normally has an important function in the respiratory 
chain (Liu, et al., 1996), assembles together with the adaptor molecule, APAF-1, ATP and 
caspase-9 into a complex called the apoptosome. This leads to aggregation and activation 
of caspase-9, which subsequently cleaves and activates downstream effector caspases 
(caspase-3, -6 and -7), which then execute cell death. Thus, downstream signalling from 
initiator caspases is the same for the intrinsic and extrinsic pathways. Several other pro-
apoptotic proteins, such as AIF, EndoG, Smac/Diablo and HtrA2/Omi are also released from 
the mitochondria. Apart from mitochondria, accumulating evidence strongly suggests a 
significant involvement for other organelles like the lysosomes, endoplasmic reticulum and 
Golgi during apoptosis as well (Ferri and Kroemer, 2001). 
 
 
Figure 1: Extrinsic and Intrinsic apoptosis pathway and crosstalk. Shown in the left side is the schematic 
reperesentation of the death receptors-mediated extrinsic signalling pathway of Fas. Shown in the right side is 
the Schematic reperesentation of the mitochondrial-mediated intrinsic signalling pathway. The extrinsic and 
intrinsic pathways can connect at different levels. I) Active caspase-8 can cleave Bid, which in its truncated form 
(tBid) activates the intrinsic pathway. Activation of the intrinsic pathway by generation of tBid can serve as an 
amplification loop for extrinsic signalling in cells with low levels of active caspase-8. II) Activation of the intrinsic 
pathway can result in the activation of caspase-8, which enhances the intrinsic apoptotic response. 
16 
 
1.1.1.3.3 Cross-talk between the extrinsic and intrinsic pathways 
Two models of Fas signalling have been described by which cells can be classified as 
type I or type II, depending on the engagement of the intrinsic pathway (Barnhart, et al., 
2003). Type I cells have high levels of Fas-induced DISC formation and consequently high 
levels of activated caspase-8, which is sufficient for sustained caspase-3 activation. On the 
contrary, low amount of DISC formation and low levels of caspase-8 activation characterize 
type II cells. Therefore, amplification of the signal via activation of the intrinsic pathway is 
needed. Low amounts of caspase-8 are sufficient to cleave Bid into an active truncated form 
(tBid). Bid is a pro-apoptotic member of the Bcl-2 family that, upon cleavage, translocates to 
the mitochondrial membrane and stimulates processes to enable cytochrome c release and 
subsequent events (Gross, et al., 1999). Caspase-8 activation can be induced during intrinsic 
apoptosis signalling (Scaffidi, et al., 1998) and it has been shown to accelerate the intrinsic 
death response (Tang, et al., 2000). In some cases, activation of caspase-8 occurs 
independently of the CD95/Fas death-inducing signalling complex and down-stream of the 
main executioner of the apoptosis signalling complexes, caspase-3, where activated caspase-
3 cleaves caspase-8 in a feed-back loop manner (Wieder, et al., 2001). Furthermore, 
activated caspase-6 has been reported to be an activator of caspase-8 (Cowling and 
Downward, 2002). In summary, it is evident that crosstalks exist between the extrinsic and 
intrinsic apoptosis signalling pathways and they function as amplification loops for each 
cascade (Figure 1). 
1.1.1.4 Regulation of apoptosis signalling 
When considering the physiological importance of apoptotic responses, it is clear 
that tight regulations of the signalling cascades are needed. Several regulators of death 
receptor mediated extrinsic and mitochondria-mediated intrinsic signalling have been 
identified and they are briefly described below because of their relevance for apoptosis 
resistance. 
1.1.1.4.1 Regulation of death receptor mediated extrinsic signalling 
One of the prime regulators of the death receptor signalling belong to a family of 
endogenous inhibitors called the cellular FLICE-like inhibitory proteins (cFLIPs). In 1997, 
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investigators identified the viral protein, vFLIP, while screening for DED-containing 
proteins that could interact with caspases (Thome, et al., 1997). The mammalian 
homologue is cFLIP, which is also refered to as cellular FLIP, CASH, FLAME, Casper, CLARP; 
FLAME, I-FLICE, MRIT and usurpin by several other groups (Budd, et al., 2006). 
 There are several splice variants of cFLIP reported but only three of them have 
been identified to be expressed as proteins. cFLIP-Long (cFLIP-L) is similar to caspase-8, as it 
contains two N-terminal DEDs and a caspase-like domain. However several important 
amino acids are different in the caspase-like domain of cFLIP-L, which abolishes the 
enzymatic activity. The two other cFLIP splice variants, cFLIP-Short (cFLIP-S) and cFLIP-Raji 
(cFLIP-R) are truncated versions,  which contain only t h e  two DEDs. All three cFLIP 
isoforms act as competitive inhibitors of caspase-8 for FADD binding thereby inhibiting Fas 
induced apoptosis (Golks, et al., 2005; Irmler, et al., 1997; Scaffidi, et al., 1999). c-FLIP-S 
completely inhibits cleavage of procaspase-8 (Krueger, et al., 2001; Peter, 2004) whereas, 
cFLIP-L function is more complex. Although cFLIP-L can compete with caspase-8 for 
recruitment to the DISC and can therefore inhibit caspase-8 activation, it also forms 
heterodimers with caspase-8 at the DISC, which leads to week activation and initial 
processing of caspase-8 that result in the release of the p10 fragment of caspase-8. 
Association of cFLIP-L with caspase-8 also mediates processing of cFLIP-L, which generates 
43kDa and 12kDa products from the 55kDa full-length protein (Krueger, et al., 2001). 
Interestingly, the p43 cFLIP fragment acts as a more potent activator of NFkappaB than 
full-length cFLIP-L (Kataoka and Tschopp, 2004) besides inhibition of Fas induced apoptosis 
through interfering with caspase-8 cleavage. However, the role of cFLIP-L in NFkappaB 
activation is complex and contradicting studies exist where cFLIP-L has also been shown to 
inhibit NFkappaB activation (Kreuz, et al., 2004; Legembre, et al., 2004). Nevertheless 
cFLIP exerts discrete regulatory functions involving inhibition of caspase-8 induced 
apoptosis, and also in other signalling cascades such as survival pathways from the death 
receptors. 
1.1.1.4.2 Regulation of mitochondrially-mediated intrinsic apoptosis signalling by Bcl-2 
family members 
 Bcl-2-family proteins play an important role in regulating the intrinsic apoptotic 
pathway. The Bcl-2 (B-cell lymphoma-2) gene was the first anti-apoptotic gene to be 
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discovered as the defining oncogene in B-cell follicular lymphomas and  is located at the 
chromosomal breakpoint of the t(14;18) (q32;q21) chromosomal translocation (Danial, 
2007; Tsujimoto, et al., 1984). To date the family consists of 20 members, which can be 
divided into three subfamilies based on the presence of conserved Bcl-2 homology (BH1-4) 
domains (Youle and Strasser, 2008). One subfamily is constituted of anti-apoptotic proteins, 
such as Bcl-2, Bcl-xL (Bcl-2 related X gene, long isoform), Bcl-w, Mcl-1 (Myeloid cell leukemia 
1), Bfl-1 and Bcl-B which contain BH domains 1–4 and are generally integrated within the 
outer mitochondrial membrane, but there are instances of cytosolic, endoplasmic and 
nuclear membrane localizations (Kaufmann, et al., 2003). The other two subfamilies 
include the pro-apoptotic proteins. Bak (Bcl-2 antagonist killer 1), Bax (Bcl-2 associated x 
protein) and Bok (Bcl2-related ovarian killer) are three important members of the Bax-like 
apoptotic subfamily. These proteins contain BH1-3 domains and they are responsible for 
mitochondrial membrane permeblization and cytochrome c release. The third subfamily is 
the more diverse pro-apoptotic BH3 only family and it includes Bad (Bcl-2 antagonist of cell 
death), Bid (Bcl-2 interacting domain death agonist), Nbk/Bik (Natural born killer/Bcl-2 
interacting killer), Bim (Bcl-2 interacting mediator of cell death), Bmf (Bcl-2 modifying 
factor), Bnip3 (Bcl-2/adenovirus E1B 19-KD protein-interacting protein 3), Hrk (Harakiri), 
Noxa (Latin for damage) and Puma (p53-upregulated modulator of apoptosis), which 
function in distinct cellular stress pathways, by protein–protein interactions with other Bcl-2 
family members (i.e. anti-apoptotic Bcl-2 proteins and/or the effector molecules Bax, Bak or 
Bok), and signal that a cellular stress has occurred (See Figure 2 for overview) (Daniel, 2000).  
 The levels and activity of pro-survival proteins Bcl-xL, Bfl-1 and Mcl-1 are regulated by 
diverse mechanisms, including transcriptional control and protein modification and 
turnover. For example, the levels and activity of pro-survival proteins are closely coupled to 
the supply of cytokines, which affects both their production and stability. Bcl-2 levels may 
also be controlled, in part, by micro-RNAs (Cimmino, et al., 2005; Xia, et al., 2008) and its 
activity is affected in complex ways by phosphorylation (Deng, et al., 2004). DNA damage 
induces deamination of Bcl-xL on two asparagine residues in its flexible loop region 
(Deverman et al., 2002), but the claim that this blocks Bcl-xL pro-survival activity may well be 
erroneous (Deverman et al., 2003). The Mcl-1 protein is rapidly lost by proteasomal 
degradation early in response to several cytotoxic signals (Cuconati, et al., 2003). Proteins 
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implicated in the regulation of its degradation include Noxa (Willis, et al., 2005), a BH3-




Figure 2: The Bcl-2 family members and their function at the mitochondrial membrane. The Bcl-2 family 
proteins can be divided into three subgroups depending on how many BH-domains they contain. All four BH-
domains are found in the anti-apoptotic Bcl-2 like subfamily, whereas the Bax-like subfamily of the pro-
apoptotic proteins only contains three BH-domains. The third subfamily consists of the BH3 only proteins, 
which along with the Bax-like subfamily function as apoptosis inducers. Several proteins in all the subgroups 
also contain a transmembrane domain (TM), which affects the protein function by anchoring them to 
intracellular membranes like the mitochondria, nuclear envelope and endoplasmatic reticulum. 
 Both pro-apoptotic groups of the Bcl-2 proteins are required for stress-induced 
apoptosis. The BH3-only proteins function as damage sensors upstream of Bak and Bax, as 
Bim, Bad, Noxa and Nbk failed to induce apoptosis in Bax and Bak double deficient cells 
(Cheng, et al., 2001; Gillissen, et al., 2003; Gillissen, et al., 2007; Zong, et al., 2001). Some 
BH3-only proteins are activated by transcriptional induction (Puma, Noxa) or post-
translational modifications, like dephosphorylation (Bad) (del Peso, et al., 1997; Zha, et al., 
1996) and cleavage (tBid) (Li, et al., 1998; Luo, et al., 1998). Whereas Bim and Bmf are 
initially associated with the microtubules and the actin cytoskeleton respectively via 
interaction with a Dynein Light Chain (DLC) their release can induce apoptosis (Puthalakath 
et al., 1999; Puthalakath et al., 2001). Bim is identified to be one of the principle regulators 
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of haematopoietic homeostasis: In its absence, leukocyte numbers rise and plasma cell 
accumulation leads to the onset of an autoimmune syndrome equivalent to that elicited by 
the overexpression of Bcl-2 (Bouillet, et al., 2002; Bouillet and Strasser, 2002). The level of 
Bim can be regulated by phosphorylation by Erk, which triggers its degradation by the 
proteasome (Akiyama, et al., 2003; Ley, et al., 2003; Luciano, et al., 2003), whereas its 
phosphorylation by c-Jun N-terminal kinase may potentiate its pro-apoptotic activity 




Figure 3: Regulation of intrinsic apoptosis pathway by BH-3 only proteins. Various stress stimuli result in the 
activation of the BH3-only proteins, which function as apoptotic sensors in the cytoplasm. Subsequently, in 
indirect model BH3 proteins, Bim, Bid and Puma bind to Bcl-2 pro-survival proteins leading to disengagement 
and activation of Bax/Bak for apoptosis induction. In the direct model the BH3 only proteins activate the Bax-
like protein directly by changing their conformation whereas the indirectly model is based on liberating the 
inhibitory binding to anti-apoptotic Bcl-2 proteins. Activation of the Bax-like proteins leads to their 
oligomerization at the mitochondrial membrane, which results in the release of pro-apoptotic proteins into the 
cytoplasm.  
 Active BH3-only proteins mediate conformational change in Bax and Bak, which 
induces protein oligomerization at the outer mitochondrial membrane, thus leading to 
MOMP and cytochrome c release. There are two models proposed for the activation of Bak 
and Bax by the BH3-only proteins (Figure 3) (Youle and Strasser, 2008). In the first model, a 
direct association between Bak/Bax and certain BH3-only proteins, i.e. Bim, tBid and Puma 
has been described (Adams and Cory, 2007; Certo, et al., 2006; Kuwana, et al., 2005; Letai, 
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et al., 2002; Oh, et al., 2006; Walensky, et al., 2006). In this model, the rest of the BH3-only 
proteins are suggested to bind anti-apoptotic proteins and abolish their inhibitory 
interaction with Bim, tBid and Puma. In the indirect activation model, the BH3-only proteins 
are believed to induce apoptosis merely by interaction with anti-apoptotic proteins, thus 
preventing them from inhibiting Bax and Bak activation (Chen, et al., 2005; Willis, et al., 
2005; Willis, et al., 2007). The functional relevance of these two activation models is 
currently debated and it is likely that they are of different importance in different cellular 
systems (Adams and Cory, 2007).  
1.1.1.4.3 Regulation of apoptosis by IAPs 
Apoptosis including both extrinsic and intrinsic signalling pathways is under the 
control of the inhibitors of apoptosis, IAPs. These proteins were initially identified in 
baculovirus (Crook, et al., 1993) and they are characterized based on the presence of 
one to three baculoviral IAP repeats (BIRs). There are at least 8 different human IAPs 
identified (Survivin, ILP2, ML-IAP, XIAP, c-IAP1, c-IAP2, NAIP and BRUCE). Structural and 
functional studies have shown that the IAPs can bind directly to different caspases, mainly 
caspase-9, -3 and -7, and inhibit their activity (Richter and Duckett, 2000; Salvesen and 
Duckett, 2002). The inhibitory effect is mediated by binding of the BIR domains to the 
caspases, which sequesters the caspases away from their targets and/or induce their 
degradation (Srinivasula and Ashwell, 2008). 
1.1.1.4.4 Regulation of apoptosis by p53 
The p53 transcription factor is often called the guardian of the genome and it has a 
pivotal role in prevention of tumor formation. Mutations, deletions or dysregulation of 
p53 are some of the most common alterations detected in tumors. The expression 
levels of p53 is generally maintained low due to its binding to mdm2, which targets p53 
for proteasomal degradation (Momand, et al., 2000). DNA damage and cellular stress 
induces p53 stabilisation and this together with specific modifications of p53, such as 
phosphorylations, acetylations and glycosylations, leads to its activation (Vogelstein, et 
al., 2000). p53 controls a large number of genes transcriptionally that influence cell cycle 
arrest, DNA repair, apoptosis, senescence and autophagy. It has been established as one 
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of the most important DNA damage cell cycle checkpoint proteins. For instance, it has a 
major regulatory role in response to radiation (Pawlik and Keyomarsi, 2004). The apoptotic 
function of p53 is mainly executed through activation of pro-apoptotic proteins, such as 
Bax, Noxa, Puma, Bid, Fas, APAF-1 and TRAIL-R2. Additionally, many studies have shown 
that p53 mediates transcriptional repression of anti-apoptotic genes like Bcl-2 and survivin 
(Haldar, et al., 1994; Hoffman, et al., 2002). Notably, p53 has also been reported to impede 
the anti-apoptotic function of Bcl-2 and Bcl-xL as well as to activate the pore- forming 
function of Bax and Bak by a direct binding (Leu, et al., 2004; Norbury and Zhivotovsky, 2004) 
Nevertheless, cytosolic or mitochondrial p53 is, per se, not sufficient to activate the 
intrinsic apoptosis pathway (Essmann, et al., 2005). 
1.1.2 Non-apoptotic cell death 
1.1.2.1 Necrosis 
Necrotic cell death is an unsheduled accidental cell lysis, which has been often 
regarded opposite to orderly execution of apoptosis. It is characterized by swelling of 
organelles and cytoplasm that eventually leads to disruption of the plasma membrane and 
is considered to be an energy-independent and un-regulated form of cell death (Leist and 
Nicotera, 1997; Nicotera and Leist, 1997). Normally, an inflammatory response is 
generated as the content of the cells leaks out to the surrounding tissue. Necrosis is often 
induced by acute and severe injuries, like in pathological conditions and ischemia 
(Galluzzi, et al., 2007). Recently, evidence has emerged showing that necrosis, under 
certain conditions, can be programmed which is cited as necroptosis. For instance, Arsenic 
trioxide induces regulated, death receptor- and caspase-independent cell death through a 
Bcl-2-controlled pathway (Degterev and Yuan, 2008; Scholz, et al., 2005; Scholz, et al., 
2005). In case of impaired normal apoptosis signalling, induction of necrosis can be an 
important alternative means of cell death. Though the signalling mechanisms leading to 
necrosis are not fully understood, there are some important findings made. For instance, in 
the absence of caspase-8, Fas induces necrosis through an effector molecule RIP-1 kinase, 
(Holler, et al., 2000) and calcium as well as reactive oxygen species are shown to play an 




Autophagy is an evolutionary conserved "self-eating” process that eliminates 
damaged or dysfunctional cell components. It is essential for cellular homeostasis, survival, 
development and differentiation. Normally, autophagy is a slow process, but it can serve 
as an adaptive response against several pathologies like infection, neurodegeneration and 
cancer. Several different forms of autophagy have been described, namely macro-, micro- 
and chaperone-mediated autophagy (CMA). Macro- and micro-autophagies are capable of 
degrading large structures, whereas CMA is only concerned about soluble proteins. 
Macroautophagy occurs at a basal level in response to environmental conditions like 
nutrients deprivation or microbial pathogens, during which double-membrane-containing 
vesicles are formed that are called phagosomes. These phagosomes enclose organelles 
and proteins, which are subsequently degraded when the vesicles fuse with lysosomes. In 
contrast, the micro-autophagy and CMA involves direct incorporation of unfolded 
substrate proteins into the lysosomes through the action of a cytosolic and lysosomal 
chaperone hsc70 along with the integral membrane receptor LAMP-2A (lysosome-
associated membrane protein type) (Mizushima, et al., 2008). Autophagy is under the 
control of a large family of autophagy-related genes (ATG). During stress conditions like 
nutrient and growth factor deprivation, autophagy can sustain cell survival by degrading 
disposable cell components (Levine and Kroemer, 2008). In case of uncontrolled up-
regulation of autophagy the outcome can be cell death. In case of uncontrolled up-
regulation of autophagy the outcome can be cell death. For instance, over expression of 
ATGs, e.g. beclin-1, leads to cell death in mammalian cells (Pattingre, et al., 2005). 
Autophagy might therefore keep damaged cells alive which can lead to potential danger 
supporting pathologies like tumor formation (Levine and Kroemer, 2008). 
1.1.2.3 Mitotic catastrophe 
 Mitotic catastrophe (MC) refers to cell death that occurs during mitosis or caused 
by mitotic failure (Figure 4). Other investigators consider mitotic catastrophe not as a mode 
of cell death but as a special case of apoptosis which is based on the observation that MC 
shares several biochemical hallmarks with apoptosis, namely mitochondrial membrane 
permeabilization and caspase activation (Bataller and Portugal, 2005; Castedo and Kroemer, 
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2004). However, it is still ambiguous whether death associated with MC occurs via caspase-
dependent or caspase-independent mechanisms. In some studies, MC is related to a cell 
survival mechanism of tumors (Mansilla, et al., 2006); (Erenpreisa, et al., 2005), while others 
interpret that MC is associated with senescence (Eom, et al., 2005; Shay and Roninson, 
2004). Despite all these definitions, there is no generally accepted characteristic of MC. 
Nevertheless, MC is often associated with the formation of giant cells with altered 
nuclear morphology, i.e. multiple nuclei or micronuclei (Galluzzi, et al., 2007) as a result of 
abnormal mitosis through the generation of lagging chromosomal material, anaphase 
bridging or multiple spindle poles. These cells may continue to divide and become polypoid 
and/or aneuploid, but eventually they die by delayed apoptosis or necrosis (Vakifahmetoglu, 
et al., 2008). Mitotic catastrophe usually results from defects mediated by impaired cell 
cycle checkpoints (Castedo, et al., 2004). Therefore, mitotic catastrophe is particularly 
prevalent in cells with compromised p53 function, as p53 is a major regulator of both G1 
and G2 checkpoints (Pawlik and Keyomarsi, 2004). Suppression of the spindle checkpoint, 
p53 function and the apoptotic program may thus lead to mitotic slippage and asymmetric 
cell division, resulting in the generation of tetraploid (4N) cells which can further result in 
aneuploid offspring, if the polyploidy checkpoint is inactivated (Bhonde, et al., 2006; Rieder 
and Maiato, 2004). In addition, it can be caused by anomalous duplication of centrosomes, as 
these are crucial for the number of spindle poles formed during mitosis and for accurate 
chromosome segregation into daughter cells (Loffler, et al., 2006). In general, resistance to 
cell death by mitotic catastrophe mainly depends on the molecular profile of the cell and the 
extent of DNA damage that will ultimately define if the cell will enter G1 as a viable entity. It 






Figure 4: Mitotic catastrophe is a cell death induced in mitosis or as a consequence of mitotic abnormalitites. 
It can be detected at multiple stages during the accumulation of DNA alterations depending on the genetic 
backround of the cell and the intensity of the DNA damaging stimuli applied. (Modified from Eriksson et.al. 
2008). 
1.2 Apoptosis resistance in malignant disease 
Acquired resistance towards apoptosis can be observed in most types of cancers, 
which supports tumor development in a profound way. There are numerous molecular 
alterations described that promotes both tumor development and progression. It is well 
established that mutations of important tumor suppressor genes and oncogenes like p53, c-
Myc, Ras, Wnt and Erk act as a major driving force for cellular transformation. These 
mutations can occur through exchange of single nucleotides, reading frame shifts or 
rearrangements of larger DNA stretches, such as deletions, inversions and translocations 
(Sjoblom, 2008). Epigenetic alterations, like DNA methylation and histone modifications, 
were also appreciated to have a great influence on tumor development (Vucic, et al., 2008). 
A significant number of proteins involved in the induction and regulation of cell death has 
been reported to be modified in various types of cancer which includes reduced function of 
pro-apoptotic molecules (for example: Bax, Fas, TRAIL-R1/2, Caspase-8, etc) and increased 
expression of anti-apoptotic proteins (for example: Bcl-2, Mcl-1, c-IAP2, Survivin, etc) 
(Daniel, et al., 1999; Igney and Krammer, 2002; Radetzki, et al., 2002; Raisova, et al., 2001; 
Sturm, et al., 1999; Sturm, et al., 2006; Zantl, et al., 2007). 
1.2.1 Apoptosis resistance confers insensitivity to cancer therapy 
In addition to the apoptosis resistance acquired during tumor formation and 
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progression, tumor cells also acquire resistance during treatment. The development of 
resistance to the drugs originally used to treat them is arduous, as it might contribute to 
cross-resistance against additional chemotherapeutics with different mode of action 
(Longley and Johnston, 2005). Recently, novel strategies have been taken to find specific 
targets in the apoptosis signalling pathways that, upon altered regulation, would promote 
apoptosis in tumor cells. Some promising therapeutic candidates include activating 
substances of molecules in the death signalling pathways (for instance: TNF-R1, TRAIL-R1, 
TRAIL-R2, etc) as well as drugs that interfere with the anti-apoptotic properties of survival 
proteins (for example: mTOR, PI3 kinase, Bcl-2, Bcl-xL, survivin, IAPs, etc) (Ghobrial, et al., 
2005; Ziegler and Kung, 2008). 
1.3 The Cell Cycle 
The cell cycle or cell division cycle is the series of events that take place in a cell 
leading to its division and duplication (replication) by mitosis unlike in cells without a nucleus 
(prokaryotes), where the cell cycle division occurs via a process termed binary fission. The 
cell-division cycle is a vital process by which a single-celled fertilized egg develops into a 
mature organism, as well as the process by which, hair, skin, blood cells and some internal 
organs are renewed. 
1.3.1 The cell cycle phases  
The cell cycle is divided into four different phases: G1, S, G2 and M phase (Fig. 5). The 
G1 and G2 phases are gaps during which the cell is preparing for DNA synthesis (S) and 
mitosis (M) respectively (Figure 5). Following mitosis, the cells may enter a quiescent G0 
phase in the absence of stimuli triggering mitosis, a state that characterizes most of the cells 
in normal adult tissues. In the presence of a sustained mitogenic stimulus, the cells progress 
to a restriction point (R), beyond which they are committed to enter S phase and growth 
factors present in the environment are no longer required for progression in S/G2 phases 
(Sherr, 1994). In vertebrates and diploid yeasts, the cells in G1 have a diploid number of 
chromosomes (2N), one inherited from each parent, in S when DNA is replicated it is 
between 2N and 4N and in G2/M the cells are tetraploids with a 4N chromosome number.  
Mitosis is further sub-divided into four phases based on morphological criteria, the 
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prophase characterized by chromosome condensation, the metaphase where chromosomes 
align in the cell center, the anaphase when sister chromatids separate and move to the 
opposite poles of the mitotic spindle and the last stage, the telophase, where the segregated 
chromosomes decondense followed by physical division of the cytoplasm that yields two 
daughter cells called cytokinesis. During this, the nuclear envelope breaks down into vesicles 
in prophase and reforms again in telophase. Besides the Golgi complex and endoplasmic 
reticulum vesiculate during mitosis and reform in the daughter cells when cell division is 
completed.  
1.3.2 Regulation of the cell cycle  
Regulation of the cell cycle involves processes crucial to the survival of a cell, 
including the detection and repair of genetic damage as well as the prevention of 
uncontrolled cell division. Progression through the cell cycle is regulated by the synthesis, 
assembly and activation of key cell cycle regulatory complexes comprised of cyclins and 
cyclin dependent kinases (Cdks), followed by their subsequent inactivation, disassociation 
and degradation in a specific order (Morgan, 1995). This process involves multiple 
mechanisms controlling at transcriptional, translational and post-translational levels via the 
ubiquitin-mediated proteolysis and regulation of the subcellular localization of proteins.  
1.3.3 Cyclin dependent kinases (Cdks) and cyclins  
In mammalians, the Cdks comprise a family of eleven serine-threonine protein 
kinases (Cdk 1-11) and four of them were shown to catalyze different cell cycle transitions 
(Pfleger and Kirschner, 2000). Cdk4 and Cdk6 are active during G1, Cdk2 in the G1/S 
transition and Cdk1 in late G2 and mitosis. Binding of cyclin to Cdk is an absolute 
requirement for their activation (Sherr, 1994). Activation of Cdk’s requires phosphorylation 
in a conserved threonine residue located in their activation loop that causes a 
conformational change and is essential for the kinase activity. This phosphorylation event is 
catalysed regulatorily by various kinases like Cdk activating kinase (CAK) (Sherr, 2000). 
Phosphorylation at conserved inhibitory sites (threonine 14 and tyrosine 15) on Cdk1/Cdc2 
inhibits their activity and is catalysed by the Wee-1 and Myt-1 kinases. These inhibitory 
phosphates are removed by another family of regulators, the cell division cycle (Cdc) 
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phosphatases including Cdc25A, Cdc25B and Cdc25C, leading to their full activation (Morgan, 
1995). Apart from site specific phosphorylation, the Cdk activity is also negatively regulated 
by binding of Cdk inhibitors (CKI) belonging to two distinct families, the kinase inhibitory 
proteins (KIP) and the inhibitor of Cdk4 (INK4) (Sherr, 2000). The KIP family includes the p21, 
p27 and p57 proteins that are able to inhibit all cyclin–CDK complexes and are not specific 
for a particular phase (Slingerland and Pagano, 2000). While the members of the INK4 family 
including p15, p16, p18 and p19, specifically act in G1 and inactivate Cdk4 and Cdk6 by 
destabilizing their association with the D-type cyclins (Sherr and Roberts, 1999). 
 The family of mammalian cyclins include cyclins A to H and all share a conserved 
sequence of about 100 amino acids referred to as the cyclin box. Different cyclins bind to and 
activate different Cdks, at specific phases of cell cycle and the activated cyclin-Cdk complexes 
in turn phosphorylate various target proteins in order to mediate transition and progression 
through the different cell cycle phases. The levels of cyclin changes significantly during cell 
cycle unlike Cdks, which remain constant thoughout cell cycle. Entry and progression through 
G1 is regulated by the three D-type cyclins (cyclin D1, D2, and D3) that bind to Cdk4 and Cdk6 
whereas entry into S phase is regulated by the cyclin E/Cdk2 complexes (Schafer, 1998). 
Cyclin A/Cdk2 complex is involved in S phase progression whereas in late G2 cyclin A binds to 
Cdk1. Entry from G2 to M and progression through early M phase, is controlled by the cyclin 






Figure 5 The cell cycle and its regulation by CDKs. In normally cycling cells, the cell cycle is composed of four 
main stages (G1, S, G2, and M) under the direction of cyclin dependent kinases (CDKs).  
Key events of the cell division are also controlled by the ubiquitin-proteasome 
pathway either using SCF (Skp1/Cullin/F-box) E3-ligase principally at the G1/S and G2/M 
transitions (DeSalle and Pagano, 2001) or the anaphase-promoting complex (APC) at M 
phase for exit and entry in G1 phase (Hagting, et al., 2002; Salah and Nasmyth, 2000). 
1.3.4 Cell cycle checkpoints and their role in tumor formation 
The cell cycle checkpoints are surveillance mechanisms that ensure fidility of the cell 
cycle. When errors are detected they arrest the cell cycle to allow sufficient time to correct 
these errors. Defects in many molecules regulating the cell cycle have been implicated in 
cancer formation and progression (Kastan and Bartek, 2004). Among these the most crucial 
are p53, the retinoblastoma protein (pRb) and its related proteins, p107 and pRb2/p130, and 
cdk inhibitors (p15, p16, p18, p19, p21, p27), all of which act to keep the cell cycle from 
progressing until all repairs to damaged DNA have been completed (Macaluso, et al., 2005). 
There are also other proteins, which play important role in cell cycle progression specifically 
during mitosis such as Bub1, BubR1, PLK’s (Polo like kinases) and the Aurora kinases. 
Alterations in cell cycle components due to mutations resulting in loss or gain of function 
may cause the cell to multiply uncontrollably, forming a tumor. The cells that are actively 
undergoing cell cycle are targeted in cancer therapy, as the DNA is relatively exposed during 
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cell division and hence susceptible to damage by drugs or ionising radiation. Notebly, PLK1 
has also begun to attract increasing attention as it is overexpressed in a variety of human 
cancers, and its expression often correlates with poor disease prognosis (Eckerdt, et al., 
2005). 
1.3.4.1 Structural and functional aspects of PLK1  
Polo, a serine/threonine kinase belongs to the Polo Like Kinase (PLK) family, which 
was first identified in Drosophila melanogaster (Sunkel and Glover, 1988). Subsequently 
other groups identified four mammalian PLK family members - PLK1, PLK2 (also known as 
SNK), PLK3 (also known as FNK or PRK) and PLK4 (also known as SAK) (Strebhardt and Ullrich, 
2006). PLK1 is a well characterized member of the human PLK family which contains two 
domains: a highly conserved N-terminal catalytic (Kinase) domain of 252 amino-acids, and a 
C-terminal region with the unique PBD comprising 2 polo-boxes, each of which are 60–70 
amino acids in length. Substrate specificity of PLK1 is modelled that PBD binding to target 
protein leads to a confirmational change of PLK1 liberating the kinase domain to 
phosphorylate the target protein (Lowery, et al., 2005). The activity and cellular 
concentrations of this kinase are crucial for the precise regulation of cell division. Along with 
the increase in PLK1 levels there is a concordant increase in kinase activity during G2 phase 
reaching to a maximum in mitosis at the metaphase-anaphase transition (Golsteyn, et al., 
1995; Golsteyn, et al., 1994; Hardy and Pautz, 1996).  
 There are various functions associated with human PLK1: in centrosome maturation 
and spindle assembly (Lane and Nigg, 1996; Liu and Erikson, 2002; Sumara, et al., 2004; van 
Vugt, et al., 2004), and in facilitating proper bipolar spindle formation during prometaphase 
and metaphase (Figure 6). In the absence of PLK1, cells fail to form a bipolar spindle and 
arrest in a prometaphase-like state with an activated mitotic spindle checkpoint (Sumara, et 
al., 2004; van Vugt, et al., 2004). PLK1 has been implicated in chromatid arm separation 
through cohesin removal (Gimenez-Abian, et al., 2004; Hauf, et al., 2005; Sumara, et al., 
2002). Additionally, it assists in mitotic exit and cytokinesis (Carmena, et al., 1998; 
Descombes and Nigg, 1998; Lindon and Pines, 2004; Seong, et al., 2002; Xie, et al., 2005). 
Notably, PLK1 has a significant role in responses and adaption to DNA damage (Smits, et al., 






Figure 6: (a) Schematic view, emphasizing the function of polo-like kinase-1 (PLK1) at multiple stages of cell 
division. DNA/chromosomes are marked in blue, microtubules in green and both centrosomes and 
kinetochores in yellow. The red colour is used to indicate the association of PLK1 with different structures. (b–
e) Immunofluorescence images, illustrating the various locations of PLK1 throughout the (HeLa) cell cycle. In 
G2, PLK1 localizes to centrosomes (b, filled triangles), then in prometaphase (c) and metaphase (d) to 
kinetochores (open triangles) and spindle poles (filled triangles), and finally, in anaphase–telophase, to the 
central spindle (e, filled triangles (Colocalization of PLK1 with tubulin results in yellow). PLK1 localization 
depends on a functional polo-box domain (PBD) and probably involves different docking proteins (Barr, et al., 
2004). 
 
On the other hand, studies in X. laevis oocytes described good evidence that PLKs 
bind and phosphorylate Cdc25, which might provide a mechanism for coordinating the 
regulation of Cdk1-cyclinB activity (Gonzalez, et al., 1998; Kumagai and Dunphy, 1996). 
Supporting this, Myt1 was identified as PLK substrate (Nakajima, et al., 2003). PLK1 also 
phosphorylates cyclin B1 on Ser133 targeting it to the nucleus during prophase (Toyoshima-
Morimoto, et al., 2001) (Figure 7). This indicates that PLKs might have an essential role in the 
control of G2/M-progression (Barr, et al., 2004). DNA damage or failure to complete DNA 
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replication results in the activation of DNA-damage checkpoints, which inhibits Cdc25 and/or 
activate Wee1/Myt1, moreover, suppress PLK1 activity. The mechanisms that mediate the 
downregulation of PLK1 are not yet clear, although destabilization through ubiquitin-
dependent degradation has been proposed (Kang, et al., 2002). Moreover, depletion of PLK1 
function arrested cells with monoastral spindles, due to inhibition of centrosome maturation 
and separation. In contrast, mislocalized PLK1 resulting from polo box domain 
overexpression showed a checkpoint-dependent mitotic arrest characterized by impaired 
chromosome congression implying that catalytic activity of PLK1 was sufficient to bring 
about centrosome maturation, centrosome separation, and spindle assembly. However, 
complete chromosome congression and continued progression through M phase was 
dependent on correctly localized PLK1 activity (Hanisch, et al., 2006). 
 
 
Figure 7: Complex regulatory network controls the activity of the principal mitotic regulatory kinase, cyclin-
dependent kinase-1 (Cdk1). The newly formed Cdk1–cyclin-B complex is maintained in an inactive state, owing 
to inhibitory phosphorylation of Cdk1 at Thr14 and Tyr15 by the Wee1 and membrane-associated Cdk1-
inhibitory kinase (Myt1) kinases. This inhibitory effect is overcome by dephoshporlyation of the dual-specificity 
phosphatase Cdc25c, which results in the activation of Cdk1–cyclin-B complex. Once activated, Cdk1 triggers a 
positive-feedback loop by phosphorylating Cdc25c and Wee1/Myt1, thereby causing their further activation 
and inhibition, respectively. PLKs also affect both Cdc25 and Myt1 (and presumably Wee1), either functioning 
as trigger kinases for the activation of Cdk1, or merely in the context of a positive-feedback loop. PLK1 also 
phosphorylates Homo sapiens cyclin B1 on Ser133, but the consequences of this phosphorylation are not yet 
known. Conversely, Cdk1–cyclin-B might contribute to PLK1 activation, most likely through indirect 
mechanisms (dashed arrow) (Barr, et al., 2004). 
33 
 
1.4 Burkitt lymphoma  
Burkitt lymphoma (BL) is non-Hodgkin's lymphoma, which is an aggressive malignant 
B-cell tumor. There are three subtypes of BL: endemic BL, sporadic BL and HIV associated BL. 
Endemic BL occurs with high frequency in tropical areas of Africa and New Guinea, where it 
is usually associated with EBV and normally observed in children between 2-14 years. 
Sporadic BL occurs with lower frequency in the United States and Europe, where its EBV-
association is less strong. And the third subtype, HIV associated BL, is distributed all over the 
world and usually associated with HIV infection (Barnett, 1968). BL is regarded as the prime 
example of a latency I malignancy, in which EBNA1 is exclusively expressed (A.B.  Rickinson  
and  E.  Kieff, 1996). EBV latency is characterized by the expression of three different viral 
gene expression programs representing different levels of viral silencing (Masucci and 
Ernberg, 1994). Among latency III, II, I and 0, latency III is the least restrictive program and 
results in the expression of six EBV nuclear antigens (EBNA1-6) and three latent membrane 
proteins (LMP1, LMP2A, LMP2B). This expression pattern is observed in B-cells that are 
immortalised by EBV infection in vitro and is found in vivo in the blood and lymphoid tissues 
of infectious mononucleosis patients (Babcock, et al., 2000). EBNA1 is thought to be 
essential for the maintenance of the episomal state of EBV in infected cells and binds to the 
origin of replication. Latent membrane protein (LMP) is a membrane-associated protein, 
which is found in the virus particle as well as the infected cells. The structure of LMP 
resembles a growth factor receptor, which may play a role in the immortalization process. 
EBNA1 is oncogenic in vivo and suggest that the gene product may play a direct role in the 
pathogenesis of Burkitt lymphoma and possibly other EBV-associated malignancies (Wilson, 
et al., 1996). However, recent studies reported the identification of a subset of BL tumors 
that express most EBNAs except EBNA2 and the LMPs, thereby partially resembling latency 
III (Kelly, et al., 2002).  
 BL is invariably associated with chromosomal translocations, preferentially the 
t(8;14)(q24;q32) translocation, bringing the c-myc proto-oncogene in proximity with the 
immunoglobulin heavy chain promoter (Dalla-Favera et al., 1982; Taub et al., 1982). The 
proto-oncogene c-myc plays a pivotal role in the regulation of numerous essential cellular 
processes such as cell proliferation, differentiation and apoptosis (Henriksson and Luscher, 
1996). The c-myc gene encodes the transcription factor c-Myc, which is a short-lived nuclear 
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phosphoprotein of the basic helix-loop-helix-leucine zipper (bHLH-LZ) class and its 
destruction is regulated by the ubiquitin-proteasome pathway (Bahram, et al., 2000; Bonvini, 
et al., 1998; Gregory and Hann, 2000). c-Myc heterodimerizes with a partner protein, named 
Max and regulates the transcription of specific E-box-containing genes (Grandori, et al., 
1996; Henriksson and Luscher, 1996). Max also heterodimerizes with the Mad family of 
proteins to repress transcription and thus it antagonizes c-Myc, and promotes cellular 
differentiation. As a result of chromosomal translocations in Burkitt lymphomas, c-myc is 
constitutively active, which is crucial to the genesis of many cancers since it may cause gene 
amplification and chromosomal rearrangements (Grandori, et al., 1996; Mai, et al., 1999; 
Taylor and Mai, 1998). Furthermore, cells overexpressing c-Myc can bypass check points that 
are induced upon spindle disruption in the G2/M phase of the cell cycle (Adachi, et al., 2001). 
Such cells harbor secondary mutations that result in abrogation of the apoptotic response 
and therefore can still survive with an abnormal DNA content. Such cells harbor secondary 
mutations that result in abrogation of the apoptotic response and therefore can still survive 
with an abnormal DNA content. Particularly, loss of p53, Bax or overexpression of Bcl-xL can 
cooperate with c-Myc in order to propagate polyploidy in various cell lines (Adachi, et al., 
2001; Gutierrez, et al., 1999; Li and Dang, 1999; Minn, et al., 1996; Yin, et al., 1999). 
Additionally, cdk2 and cyclins A and B1 have been proposed as downstream effector 
molecules that could enable c-Myc to bypass these checkpoints (Adachi, et al., 2001; Li and 
Dang, 1999; Yin, et al., 1999). In line with these findings, c-Myc has been shown to disrupt 
signaling pathways that control cell cycle including deregulation of the cyclin/cdk2 
complexes (Amati, et al., 1998). Interestingly, cdk2 activation is necessary for centrosome 
duplication (Tarapore, et al., 2002) and numerical as well as centrosome aberrations have 
been reported in many tumor types (Pihan, et al., 1998) but not in BL.  
EBV infection of a c-myc translocation-carrying cell may provide an additional growth 
advantage and drives the cell further towards a fully malignant state (Bornkamm, et al., 
1987). In contrast, there are speculations that Epstein-Barr virus may contribute to the 
deregulation of the c-myc gene and that this interaction may be required for tumorigenesis 
in the presence of some, but not all types of c-myc damage arising from chromosomal 
translocations (Ambinder and Griffin, 1991). However, it is believed that the combined effect 




Tumor development is a multi-step process in humans. It is associated with genetic 
alterations, like mutations in tumor promoting (oncogenes), tumor suppressing 
(suppressor) genes and stability genes, which progressively drive transformation of a 
normal cell into a malignant form (Evan and Vousden, 2001; Evan, et al., 1992; Igney and 
Krammer, 2002). Thus, many cancers are age-dependent and occur later in life (Renan, 
1993). Different insults, like chemical, physiological or viral agents, can induce changes in 
DNA that result in increased survival and proliferation. At least six important alterations 
have been reported to be important for tumor development including self-sufficiency in 
growth signals, evasion of apoptosis, insensitivity to anti-growth signals, limitless 
replication capacity, sustained angiogenesis and an ability to invade other tissues (Hanahan 
and Weinberg, 2000). 
1.5.1 Treatment modalities 
At present, the traditional ways to treat cancers are through surgery, chemotherapy 
or radiotherapy. Combinations of these techniques are often applied to achieve better 
results (Elshaikh, et al., 2006). Several novel therapeutics like gene therapy, 
immunotherapy, angiogenetic compounds and small molecular (kinase) inhibitors, are in 
basic and clinical development. These modalities are aiming to improve target specificity 
and minimise the toxic side effects on normal tissue.  
1.5.1.1 Chemotherapy 
In cancer therapy, chemotherapy includes all chemical drugs that are used in cancer 
treatment. Today, there are several different classes of anticancer substances approved for 
treatment, e.g. DNA-damaging agents, antimetabolites of RNA and DNA synthesis, 
microtubule inhibitors, nucleotide analogues and inhibitors of topoisomerases. In general, 
these therapeutic agents induce a cellular stress response that leads to growth inhibition 
and cell death. Chemotherapeutic drugs generally target fast growing cells, as they are 
more sensitive to DNA damage and cellular stress. Since tumor cells generally have a 
higher growth rate than normal cells, they are more severely affected as compared to 
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normal cells (Herr and Debatin, 2001). Most drugs induce activation of the intrinsic 
apoptotic pathway and altered functions of several Bcl-2 family proteins are important for 
anticancer drug resistance (Daniel, et al., 2003; Igney and Krammer, 2002). In addition, 
several chemical agents have also been clamied to activate the death receptors 
pathway (Debatin and Krammer, 2004), but the extrinsic pathway is generally not 
regarded as  the  major regulator of  drug induced apoptosis in tumor cells (Kaufmann and 
Vaux, 2003; Klopfer, et al., 2004; Scholz, et al., 2005; Wieder, et al., 2001). 
1.5.1.1.1 Taxol 
 Paclitaxel (Taxol), the first taxane in clinical cancer therapy, is active against a broad 
range of cancers that are generally considered to be refractory to conventional 
chemotherapy. In 1963, a crude extract from the bark of the Pacific yew Taxus brevifolia, a 
scarce and slow-growing evergreen found in the old-growth forests of the Pacific Northwest, 
was found in preclinical studies to have cytotoxic activity against many tumors (Wani, et al., 
1971). But only in 1979 paclitaxel’s unique mechanism of action as an antitumor drug was 
identified (Rowinsky and Donehower, 1995). The cytotoxicity of taxol is based on its ability to 
interfere with microtubule dynamics by binding to β-tubulin subunits in microtubules leading 
to inhibition of microtubule disassembly (Horwitz, 1992; Nicolaou, et al., 1994; Pazdur, et al., 
1993). Microtubuli have a significant role during mitosis including the cytoskeleton break 
down and the mitotic spindle apparatus. Taxol operates, however, in all phases of the cell 
cycle. During mitosis star-shaped microtubuli formation is observed and in other cell cycle 
phases microtubuli bundles are formed (Horwitz, 1994; Schiff, et al., 1979). Taxol-induced 
apoptosis at clinically relevant doses may occur either directly after a mitotic arrest or 
following an aberrant mitotic exit into a G1- like multinucleated state (Abal, et al., 2001; 
Jordan, et al., 1993; Jordan, et al., 1996; Lin, et al., 1998; Woods, et al., 1995).  
1.5.1.1.2 Vincristine and nocodazole 
 Vincristine belongs to the family of vinca alkaloids, which was isolated from the leaves 
of the periwinkle plant Catharanthus roseus (L.). Though the leaves of the periwinkle plant 
have been used for their medicinal properties since the seventeenth century, groups both at 
Eli Lilly Research Laboratories and at the University of Western Ontario discovered its cancer 
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chemotherapeutic potential in the late 1950s. Tubulin and microtubules (β-tubulin subunit 
on /β-tubulin) are the main targets of the Vinca alkaloid. Functional studies showed the 
mitotic-blocking action of low Vinca alkaloid concentrations in living cancer cells and 
indicated that the block is due to suppression of microtubule dynamics rather than 
microtubule depolymerization (reviewed(Jordan and Wilson, 2004)). It is used in treatment 
of several cancers including leukaemias, lymphomas, breast and lung cancer. Vincristine was 
found to affect cells at mitotic phase and also in interphase, producing a transient G2 block 
at drug concentrations and drug exposure durations studied. With increasing drug exposure 
duration, the proportion of cells undergoing polyploidy increased progressively (Mujagic, et 
al., 1983). There are interesting evidences showing that knockdown of βII- or βIVb-tubulin 
increases sensitivity to Vinca alkaloids but not the taxanes. (Gan and Kavallaris, 2008).  
 Another drug, nocodazole, is similar to vincristine in its mode of action and binds to β 
subunit of microtubule thereby interfering with microtubule polymerization. Nocodazole 
induced inhibition is readily reversible (Samson, et al., 1979). Nevertheless, treatment of cells 
with nocodazole and other microtubule-interfering agents evokes the activation of stress 
response pathways, cell cycle arrest, and the induction of apoptosis. This accounts for the 




2 Aim of the study 
Burkitt lymphoma is an uncommon but highly aggressive form of non-Hodgkin’s lymphoma 
involving B cells. The rate of cell division in Burkitt’s lymphoma is one of the highest among 
human tumors and often life threatening. It accounts for 40-50% of childhood non-
Hodgkin’s lymphoma. Pediatric lymphomas are high-grade lymphomas that are diffuse and 
aggressive with propensitiy for wide spread dissemination. Unlike adults with NHL, who 
most often present with lymph-node disease, children typically have extranodal disease 
involving the mediastinum (26% of cases), abdomen (31%) or head and neck (29%). 
Pathogenesis of Burkitt's lymphoma is associated with c-Myc translocation and/or Epstein-
Barr virus infection. Notebly, PLK1 a cell cycle check point regulator gene has also begun to 
attract increasing attention as it is overexpressed in variety of human cancers including 
Burkitt lymphomas, and its expression often correlates with poor patient prognosis. The 
general objective of this thesis is to elucidate the molecular apoptosis signalling 
mechanisms that occur during resistance development and Burkitt lymphoma 
treatment in the context of mitosis regulation and ploidy control. 
 
The specific objectives: 
 
 To elucidate molecular mechanisms that are important for resistance development 
in Burkitt lymphomas against microtubule inhibitors induced apoptosis or mitotic 
catastrophe. 
 Role of Bcl-2 family members and caspases in induction of apoptosis and polyploidy 
in Burkitt lymphomas. 
 The contribution of cell cycle checkpoint gene PLK1 to the development of the 





3.1 Inverse relationship between apoptosis and polyploidy in various Burkitt 
lymphoma cells upon microtubule inhibitors treatment 
 To understand the mechanism of cell death induced by anticancer drugs in Burkitt 
lymphomas, 15 different Burkitt lymphoma cell lines were investigated for sensitivity to 
apoptosis with microtubule inhibitors. In this approach, cells were incubated with different 
concentrations of taxol or nocodazole for different periods of time. Apoptosis and polyploidy 
were determined by flow cytometry using a modified cell cycle assay for measurement of 
hypodiploid and hyperploid DNA content. The range of tested concentrations was 1.0 nM to 
1000 nM and time of incubation was 24 to 96 h. For example, BL2 cells showed enhanced 
apoptosis in response to microtubule inhibitor nocodazole and taxol, ranging up to 56% and 
53%, respectively compared to <5% in control cells (Figure 8-panel A). In contrast, other cell 
lines like DG75, nocodazole and taxol treatment induced apoptosis up to 35% and 22%, 
respectively compared to <6% in control cultures in the absence of drug (Figure 8-panel B). 
These variations in apoptosis induction can be attributed to cell type specific phenotypes. 
Similiarly, all the remaining cell lines were treated and analyzed as explained above, (data 
not shown). Taken together the data from the investigated cell lines, it turned out that 100 
nM taxol and nocodazole efficiently induced apoptosis after 72 h of treatment in many cell 
lines. Therefore, this concentration and time point were used as standard conditions 
throughout this study. 
 To determine the effect of taxol, a microtubule stabilizer, 15 different Burkitt 
lymphoma cell lines were incubated for 72 h in the presence or absence of 100 nM taxol.  
Hypodiploid and hyperploid DNA content was measured using flow cytometry to determine 
the percentage of cells undergoing apoptosis or polyploidy. Table 2 gives an overview of p53 
status, Epstein Barr Virus status and translocation associated with each cell line. Taxol 
treatment showed apoptosis sensitivity ranging from 11% (HH514) to 69% (MutuI) as shown 
in Figure 9A and hyperploidy ranging from 1% (BL41 B95-8) to 58% (HH514) as shown in 
Figure 9B. All the cell lines left untreated exhibited less than 10% apoptosis or polyploidy. 
Interestingly, cell lines resistant to apoptosis displayed enhanced hyperploid DNA content, 
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which is considered as polyploidy and vise versa. For instance, 13% of DG75 cells displayed 
apoptosis compared to 45% of cells with polyploidy, whereas 50% of BL2 cells showed 
apoptosis compared to 3.4% cells with polyploidy. These data clearly show that taxol treated 




Figure 8: Microtubule inhibitors taxol and nocodazole induce apoptosis in BL2 and DG75 cells. Cells were 
cultured for 24 h, 48 h, 72 h and 96 h in presence or absence of taxol or nocodazole with concentration ranging 
from 0.1-1000 nM and subjected to flow cytometric analysis of DNA content. (A) BL2 cells with sub-G1 
hypodiploid DNA content were considered apoptotic. (B) DG75 cells with sub-G1 hypodiploid DNA content 
were considered apoptotic. The results represent means ± SD of triplicates 
 
Similarly, the effect of nocodazole, a microtubule destabilizer, was investigated on 15 
different Burkitt lymphoma cell lines. Cells were incubated with or without nocodazole for 
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72 h and analyzed for the percentage of apoptotic and polyploid cells using flow cytometry 
for measurement of hypodiploid and hyperploid DNA content. Nocodazole treatment 
induced a varied percentage of apoptosis (Figure 10A) and hyperploidy (Figure 10B) in 
different cell lines. Similar to taxol treatment, nocodazole treatment also demonstrated 
enhanced polyploidy in cell lines resistant to apoptosis and vice versa. For example, 15% of 
CA46 cells exhibited apoptosis compared to 40% polyploidy. Whereas, 36% of BL2 cells 
showed apoptosis compared to 6% polyploidy, thereby confirming the inverse relationship 
between induction of apoptosis and polyploidy. 
Table 2: Shown are the Burkitt or Burkitt like lymphoma cell lines and their EBV and c-Myc translocation 
status 
BL Cell line EBV status c-Myc translocation 
A1 Positive 
Derived from the EREB2-5 cell line transfected 
with an Ig-c-myc minilocus construct and 
deprived of estrogen 
Akata Positive t(8,14) 
BJAB-BclxL Negative 8q+ 
BJAB-WT Negative 8q+ 
BL like P493-6 Positive 
An EREB2-5-derivative cell line transfected with a 
Tet-off-inducible c-myc vector grown 
continuously in the absence of estrogen and 
tetracycline 
BL2 Negative t(8,22) 
BL29 Positive t(8;14) 
BL41 Negative t(8,14) 
BL41 B95-8 Positive t(8,14) 
BL41-P3HR1 Positive t(8,14) 
BL70 Negative t(8;14), t(12;22) 
CA46 Negative t(8;14) 
DG75 Negative t(8;14) 
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HH514 (Single clone 
of P3HR-1) 
Positive t(8,14) 
Mutu1 Positive t(8;14) 
 
 
Figure 9: Taxol treated burkitt lymphoma cells show an inverse relationship between induction of apoptosis 
and polyploidy. 15 different Burkitt lymphoma cell lines shown in the figure were cultured for 72h in presence 
or absence of 100 nM taxol and subjected to flow cytometric analysis of DNA content. (A) Cells with a sub-G1 
hypodiploid DNA content were considered apoptotic. (B) Cells showing hyperploid (>4N) DNA content were 







Figure 10: Nocodazole treated Burkitt lymphoma cells show an inverse relationship between induction of 
apoptosis and polyploidy. 15 different Burkitt lymphoma cell lines shown in the figure were cultured for 72h in 
presence or absence of 100 nM nocodazole and subjected to flow cytometric analysis of DNA content. (A) Cells 
with a sub-G1 hypodiploid DNA content were considered apoptotic (B) Cells showing showing hyperploid (>4N) 
DNA content were considered polyploid. The results represent means ± SD of triplicates 
 
 To further elucidate the mechanism underlying the inverse relationship between 
induction of apoptosis and polyploidy, four apoptotic sensitive cell lines BL2, BL70, BJAB-WT, 
and BL41 and three apoptosis resistant cell lines BL41-P3HR1, DG75, CA46 were chosen for 
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further experiments. Apoptosis sensitive cell lines are depicted throughout the thesis with 
an underline for better distinguishability from apoptosis resistant cells. 
 
 Figure 11: Taxol and nocodazole induce G2/M arrest leading to either apoptosis or polyploidy in Burkitt 
lymphoma cells. Data shown are from flow-cytometric analysis of cell cycle of the cells cultured for 72 h in 
presence or absence of 100 nM taxol or nocodazole. Linear emission of PI dye from cells was measured and 
percentage hyperploidy (>4N DNA content) was analyzed using MODFIT-LT software.  Left red peak = G0/G1; 
right red peak = G2/M; hatched peak = S; Yellow peak = >4N DNA content; values in red = % of cells in G2/M 
(4N); values in black = % of cells with >4N DNA content. 
 
 To determine the impact of microtubule inhibitors on cell cycle, the selected 7 cell 
lines were incubated for 72 h in presence or absence of taxol and nocodazole respectively 
and assayed for cell cycle distribution and analyzed using MODFIT-LT software. As shown in  
Figure 11, both taxol and nocodazole induced arrest in G2-M phase of the cell cycle in 
apoptotic sensitive cells, compared to untreated control cells. Whereas, in apoptotic 
resistant cells, they induced enhanced polyploidy (>4N DNA content) in addition to G2-M cell 
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cycle arrest. Specifically, nocodazole treatment induced polyploidy to a greater extent. For 
example, up to 85% in DG75 cells compared to 28% in taxol treated cells. Although there is a 
difference in the extent of polyploidy induction between nocodazole and taxol treatment, 
both these microtubule inhibitors promote induction of polyploidy. This implies that BL cells 
undergo either apoptosis or polyploidy following G2/M cell cycle arrest upon treatment with 




Figure 12: Vincristine induces G2/M arrest leading to apoptotic DNA fragmentation but not polyploidy in 
apoptotic resistant Burkitt lymphoma cells. Indicated cell lines were cultured for 72 h in presence or absence 
of 100 nM vincristine and subjected to flow cytometric measurement of DNA content. (A) Cells with sub-G1 
hypodiploid DNA content were considered apoptotic. The results represent means ± SD of triplicates. (B) 
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Percentage hyperploidy (>4N DNA content) was analyzed using MODFIT-LT software. Left red peak = G0/G1; 
right red peak = G2/M; hatched peak = S; Yellow peak = >4N DNA content; values in red = % of cells in G2/M 
(4N); values in black = % of cells with >4N DNA content. 
 
3.2 Vincristine treatment does not induce polyploidy implying different cell 
death mechanism compared to that of taxol and nocodazole  
 Vincristine a ‘microtubule destabilizer’ is known as a better chemotherapeutic drug 
for treatment of Burkitt lymphomas than taxol or nocodazole. To investigate the basis of its 
action, the 7 chosen Burkitt lymphoma cell lines were incubated for 72 h in the presence or 
absence of vincristine. Apoptosis was determined by measurement of hypodiploid DNA 
content using flow cytometry. Similar to taxol and nocodazole, vincristine treatment showed 
varied percentages of apoptosis in different cell lines ranging between 14% (DG75) and 72% 
(BL2) as shown in Figure 12A. All the cell lines left untreated displayed less than 10% 
apoptosis. In cells similarly treated, when analyzed for cell cycle distribution, the 
accumulation of G2/M cell population was observed. Surprisingly, apoptosis resistant cells 
did not show enhanced hyperploidy as shown in Figure 12B. This is in contrast to taxol or 
nocodazole treated cells. This implies that vincristine has a different mechanism of cell death 
induction as compared to taxol and nocodazole. 
3.3 Microtubule inhibitors induce endoreduplication during mitosis leading to 
enhanced ploidy in apoptosis resistant cell lines 
 It is clear from the above results that microtubule inhibitors induce cell cycle arrest in 
the G2/M phase of the cell cycle. However, it is unclear, whether the cells are arrested in G2 
or mitotic phase of cell cycle. It is possible that microtubule inhibitor treatment specifically 
induces aberrant mitosis in Burkitt lymphoma cells. To investigate this possibility, 
nocodazole, taxol or vincristine treated cells were examined by MPM2 staining against 
mitosis-specific phosphoepitopes and analyzed for MPM2 positive cells by flow cytometry. 
As shown in Figure 13A, treatment with microtubule inhibitors induced enhanced 
accumulation of a mitotic cell population in all cell lines. For example, up to 60% of cells 
showed mitotic accumulation in taxol-treated DG75 cells by 24 h. However, at this time 
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point there was very little effect on induction of polyploidy in most of the cell lines 
examined. This is similar to <10% of untreated control cells with polyploidy, except for a 




Figure 13: Microtubule inhibitors induce mitotic arrest in Burkitt lymphoma cells. Indicated cell lines were 
cultured for 24h in presence or absence of 100 nM nocodazole, taxol or vincristine (A) Cells were stained with a 
fluorescein isothiocyanate (FITC)-labeled MPM2 antibody. Bi-variate analysis of DNA content (propidium 
iodide) and MPM2 positive staining was performed. Data are presented as percent of mitotic cells from the 
total cell population. (B) Percentage of mitotic cells showing hyperploid (>4N) DNA content and were 




 Intriguingly, only apoptosis resistant cells continued to be accumulated in the mitotic 
phase of the cell cycle for prolonged time periods of up to 72 h. For instance, nocodazole 
treated DG75 cells exhibited a maximum mitotic index of up to 44% (Figure 14A). In contrast, 
apoptosis sensitive cell lines did not show mitotic accumulation. This is comparable to that 
of control or untreated cells (<10%) indicating that mitotic arrest is followed by apoptosis 
only in apoptosis sensitive cells.  
 
 
Figure 14: Microtubule inhibitors induce prolonged mitotic arrest and trigger polyploidy in apoptosis 
resistant Burkitt lymphoma cells. Indicated cell lines were cultured for 72 h in presence or absence of 100 nM 
nocodazole, taxol or vincristine (A) Cells were stained with a fluorescein isothiocyanate (FITC)-labeled MPM2 
antibody. Bi-variate analysis of DNA content (propidium iodide) and MPM2 positive staining was performed. 
Data represented as percent of mitotic cells from the total cell population. (B) MPM2 positive cells showing 




 Since the apoptosis resistant cells exhibited enhanced polyploidy after nocodazole or 
taxol treatment, it’s befitting to verify if the enhanced ploidy is a result of endoreduplication, 
a mechanism involving chromosomal DNA replication without intervening mitosis or 
cytokinesis, leading to an increase in the ploidy level. In this regard, positive cells for MPM2, 
an antibody recognising mitotic phosphoepitopes, were gated and cells exhibiting polyploid 
DNA content were analyzed by flow cytometry. Most of the cells positive for MPM2 (Figure 
14A) displayed polyploid DNA content (Figure 14B). For instance, nocodazole treatment 
showed 43% of DG75 cells in mitotic phase. Interestingly, 37% of nocodazole treated DG75 
cells showed both MPM2 positive and hyperdiploid DNA content. These data suggests that, 
cells resistant to the microtubule inhibitors nocodazole and taxol undergo endoreduplication 
leading to an increase in ploidy level and this event of endoreduplication is happening at the 






Figure 15: Loss of cell viability is not associated with immediate cell death in microtubule inhibitors induced 
apoptosis resistant Burkitt lymphoma cells. Cells were cultured for 72 h in presence or absence of 100 nM 
nocodazole, taxol or vincristine (A) Cell death measurement by PI uptake. Cells were stained with PI and% PI 
positive (dead) cells were measured by flow cytometry. (B) Cell viability measurement by colorimetric XTT 
assay. The viability of treated cells is expressed relative to that of untreated cells, which were set to 1. The 
results represent means ± SD of triplicates. 
 
However with vincristine treatment, apoptosis resistant cells showed prolonged mitotic 
arrest for up to 72 h but displayed no sign of enhanced polyploid DNA content in mitotic cell 
population compared to control cells. This suggests that vincristine fails to induce 
endoreduplication and this is in contrast to nocodazole and taxol. 
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3.4 Mitotic catastrophe is not associated with immediate cell death 
 To verify if cells resistant to microtubule inhibitors would undergo other means of 
cell death or growth inhibition, cells were incubated in the presence or absence of 
nocodazole, taxol or vincristine for 72 h. Induction of cell death was confirmed by propidium 
iodide (PI) uptake by flow cytometric analysis. As shown in Figure 15A, apoptosis sensitive 
cells showed enhanced PI uptake. Microtubule inhibitors induced PI uptake ranging between 
46% and 97%, representing the dying cells, compared to < 10% in untreated cells. In 
contrast, there was no enhanced PI uptake in apoptosis resistant cells upon microtubule 
inhibitor treatment, compared to that of untreated cells. To check the proliferative ability 
after microtubule inhibitor treatment, cells were subjected to a XTT cell proliferation assay 
and analyzed for relative cell viability. Untreated control cells were normalized to 1. Highly 
decreased cell viability was observed in all cell lines treated with microtubule inhibitors, 
irrespective of their sensitivity (Figure 15B), suggesting a prominent loss of cell proliferative 
ability in presence of microtubule inhibitors in all cell lines tested. 
3.5 Taxol induced loss of viability is irreversible 
 To investigate if microtubule inhibitor induced loss of viability can be rescued, cells 
were incubated in the presence or absence of taxol. After 72 h of incubation the cells were 
washed and resuspended in a drug free medium for another 72 h and analyzed for cell 
viability by XTT cell proliferation assay. Taxol treated cell population demonstrated reduction 
in viability relative to that of cells untreated for 72 h, which was set to 1. Interestingly, cells 
that were rescued from taxol treatment did not show restoration of viability (Figure 16A). To 
confirm the above result, cells were treated in a similar way and analyzed for cell viability by 
trypan blue exclusion. As shown in Figure 16B, treated cells failed to recover and proliferate 
even after reculturing them in taxol free medium for 72 h, thereby implying that the effect of 





Figure 16: Loss of cell viability in Burkitt lymphoma cells is irreversible. Cells were cultured for 72h in presence 
or absence of 100 nM taxol. Cells were then washed and cultured in medium without taxol for an additional 72 
h. (A) Cell viability was determined by colorimetric XTT assay. The viability of treated cells was expressed 
relative to that of untreated cells cultured, which were set to 1. (B) Cell viability was also determined by trypan 
blue exclusion assay. The results represent means ± SD of triplicates. 
3.6 Taxol induced caspase activation 
 To unravel the apoptotic signalling pathway triggered by microtubule inhibitors, cells 
were treated with taxol or left untreated (control) for 24 h and 48 h time periods. Western 
blot analysis was performed to assess processing of individual procaspases (9, 3, and 8), and 
the caspases-3 and -8 substrate Bid, a known activator of mitochondrial apoptosis. Taxol 
induced caspases-9, -3, and -8 processing by 24 h (Figure 17A) and even more by 48 h (Figure 
17B) in apoptosis sensitive cell lines. Cleavage of caspases-9, -3, and -8 was inhibited in cells 
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resistant to taxol-induced apoptosis, which may be interpreted as a lack of signals for 
caspase processing as measured by western blot analysis. Caspase processing was paralleled 
by a reduction in Bid protein levels after exposure to taxol. However this reduction in the Bid 
proform upon taxol treatment was observed in both apoptosis sensitive and resistance cell 





Figure 17: Taxol induces caspase processing in apoptosis sensitive but not in resistant Burkitt lymphoma 
cells. Indicated cell lines were cultured in presence or absence of 100 nM taxol and lysates were subjected to 
immunoblot analysis for Bid, and cleavage of caspase-9, -3 and -8. (A) 24 h treated cells (B) 48 h treated cells. 
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Molecular masses are indicated at the left. C = control or untreated cells and T= taxol treated cells. -actin was 
used as a loading control. 
 Detection of caspase-9 p35 subunit or caspase-3 p17 and p12 subunits indicates 
cleavage of the zymogen to their active form. Further, caspase-9 and -3 activity was 
confirmed by flow cytometric analysis. To study this, the substrates FAM-LEHD-FMK and 
FAM-DEVD-FMK were used to assay caspase-9- and -3-like activity, respectively, in cells 
treated with nocodazole, taxol or vincristine for 48 h. Caspase-9 (Figure 18A) and caspase-3 
activity (Figure 18B) were detected. This confirmed the previous observations that taxol 
induces apoptosis through caspase activation in apoptosis sensitive cell lines but not in 
resistant cell lines. 
 
Figure 18: Taxol induces caspase like activity in apoptotic sensitive but not in resistant Burkitt lymphoma 
cells. Flow cytometric analysis of cells with increased Caspase-9- and -3-like activity after culturing for 48 h in 
presence or absence of 100 nM taxol, nocodazole or vincristine, respectively (A) Caspase-9-like activity using 
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FAM-LEHD-FMK substrate (B) Caspase-3-like activity using FAM-DEVD-FMK substrate. The results represent 
means ± SD of triplicates. 
3.7 Taxol induced cell death is p53 independent 
Exposure to cellular stress can trigger the p53 tumor suppressor, a sequence-specific 
transcription factor, to induce cell growth arrest and apoptosis. It is known that cell death 
induced through the p53 pathway is executed by the caspase proteases, which, by cleaving 
their substrates, lead to the characteristic apoptotic phenotype. In connection to earlier data 
showing caspase activation in apoptotic sensitive cell lines, it is befitting to check for p53 in 
taxol induced apoptosis and polyploidy.  
Table 3: Showing the EBV, p53 and type of p53 mutations associated with each cell line. WT: Wild type; (SM): 
Single mutation; (DM): Double mutation; (-): Negative; (+): Positive 
Burkitt Lymphoma EBV p53 Mutation Sequence 
BL2 - WT  
BL70 - Mutant R273C (SM) 
Bjab WT - Mutant H193R (SM) 
BL41 - Mutant R248Q (SM) 
BL41-P3HR1 + Mutant Y163H, E287Stop 
(DM) 
DG75 (B Cell Line) - Mutant R283H (SM) 
CA46 - Mutant R248Q (SM) 
 
Table 3 gives an overview of p53 status, type of p53 mutations and Epstein Barr Virus status 
associated with each cell line. Cells were treated (T) or left untreated (C) with taxol for 24 h 
and 48 h and the cell lysates were analyzed for p53 by immunoblotting. Wildtype p53 is 
undetectable due to its rapid turnover in basal conditions and activation of p53 or 
mutation(s) in p53 involve its stabilization, which can be detected by immunoblotting. 
Apoptosis sensitive cell line BL2, having wild type p53 did not show stabilization of p53 after 
taxol treatment (Figure 19A). A similar response was observed as well at 48 h after taxol 
treatment (Figure 19B). This indicated that p53 is not involved in taxol-induced apoptosis. 
Moreover, cell lines with mutated p53 displayed distinct behaviour either exhibiting 
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sensitivity or resistance to taxol induced apoptosis. This clearly indicated lack of correlation 




Figure 19: Regulation of p53 in Burkitt lymphoma cells upon taxol treatment. Indicated cells lines were 
cultured in presence or absence of 100 nM taxol and lysates were subjected to immunoblot analysis for p53. 
(A) 24 h treated cells (B) 48 h treated cells. C = control or untreated cells and T= taxol treated cells. -actin was 
used as a loading control. 
3.8 Lack of Bax and Bak can be the cause of apoptosis resistance to taxol in 
Burkitt lymphomas 
 Bax and Bak constitute an essential apoptosis gateway specifically operating at the 
mitochondria to regulate the intrinsic apoptotic pathway. To further investigate the role of 
Bax and Bak behind these discrete phenotypes (Apoptosis sensitivity and resistance) to taxol, 
cells were treated with taxol (T) or left untreated (C) for 24 h and 48 h. The cell lysates were 
analyzed for Bak and Bax protein expression by immunoblotting. As shown in Figure 20A and 
B, cell lines showing induction of apoptosis to taxol treatment are Bax and Bak proficient, 
whereas cell lines highly resistant to apoptosis induced by taxol treatment lack Bax and have 
very low Bak protein expression levels. However, BL41-P3HR1 cell line is an exception 
showing Bax and Bak proficiency. This can be justified by its EBV positive status carrying 
latent P3HR1 virus (and express only EBNA1), which is associated with conferring apoptosis 
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resistance and genomic instability. Bax protein level was reduced upon treatment with taxol, 
possibly due to proteolytic cleavage, which is known to enhance cell death function at the 
mitochondria. In conclusion, Bax and Bak appear to be involved in taxol-induced apoptosis 
since a loss or reduction of Bax or Bak in DG75 and Ca45 cells seems to be associated with 




Figure 20: Apoptosis resistance Burkitt lymphomas DG75 and CA46 lack Bax and show low Bak protein 
expression. Indicated cell lines were cultured in presence or absence of 100 nM taxol and lysates were 
subjected to immunoblot analysis for Bax and Bak. (A) 24 h treated cells (B) 48 h treated cells. Molecular 
masses are indicated at the left. C = control or untreated cells and T= taxol treated cells. -actin was used as a 
loading control. 
3.9 Role of pro-apoptotic BH3-only proteins in taxol induced cell death 
 Since Bax and Bak seemed to be crucial regulators of taxol mediated cell death, 
deciphering the regulation of BH3-only proteins, (which play a key role in sensing apoptotic 
stimuli and initiating apoptosis by activation of Bax or Bak) may provide the basis of taxol 
mediated cell death. To investigate the role of BH3-only proteins, cells were treated (T) or 
left untreated (C) with taxol for 24 h and 48 h and cell lysates were analyzed for BH3-only 
proteins Noxa, Bim, Puma and Nbk by immunoblotting. Surprisingly, most of the BH3 protein 
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expression levels analyzed decreased after treatment with taxol by 24 h time point except 
Puma, which was differently regulated depending on the cell line (Figure 21A). Further, 
similar response was shown at 48 h time point (Figure 21B). Downregulation of BH3-only 
proteins might be a survival mechanism of cells to counteract taxol-induced apoptosis. 
 
 
Figure 21: Taxol induces downregulation of proapoptotic BH3-only proteins in Burkitt lymphoma cells. 
Indicated cell lines were cultured in presence or absence of 100 nM taxol and lysates were subjected to 
immunoblot analysis of Noxa, Bim, Puma and Nbk (A) 24 h treated cells (B) 48 h treated cells. Molecular masses 




3.10 Taxol induces downregulation of the anti-apoptotic Bcl-2 family protein 
Mcl-1  
Since BH3-only proteins are not regulated in taxol-induced apoptosis, it is interesting to 
examine whether modulation of pro-survival proteins is involved in taxol-induced cellular 
death. In this regard, cells were treated with taxol (T) or left untreated (C) for 24 h and 48 h 
and cell lysates were analyzed for antiapoptotic proteins Bcl-xL and Mcl-1 expression by 
immunoblotting. Most of the cell lines showed no effect on Bcl-xL expression upon taxol 
treatment except for BL41 and CA46 cell lines with a slight downregulation, which might be a 
cell type specific consequence. In contrast, the Mcl-1 protein level was decreased by 24 h 
(Figure 22A) and grossly reduced by 48 h (Figure 22B) after treatment with taxol. These 
results suggest that taxol induces downregulation of Mcl-1, thereby disengaging the pro-
apoptotic proteins t-Bid and Bak to execute apoptosis. However, dowregulation of Mcl-1 is 
observed in both apoptosis sensitive and resistant cell lines, indicating that Mcl-1 is not 
involved in apoptosis resistance and polyploidy induction. 
 
 
Figure 22: Taxol induces down-regulation of the anti-apoptotic BH3 only protein Mcl-1 in Burkitt lymphoma 
cells. Indicated cell lines were cultured in the presence or absence of 100 nM taxol and lysates were subjected 
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to immunoblot analysis of Bcl-xL and Mcl-1 (A) 24 h treated cells (B) 48 h treated cells. Molecular masses are 
indicated at the left. C = control or untreated cells and T= taxol treated cells. -actin was used as a loading 
control. 
 Taken together, these results indicated that taxol activates profound mitochondria-
dependent death events by 24 h - 48 h. Upstream apoptotic regulators Bid and Mcl-1 seem 
to be regulated in both apoptosis resistant and sensitive cell lines, indicating that they are 
important for apoptosis induction but not for conferring resistance and induction of 
polyploidy. However, Bax and Bak play an important role in apoptosis resistance as taxol 
failed to induce caspase activation in cell lines without Bax and with weak expression of Bak. 
3.11 Taxol induced apoptosis is Bax and Bak dependent 
 It is evident from earlier data that lack of Bax and Bak leads to apoptosis resistance 
upon taxol treatment. To confirm whether taxol induced apoptosis exclusively depends on 
Bax and Bak proficiency and represents the deciding factor for polyploidy induction, FDM-
WT, FDM-bax-/- and FDM-bak-/- and FDM bax/bak-/- cells, respectively were incubated with 
different concentrations of taxol ranging from 1-100 nM for 24 h to 96 h. Hypodiploid DNA 
content was measured by flow cytometry to determine apoptosis induction. Taxol treatment 
resulted in enhanced apoptosis reaching up to 65% in FDM-WT cells (Figure 23A) by 96 h. 
There was little inhibition of apoptosis reaching up to 54% and 46% in FDM-bax-/- and FDM-
bak-/- cells respectively, proving their functional redundancy (Figure 23C-D). In contrast, 
bax/bak double knock out FDM cells were highly resistant to apoptosis, irrespective of taxol 
concentration and duration of treatment (Figure 23B).  
 Treatment of cells with 100 nM taxol for 72 h was chosen to further analyze the 
correlation between induction of apoptosis and polyploidy using flow cytometry. FDM-WT, 
FDM-bax-/- or FDM-bak-/- cells exhibited enhanced apoptosis (upto 55% of cells) as shown in 
Figure 24A, but not polyploidy (<8% of cells) upon taxol treatment (Figure 24B). In contrast, 
FDM bax/bak-/- cells were highly resistance to apoptosis, with less than 5% of cells 
undergoing apoptosis. Interestingly, 28% of FDM bax/bak-/- cells showed enhanced 
polyploidy (Figure 24A-B). Thereby, confirming the inverse correlation between apoptosis 

















 cells were cultured with different concentrations of taxol 
for24 - 96 h as depicted and subjected to flow cytometric analysis of DNA content. Cells with a sub-G1 
hypodiploid DNA content were considered apoptotic. (A) Taxol-induced apoptosis in FDM-WT cells (B) Taxol-
induced apoptosis in FDM- bak/bax
-/-
 (C) Taxol-induced apoptosis in FDM-bax
-/-
 (D) Taxol-induced apoptosis in 
FDM-bak
-/-
















Figure 24: Taxol induces apoptosis in WT, bax or bak deficient but leads to polyploidy in bax/bak double 






 cells were cultured for 72 h in the 
presence or absence of 100 nM taxol and subjected to flow cytometric measurement of DNA content. (A) Cells 
with a sub-G1 hypodiploid DNA content were considered apoptotic. (B) Cells showing hyperploid (>4N) DNA 
content were considered polyploid. (C) Representative DNA histograms for 100 nM taxol-induced genomic DNA 
fragmentation and polyploidy histograms (in black) overlayed with control histograms (in red). Percentages of 




3.12 Individual pro-apoptotic BH3-only proteins have no impact on taxol 
induced apoptosis in FDM cells 
 To investigate whether the loss of function of various pro-apoptotic BH3-only 
proteins in FDM cells have an impact on taxol induced cell death, FDM cells with knockout of 
puma, bim, bid and noxa, respectively were incubated with different concentrations of taxol 
ranging from 0 to 100 nM for 72 h and 96 h. Apoptosis was determined by flow cytometry 
using a modified cell cycle assay for measurement of hypodiploid DNA content. Taxol 
treatment induced apoptosis reaching up to 65% in FDM-WT cells (Figure 23A) at 96 h. But 
none of the taxol treated proapoptotic BH3-only protein knockout cells showed a decrease 
in apoptosis induced by taxol treatment (Figure 25A-D). These results suggest that individual 







Figure 25: Taxol induces apoptosis but fails to induce polyploidy in bid, bim, noxa, puma deficient and wild 








 cells were cultured with different 
concentrations of taxol for different durations as depicted and subjected to flow cytometric analysis of DNA 
content. Cells with a sub-G1 hypodiploid DNA content were considered apoptotic. (A) Taxol induced apoptosis 
in FDM-puma
-/-
 cells (B) Taxol induced apoptosis in FDM- bim
-/-





 cells. The results represent means ± SD of triplicates. 
 
 Treatment of cells with 100 nM taxol for 72 h was chosen to further analyze 
induction of polyploidy in relation to apoptosis. Cells were incubated for 72 h in the 
presence or absence of 100 nM taxol and induction of apoptosis and polyploidy were 
determined by flow cytometry. As shown in Figure 26A, FDM WT exhibited enhanced 
apoptosis and cells deficient for bid, bim, noxa and puma, respectively, did not show a 
reduction in apoptosis induction. Besides, these cells did not show an enhanced hyperploid 
DNA content (Figure 26B & C), confirming earlier data that apoptosis sensitive cells show no 






Figure 26: Taxol induces apoptosis but fails to induce polyploidy in WT, bid, bim, noxa and, puma deficient 








, cells were cultured for 72 h in the 
presence or absence of 100 nM taxol and subjected to flow cytometric analysis of DNA content. (A) Cells with a 
sub-G1 hypodiploid DNA content were considered apoptotic. (B) Cells showing a hyperploid (>4N) DNA content 
were considered polyploid. (C) Representative DNA histograms for 100 nM taxol-induced genomic DNA 
fragmentation histograms (in black) overlayed with control histograms (red). Percentages of apoptotic cells are 
given in the histograms for taxol treated cells. The results represent means ± SD of triplicates. 
3.13 Apoptosis induced by the microtubule inhibitors is caspase dependent and 
inhibition of caspase activity leads to polyploidy 
 To preclude the possibility of a caspase independent induction of cell death, cells 
were preincubated with the pan-caspase inhibitor Q-VD-OPh for 2 h prior to taxol treatment. 
Burkitt lymphoma cells were harvested after 72 h of taxol treatment and apoptosis was 





Figure 27: Inhibition of caspase activity leads to decreased induction of apoptosis and enhanced polyploidy in 
taxol treated Burkitt lymphomas cells. Indicated cell lines were cultured for 72 h in presence or absence of 100 
nM taxol and/or 10 µM pan-caspase inhibitor Q-VD-OPh and subjected to flow cytometric analysis of DNA 
content. Control indicates the cells cultured in medium with out microtubule inhibitor treatment. (A) Cells with 
sub-G1 hypodiploid DNA content were considered apoptotic. (B) Cells showing hyperdiploid (>4N) DNA content 
are considered polyploidy. Asterisks indicate statistical significance calculated using Student's t test (p < 0.05). 
The results represent means ± SD of triplicates. 
 
The pan-caspase inhibitor Q-VD-OPh inhibited apoptosis in the apoptotic sensitive cells. For 
example, in BJAB-WT cells apoptosis was reduced from 39% to 24%, which accounts to a 
39% reduction (Figure 27A). There was little or no effect in apoptosis resistant cells. When 
analyzed for hyperploid DNA content, most of the cell lines sensitive to apoptosis induced by 
taxol, incited polyploidy. The stongest effect was seen in BJAB-WT cells where up to 35% 
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displayed polyploidy when apoptosis was inhibited by pan-caspase inhibitor Q-VD-OPh 
compared to 2% of cells with taxol treatment alone (Figure 27B). Similarly, other apoptotic 
sensitive cell lines also displayed enhanced polyploidy after inhibition of caspase for which 
significance was calculated, indicating that deregulation of caspase activation can trigger 
polyploidization upon culture in the presence of microtubule inhibitors. 
 To verify whether nocodazole treatment also incites polyploidy in the presence of a 
pan-caspase inhibitor as observed in taxol treated cells, cells were preincubated with the 
pan-caspase inhibitor Q-VD-OPh for 2 h prior to nocodazole treatment. Cells were harvested 
after 72 h of nocodazole treatment and apoptosis was determined using flow cytometry. The 
pan-caspase inhibitor Q-VD-OPh inhibited apoptosis to a large extent in apoptosis sensitive 
cells. For example, in BJAB-WT cells apoptosis was reduced from 36% to 20%, which 
accounts to a 44% reduction (Figure 28A). Caspase inhibition had little effect on apoptosis 
resistant cells similar to the observations made with taxol treatment. Whereas, inhibition of 
nocodazole-induced apoptosis by pan-caspase inhibitor triggered cells to undergo 
polyploidy. The strongest effect was seen again in BJAB-WT cells where 45% showed 
polyploidization when treated with nocodazole and pan-caspase inhibitor Q-VD-OPh as 
compared to 2% in cells with nocodazole treatment alone (Figure 28B). This clearly indicates 
that taxol and nocodazole induce apoptosis in a caspase dependent manner and inhibition of 
caspase activity leads to polyploidization. This implies that apoptosis might serve as a fail-







Figure 28: Inhibition of caspase activity leads to decreased induction of apoptosis and promotes polyploidy in 
nocodazole treated Burkitt lymphoma cells. Indicated cell lines were cultured for 72 h in presence or absence 
of 100 nM nocodazole and/or 10 µM pan-caspase inhibitor Q-VD-OPh and subjected to flow cytometric analysis 
of DNA content. Control indicates the cells cultured in medium with out microtubule inhibitor treatment. (A) 
Cells with sub-G1 hypodiploid DNA content were considered apoptotic. (B) Cells showing hyperdiploid (>4N) 
DNA content are considered polyploid. Asterisks indicate statistical significance calculated using Student's t test 
(p < 0.05). The results represent means ± SD of triplicates. 
 
 It is interesting to know what happens in cells treated with vincristine and a pan-
caspase inhibitor, as vincristine did not promote polyploidy in cells resistant to apoptosis as 
shown in Figure 11A-B. Cells were treated similarly with the pan-caspase inhibitor Q-VD-OPh 
and vincristine and subjected to flow cytometric analysis of apoptosis and polyploidy. A 
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decrease in apoptosis induced by vincristine treatment was observed, when cells were 
additionally incubated with the pan-caspase inhibitor Q-VD-OPh. For example, in BJAB-WT 
cells apoptosis was reduced form 51% to 30%, which accounts to a 42% reduction (Figure 
29A), similar to the observations made with taxol and nocodazole treatment. However, less 
than 3% cells showed polyploidy induction upon caspase inhibition and vincristine treatment 
(Figure 29B), which is in contrast to taxol and nocodazole treatment. This further confirms 
earlier results, that vincristine fails to induce polyploidy.  
 
 
Figure 29: Inhibition of caspase activity leads to decreased induction of apoptosis and does not induce 
polyploidy in vincristine treated Burkitt lymphomas. Indicated cell lines were cultured for 72 h in presence or 
absence of 100 nM vincristine and/or 10 µM pan-caspase inhibitor Q-VD-OPh and subjected to flow cytometric 
analysis of DNA content. Control indicates the cells cultured in medium with out microtubule inhibitor 
treatment. (A) Cells with sub-G1 hypodiploid DNA content were considered apoptotic. (B) Cells showing 
hyperdiploid (>4N) DNA content are considered polyploid. The results represent means ± SD of triplicates. 
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3.14 Caspase-8 plays an important role in taxol induced apoptosis 
To test if caspase-8 inhibition abrogates taxol induced cell death, cells were incubated for 2 h 
with caspase-8 fmk inhibitor z-IETD-fmk prior to taxol treatment. Cells were harvested after 
72 h and analyzed for apoptosis. Taxol sensitive cells showed reduced apoptosis as 
compared to the control untreated cells, when analyzed for hypodiploid DNA using modified 
a cell cycle assay. For example, in BJAB-WT cells apoptosis was reduced from 46% to 24%, 
which accounts to a 48% reduction (Figure 30). This supports the possibility of caspase-8 




Figure 30: Caspase-8 inhibition represses apoptosis induced by taxol in Burkitt lymphoma cells. Indicated cell 
lines were cultured for 72 h in presence or absence of 100 nM taxol and/or 20 µM caspase-8 inhibitor and 
subjected to flow cytometric analysis of DNA content. Control indicates the cells cultured in medium with out 
microtubule inhibitor treatment. Cells with sub-G1 hypodiploid DNA content were considered apoptotic. The 











 Understanding the relation between cell cycle deregulation and induction of 
apoptosis by microtubule inhibitors is crucial for improving therapy and consequently 
improving the prognosis of cancer patients. Polo like kinase which is involved in G2/M cell 
cycle checkpoint regulation and known to be upregulated in most of the cancers, was used 
to deregulate mitotic cell cycle checkpoint control by ectopic over-expression of PLK1 (Polo 
like kinase 1), PBD (Polo box domain of PLK1) and KD (Kinase domain of PLK1). The aim was 
to investigate if manupulation of PLK1 has any added benefit to chemotherapy in aggressive 




Figure 31: Illustration depicts the structure of PLK1 and its mutants cloned for the intended study 
 
 In this approach, the open reading frames of PLK1, PBD and KD were cloned into 
inducible mammalian expression plasmid pRTS-1. pRTS-1 is a novel, EBV-derived episomally 
replicating plasmid that carries all the elements for conditional expression of a gene of 
interest via Tet regulation (Georg W. Bornkamm et al.). The vector is characterized by low 
background activity and high inducibility in the presence of tetracycline (tet) or doxycycline 
(Dox). The gene of interest is expressed from the bidirectional promoter Ptetbi-1 that allows 
simultaneous expression of two genes, of which one may be used as surrogate marker like 
GFP for the analysis of expression of the gene of interest. Tight downregulation is achieved 
through binding of the silencer tTSKRAB to Ptetbi-1 in the absence of Dox. Addition of Dox 
releases repression and, via binding of rtTA2S-M2, activates Ptetbi-1. Similar cloning efforts 
were made before hand in pcDNA3 and an adeno associated viral (AAV) construct. Due to 
the low and, incase of AVV, cell line variable low transfection and transduction efficiency, 
these experiments were abandoned in favour of pRTS-1. 
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3.15 Induction of apoptosis upon deregulation of PLK1 function in Burkitt 
lymphomas 
 CA46, BL41, BJAB cells were transfected with PLK1, PBD and KD, respectively by 
electroporation and the transfectants were selected in presence of hygromycin 
concentration respectively for 4 weeks. These cells were checked for overexpression of PLK1 
using an anti-PLK1 antibody and PBD, KD with c-Myc antibody by immunoblotting. Figure 
32A depicts the overexpression of PLK1, c-Myc tagged PBD and c-Myc tagged KD in CA46 
Burkitt lymphoma cells after incubating cells in presence of doxycycline for 24 h, 48 h and 72 
h. Only the respective transfectants showed overexpression but not the mock transfected 
cells confirming the functionality of the cell lines.  
 To assess if deregulation of PLK1 function would lead to induction of apoptosis, BL41 
transfectants were induced to overexpress PLK1, PBD, KD for different time points as 
indicated in Figure 32B. Apoptosis was determined by flow cytometry using a modified cell 
cycle assay for measurement of hypodiploid DNA content in the GFP positive cells, which 
were also considered positive for the gene expression. Only GFP positive cells were gated 
due to lack of 100% positive transfectants, which can be ascribed to few untransfected cells 
resistant to hygromycin selection and their overgrowth with time compared to positive 
transfectants. PLK1, PBD or KD overexpression did not induce enhanced apoptosis in BL41 
cells when compared to mock transfectants, Of note, there was slight induction of apoptosis 
up to 10% at 48 h time point in BL41 cell line upon PBD overexpression compared to <2% of 
control cells. 
 To verify, if the observations made in BL41 cells overexpressing PLK1, PBD, KD or 
mock are ubiquitous among Burkitt lymphoma cells, CA46 and BJAB transfectants were 
induced to express PLK1 or the mutants and were analyzed for the apoptosis at the indicated 
time points as shown in Figure 32C-D. Apoptosis was determined by flow cytometry using a 
modified cell cycle assay for measurement of hypodiploid DNA content in GFP positive cell 
population. Similar to earlier observation in BL41 cells, CA46 and BJAB transfectants did not 
induce high levels of apoptosis upon overexpression of PLK1, KD, and PBD. This implies that 







Figure 32: Ectopic overexpression of PLK1, PBD and KD respectively failed to induce high rates of apoptosis in 
BL41, BJAB and CA46 cells. BL41, BJAB and CA46 cells were transfected with pRTS-1 plasmid carrying PLK1, PBD 
or KD respectively and empty vector as control. Cells were cultured for indicated time points in the presence of 
doxycycline (Dox) to induce expression. (A) Immunoblot analysis of PLK1, PBD and KD expression levels in 
different CA46 cells. GFP positive cells were gated which are also considered positive for PLK1, PBD or KD 
expression and the gated population were analyzed for DNA fragmentation for indicated time points (B) in 
CA46 cells (C) in BL41 cells and (D) in BJAB cells. Cells with sub-G1 hypodiploid DNA content were considered 
apoptotic. Data shown are means ± SD of triplicates. 
 
3.16 PLK1 deregulation leads to G2/M cell cycle arrest, while PLK1 
overexpression promotes cell cycle progression 
 Combinatorial drug therapy is a treatment paradigm that has proved to be effective 
in cancer. Towards this approach and to determine the function of PLK1 in taxol-induced 
apoptosis and ploidy control, the effect of PLK1, KD or PBD and in combination with taxol on 
cell cycle distribution was analyzed. The respective BL41 transfectants were cultured in the 
presence of doxycycline. After 24 h of induction, GFP positive cells were sorted by FACS. 
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These cells were then treated for 24 h and 48 h with taxol and were assayed for cell cycle 
distribution. Time points shown in Figure 33A are total time of treatment starting from initial 
induction of cells with doxycycline. As shown in Figure 33A, overexpression of PLK1 showed 
a slight increase in the G2/M cell population to 19.0% and 25.2% compared to 6.5% and 
19.8% in mock cells by 48 h and 72 h, respectively. It was shown Figure 11 and Figure 33 that 
taxol induces accumulation of cells in the G2/M phase. Overexpression of PLK1 in addition to 
taxol treatment showed, however, a reduction of G2/M phase arrested cells accounting to 
35.2% by 48 h and 64.4% by 72 h compared to 63.0% and 81.1% in taxol treated mock cells.  
 
 
Figure 33: Overexpression of PLK1 leads to reduction in taxol-mediated G2/M arrested cell population. BL41 
cells transfected with mock, PLK1, PBD or KD were induced with doxycyclin for 24 h and GFP positive cells were 
FACS sorted. These sorted cells were cultured for 48 h and 72 h in presence or absence of 100 nM taxol and 
subjected to flow-cytometric analysis of cell cycle. (A) Linear emission of PI dye from cells was measured and 
percentage G2/M (4N) DNA content was analyzed using MODFIT-LT software.  Left red peak = G0/G1; right red 
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peak = G2/M; hatched peak = S; (B) representative bar graph of the percentage G2/M cells. Data shown are 
means ± SD of triplicates. 
Supporting the PLK1 effect on BL41 cells, overexpression of KD also diplayed a slightly 
higher G2/M population of 14.0% and 22.0% compared to mock cells displaying 6.5% and 
19.8% by 48 h and 72 h respectively. Additional treatment with taxol showed a reduced 
percentage of G2/M phase arrested cells in the KD transfectants accounting to 42.4% by 48 h 
and 62.5% by 72 h compared to 63.0% and 81.2% in taxol treated mock cells. This clearly 
suggests that excessive kinase activity of PLK1 assists cell cycle progression, ascribing why 
PLK1 is highly expressed in most of the cancer cells. 
 In PBD overexpressing cells, G2/M arrest is more pronounced displaying 54.3% and 
65.4% G2/M cell cycle arrested cells compared to control transfectants with 6.6% and 19.8% 
by 48 h and 72 h, respectively (Figure 33A-B). Additional treatment with taxol had only a 
slight effect by enhancing G2/M arrested cell population to 61.7% and 83.4% by 48 h and 72 
h, respectively which were similar to the percentages of G2/M arrested cell population 
exhibited by taxol treated mock cells. Of note, abrogation of PLK1 function hinders the cell 
cycle progression by activating G2/M checkpoint control and, in combination with taxol, has 
little effect on PBD induced G2/M cell cycle arrest. 
3.17 PLK1 deregulation triggers G2 and mitotic arrest  
 To further analyze mitotic entry in BL41 cells overexpressing PLK1, PBD or KD with 
regard to taxol treatment, BL41 cell transfected with PLK1, PBD, KD or mock were cultured in 
the presence of doxycycline to induce transgene expression. After 24 h of induction, GFP 
positive cells were sorted by FACS. These cells were additionally treated for 24 h and 48 h 
with taxol and examined by mitosis-specific MPM2 staining. The MPM2 antibody detects 
mitosis specific phospho-epitopes, e.g. in topoisomerase-II The MPM2 positive cells were 
then analyzed by flow cytometry. After 48 h of PLK1 and KD overexpression, 7.2% and 5.5% 
cells, respectively were observed to be in the mitotic phase of cell cycle which was 
comparable to mock cells with 2.2% mitotic cell population (Figure 34A and left column of 
Figure 34B) and this proportion remained more or less the same by 72 h (Figure 34A). 
Additional treatment with taxol greatly enhanced mitotic arrest in mock transfectants 
displaying 40.1% mitotic cells by 48 h. But, PLK1 and KD overexpression together with taxol 
treatment induced mitotic arrest to a much lesser extent, exhibiting 19.5% and 20.8% 
mitotic cells, respectively indicating release from mitotic arrest (Figure 34A and right column 
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of Figure 34B). This proportion remained similar for 72 h (Figure 34A). These results 
strengthened the earlier data indicating that the kinase activity of PLK1 promotes cell cycle 




Figure 34: Ectopic overexpression of PLK1, PBD or KD in BL41 cells in combination with taxol shows a 
differential impact on mitotic cells. BL41-mock, -PLK1, -PBD or -KD cells were induced with doxycyclin for 24 h 
and GFP positive cells were FACS sorted. These sorted cells were cultured for 48 h and 72 h in the presence or 
absence of 100 nM taxol. Cells were stained with a fluorescein isothiocyanate (FITC)-labeled MPM2 antibody. 
Bi-variate analysis of DNA content (propidium iodide) and MPM2 antibody staining were performed, and 4N, 
MPM2-positive, i.e. M phase cells were identified by gating. (A) Data are given as percentage of mitotic cells 
from total cell population. (B) Representative histograms for 48 h showing percentages of 4N cells positive for 
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MPM2 indicated between markers. (C) Representative histograms for 48 h showing percentage of cells with 
hyperdiploid (>4N) DNA content which were considered polyploid. Data shown are means ± SD of triplicates. 
 In contrast to PLK1 and KD, cells overexpressing PBD displayed an increased 
percentage of mitotic cells accounting up to 23.7% compared to 2.6% in mock transfectants. 
Additional treatment with taxol for 48 h, manifested limited accumulation of the mitotic cell 
population accounting 27.9% in PBD overexpressing cells compared to 40.1% in mock cells. 
This proportion remained similar for 72 h (Figure 34A). From earlier data (Figure 33A-B) it is 
known that PBD overexpression in combination with taxol and taxol treated mock cells 
showed similar percentage of a G2/M population. Interestingly, this does not appear to be 
the same case with mitotic index. This indicates that overexpression of PBD decreases the 
mitotically arrested cell population upon taxol exposure, possibly due to enhanced check 
point activation at the G2 phase of the cell cycle. 
To verify whether deregulation of PLK1 function would lead to polyploidy, cells 
overexpressing PLK1, PBD or KD were further analyed for hyperdiploid DNA content in the 
presence or absence of taxol. There was no enhanced polyploidy in any of the transfectants 
compared to mock cells (Figure 34C), implying that deregulating PLK1 function does not 
induce polyploidy in BL41 cells regardless of taxol treatment.  
3.18 Similar cell cycle characteristics observed in different Burkitt lymphomas: 
DG75 and CA46 in response to PBD overexpression. 
 Furthermore, to understand if the observed effect of G2 and mitotic arrest in BL41 
cells is a general phenomenon among resistant Burkitt lymhomas in response to PLK1 
deregulation, DG75 and CA46 transfectants were analyzed as shown in Figure 35. After 72 h 
of induction of gene expression, apoptosis was determined by flow cytometric measurement 
of hypodiploid DNA content. Similar to earlier observations, PBD overexpression in BL41 cells 
led to a slight induction of apoptosis. DG75 and CA46 cells also showed apoptosis induction 
upon PBD expression, albeit to a lesser extent as compared to BL41 cells (Figure 35A-B). 
DG75 and CA46 cells overexpressing PBD displayed, however, increased G2/M arrest up to 
72% and 68%, respectively, with mock cells showing less than 15% 4N cells (Figure 35E-F). In 
concordance with BL41 cells, only a part of DG75 and CA46 cells in G2/M displayed as well 
markers i.e. MPM2 positivity up to 25% and 16% as compared to 8% and 7% in mock 
transfectants, respectively (Figure 35E-F). Yet, DG75 and CA46 cell lines are different from 
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BL41 in their endogeneous Bax and Bak expression. They lack Bax and showed weak Bak 
expression contrary to Bax and Bak proficiency in the BL41 cell line (Figure 20). All the three 




Figure 35: Deregulation of PLK1 function in apoptosis resistant DG75 and CA46 as compared to apoptosis 
sensitive BL41 cell line induces G2 and mitotic arrest but fails to induce prominent apoptosis. DG75 and CA46 
cells were transfected with pRTS-1 plasmids carrying PLK1, PBD or KD, respectively, or the empty vector as a 
control. Cells were cultured for 72 h in the presence of doxycycline (Dox). (A-C) Cells were analyzed for DNA 
fragmentation by flow cytometry. Cells with sub-G1 hypodiploid DNA content were considered apoptotic. (D-F) 
Percentage of cells with a G2/M (4N) DNA content was analyzed using MODFIT-LT software. (G-I) Bi-variate 
analysis of DNA content (propidium iodide staining) and MPM2 antibody staining were performed, and MPM2-
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positive, 4N, i.e. M phase cells were identified. Data are given as percentage of mitotic cells from total cell 
population. Data shown are means ± SD of triplicates.  
 




Figure 36: Burkitt lymphoma cell lines DG75 and CA46 promote polyploidy but not BL41 in response to PLK1-
PBD overexpression. Data shown are from flow-cytometric analysis of cell cycle of the cells cultured for 72 h in 
the presence or absence of doxycyclin. (A) percentage hyperploidy (>4N DNA content) was analyzed using 
MODFIT-LT software. Left red peak = G0/G1; right red peak = G2/M; hatched peak = S; Yellow peak = >4N DNA 




To investigate whether PBD overexpression leads to polyploidy, cell cycle distribution was 
analyzed in DG75, CA46 and BL41 cell lines after 72 h of induction with doxycyclin. Only 
DG75 and CA46 cells displayed enhanced constitutive polyploidy whose significance was 
measured by t-test. Upon PBD overexpression, DG75 and CA46 cells showed 8% and 3% 
compared to mock cells displaying 2% and 0% polyploidy cells, respectively (Figure 36B-C). 
Conversely, BL41 cells did not show enhanced polyploidy compared to mock cells (Figure 
36D). This difference in response may be attributed to Bax and Bak proficiency that would 
lead to deletion of aberrant cell populations. 
3.20 Deregulation of PLK1 function has an antiproliferative effect followed by 
necrosis in Burkitt lymphomas 
Further, CA46 and BL41 transfectants were examined for their survival, as they did not 
undergo prominent apoptosis. As shown in Figure 37A-B, both BL41 and CA46 cell lines 
displayed reduced proliferation ability in response to PBD overexpression. BL41 and CA46 
transfectants for PBD 72 h after induction of gene expression showed up to 50% and 38% 
reduction in proliferative ability (viability) respectively, when measured by XTT assay. 
However, there was no decrease in proliferative ability of KD and PLK1 tranfectants upon 
induction of gene expression, which is comparable to control cells. Further, respective 
transfectants were analyzed for cell death by a flow cytometric single cell propidium iodide 
(PI) uptake assay. Uninduced transfectants stained for PI in less than 8% of cells. When 
analyzed for PI uptake in the induced condition, mock and PLK1 overexpressing cells showed 







Figure 37: Abrogation of PLK1 function leads to loss of proliferative ability and induction of cell death. Cells 
transfected with empty vector, PLK1, PBD or KD were cultured for 72 h in the presence or absence of 
doxycyclin (A-B) Cell viability measurement by colorimetric XTT assay. (C-D) Cell death measurement by PI 
uptake. Cells were stained with PI and % PI positive (dead) cells were measured among GFP positive cells using 
flow cytometric analysis. Data shown are means ± SD of triplicates. 
Nevertheless, PBD and KD under induced condition in BL41 cell line showed enhanced PI 
uptake up to 29% and 27% cells with PI positivity, respectively compared to uninduced 
tranfectants exhibiting below 7% cells with PI positivity (Figure 37C). Similarily CA46 
transfectants of PBD and KD, under induced condition showed enhanced PI uptake up to 
29% and 21% cells with PI positivity, respectively, with uninduced cells remaining below 6% 
(Figure 37D). These results imply that deregulation of PLK1 function leads to cell death 
probably in part via a necrosis like pathway in Burkitt lymphomas. 
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3.21 Deregulation of PLK1 and treatment with microtubule inhibitors failed to 
show an increase or inhibition of apoptosis induction 
 It is interesting to check, if deregulating the cell cycle in addition to microtubule 
inhibitors would lead to synergistic induction of apoptosis. BL41 cells overexpressing PLK1, 
PBD, KD or mock were cultured in the presence of doxycycline and additionally treated with 
taxol or vincristine or left untreated for 72 h. Hypodiploid DNA content was measured using 
flow cytometry to determine induction of apoptosis. All the cell lines left untreated exhibited 
approximately 9-15% background apoptosis. In contrast, taxol-treated cells showed 
enhanced apoptosis up to 50% in all the transfectants (Figure 38), irrespective of differences 
in cell cycle distribution and PI uptake shown Figure 33, 34, 37. 
 
 
Figure 38: Microtubule inhibitor treatment and deregulation of PLK1 function show no additive or synergistic 
induction of apoptosis. BL41 cells were transfected with pRTS-1 plasmid carrying PLK1, PBD or KD, respectively, 
or empty vector as control. Cells were cultured for 72 h in the presence (on) of doxycycline (Dox) additionally in 
the presence or absence of 100 nM taxol or vincristine. GFP positive cells were gated which are considered 
positive for PLK1, PBD or KD expression and the gated populated were analyzed for DNA fragmentation by flow 
cytometry. Cells with sub-G1 hypodiploid DNA content were considered apoptotic. Data are means ± SD of 
triplicates. 
 
Similar to observations made with taxol treatment in PLK1, PBD or KD overexpressing cells, 
vincristine also displayed enhanced apoptosis up to 53% in all the transfectants without any 
synergism, additive or inhibitory effect, disregarding cell cycle perturbation that resulted 
from PLK1 deregulation. This indicates that microtubule inhibitors and deregulation PLK1 
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function induces cell death via the same pathway. Of note, full completion of miotisis is not 
required for cell death induction as PBD induces M arrest. 
3.22 Deregulation of PLK1 function induces apoptosis but lacks synergistic 
effect with microtubule inhibitors in HeLa cells 
 Since PLK1 deregulation studies by other groups were mainly performed in HeLa, it is 
interesting to see if the obsevation made with Burkitt lymphomas are similar in the HeLa cell 
system. In this approach, HeLa cells were transfected with PLK1, PBD and KD, respectively, 
and were checked for overexpression of PLK1 using PLK1 antibody by immunoblotting, while 
PBD and KD were detected by using c-Myc antibody. Figure 39 depicts the overexpression of 
PLK1, c-Myc tagged PBD and c-Myc tagged KD in HeLa transfectants after incubating cells in 
presence of doxycycline for 72 h. Only respective transfectants showed overexpression but 
not the mock transfected cells confirming the genetic status of the cell lines and transgene 
expression. 
 Overexpression of PLK1 and KD induced apoptosis up to 14% and 11% compared to 
<5% in control cells, indicating little or no effect of PLK1 and KD on apoptosis induction. 
However, deregulation of PLK1 function by overexpressing PBD induced 41% apoptosis, 
confirming the earlier reports that PBD overexpression induces apoptosis in HeLa cells (Fink, 
et al., 2007). Since deregulating cell cycle by PBD expression induced apoptosis in HeLa cells 
(Figure 39A), it was tempting to speculate whether PBD expression would yield a synergistic 
effect on apoptosis in addition to microtubule inhibitors. To test this, HeLa cell transfectants 
for PLK1, PBD, KD or mock were cultured in the presence of doxycycline and additionally 
treated with nocodazole, taxol or vincristine or left untreated for 72 h. Apoptosis and 
polyploidy were determined by flow cytometry using a modified cell cycle assay for 
measurement of hypodiploid and hyperdiploid DNA content. Additional treatment with 
nocodazole showed a sub-additive effect with apoptosis in around 60% in all the cells 
overexpressing PLK1 or PBD or KD (Figure 39B) irrespective of differences in cell cycle 
distribution. These results further confirm that deregulation of PLK1 function in combination 





Figure 39: Polo box domain of PLK1 induces apoptosis in HeLa cells but shows no synergistic activity with 
microtubule inhibitors nocodazole, taxol or vincristine. HeLa transfectants of mock, PLK1, PBD or KD, 
respectively, were cultured for 72 h in the presence of doxycycline (Dox) (on). (A) Immunoblot analysis of PLK1, 
PBD and KD expression levels in HeLa cells (B) Cells were aditionally treated with 100 nM nocodazole, taxol or 
vincristine and analyzed for DNA fragmentation by flow cytometry. Cells with sub-G1 hypodiploid DNA content 
were considered apoptotic. (C) Cells showing hyperploid (>4N) DNA content were considered polyploid. Data 
are means ± SD of triplicates. 
 
 Concordant to observations made with nocodazole, treatment of PLK1, PBD, KD 
overexpressing cells with taxol, vincristine also induced apoptosis up to 53% and 59%, 
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respectively. This further confirms that there is no or lack of synergistic effect of PLK1, PBD 
and KD overexpression and microtubule inhibitor treatment (Figure 39B). At the same time 
when looking for polyploidy, none of the cells carrying PLK1, PBD or KD displayed enhanced 
enhanced number of cells with a hyperploid DNA content regardless of microtubule inhibitor 
treatment (Figure 39C). This supports earlier results in the Burkitt lymphoma and FDM cell 
systems confirming that apoptosis sensitive cell lines show no polyploidy induction. 
3.23 PBD induces aberrant spindle formation and chromosomal congressional 
defects  
 To better understand the physiological importance of Plk1 localization, the phenotypes 
of the mitotically arrested cells produced upon PBD overexpression were studied. HeLa-PBD 
and HeLa-Mock (empty plasmid) stable cells were cultured in presence of doxycyclin for 48 h 
and were subjected to an immunofluorescence staining by using tubulin antibody against 
spindle microtubules (red) and DAPI to stain DNA (blue). The overlay of microtubule and 
DNA of HeLa cells with empty plasmid acting as control showed clear bipolar spindle and 
normal segregation of chromosomes. In response to PBD overexpression, HeLa cells in 
mitotic phase exhibited aberrant spindles with multipolar or bipolar microtubule arrays, but 
these most often had unfocussed spindle poles with lagging chromosomes (Figure 39A).  
 Further, similar phenotypes were observed in Burkitt lymphoma cells (BJAB cells). BJAB 
transient transfectants overexpressing PBD were subjected to immunofluoresence staining 
as stated above. Deregulation of PLK1 by PBD overexpression induced aberrant mitosis with 
monopolar, multipolar spindle or bipolar microtubule with lagging chromosomes. In some 
cases, unequal segregation of chromosomes leading to exclusion of a very small portion of 
DNA leading to distinct progeny with hyperploid DNA content and other one with insufficient 
DNA content, which would probably perish (Figure 39B). This indicates that PBD induces 
mitotic arrest with aberrant spindle events and chromosomal missegregation followed by 





Figure 38: Deregulation of PLK1 function by PBD overexpression induces mitotic aberrations leading to 
chromosomal instability. The PBD stable cell line was induced for 48 h with doxycycline. After fixation and 
permeabilization, cells were analyzed by indirect immunofluorescence microscopy using anti--tubulin (red) 
antibody, and DAPI (blue) staining. (A) Mitotic phenotypes of PBD expressing HeLa cells (B) Mitotic phenotypes 
of PBD expressing BJAB cells.  
3.24 PBD induced apoptosis in HeLa cells is caspase dependent  
To investigate whether apoptosis induced by PBD overexpression is caspase dependent, cells 
were preincubated with pan-caspase inhibitor Q-VD-OPh for 2 h prior to doxycycline and 
taxol treatment, leaving unteated cells as controls. Cells were harvested after 72 h of taxol 
treatment and analyzed for apoptosis using flow cytometry. PBD overexpression induced 
apoptosis accounting up to 37% compared to 11% in uninduced cells (Figure 40A). The pan-
caspase inhibitor Q-VD-OPh completely inhibited apoptosis in PBD expressing cells, down to 
the level of control cells (Figure 40A). Taxol alone and taxol with PBD overexpression showed 
apoptosis up to 53%, which was inhibited by 44% in presence of pan-caspase inhibitor Q-VD-
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OPh, indicating apoptosis induced by PBD, taxol or in combination is caspase dependent in 
HeLa cells. 
 Interestingly, as shown in Figure 40B, PBD overexpressing cells cultured in the 
presence of the pancaspase inhibitor displayed enhanced polyploidy up to 21% by 72 h, 
compared to uninduced cells showing 3% polyploidy. Taxol alone upon caspase inhibition 
failed to induce polyploidy unlike in BL41 cell lines. Additional treatment with taxol of PBD 
overexpressing cells did not show synergistic polyploidy induction, which leveled out at 18%. 
It is clear form the data that inhibition of apoptosis induced by PBD overexpression by 
caspase inhibtion promotes polyploidy. This confirms the inverse relationship between 




Figure 40: Inhibition of caspase activity led to inhibition of apoptosis induced by PBD and enhanced 
polyploidy induction in HeLa cells. HeLa-PBD cells were culture in presence (on) or absence (off) of doxycycline 
(Dox). (A) Cells additionally treated with or without taxol and pan-caspase inhibitor Q-VD-OPh were subjected 
to flow cytometric analysis of DNA content. Cells with sub-G1 hypodiploid DNA content were considered 
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 Cancer is a genetic disease that develops through continuous accumulation of 
mutations and epigenetic events. Many important tumor-promoting genes have been 
identified during the last two decades and their functions have been well characterized 
(Vogelstein and Kinzler, 2004). However, recent genome-wide screenings of different tumor 
samples have pointed out that more gene mutations are still to be discovered and 
elucidation of their unique characteristics will be important to understand cancer 
progression (Sjoblom, 2008). 
 Evasion of apoptosis by tumor cells has gained much attention since it allows tumor 
cells to escape from elimination by endogenous default apoptosis mechanisms, immune 
surveillance and cancer therapeutics. Several molecular alterations that contribute to 
apoptosis resistance have been demonstrated but identification of novel apoptotic 
regulators is still important to improve tumor treatment (Malaguarnera, 2004). 
 Burkitt lymphomas are known as aggressive malignant B cells, as they show the 
highest rate of cell division among any human tumor (Hecht and Aster, 2000). Therefore, 
several chemotherapeutic drugs are used in cancer treatment, which generally target fast 
growing cells, as they are more sensitive to DNA damage and cellular stress. 
Polychemotherapy is also intended to circumvent rapid outgrowth of resistant clones, 
which represent a major therapeutic problems in Burkitt lymphomas and B-ALL therapy. 
Since tumor cells generally have a higher growth rate than normal cells, they are more 
severely affected. Development of improved therapies remains increasingly challenging, as 
there are certain cancer types or sub-populations, which are difficult to kill by apoptosis 
due to alterations in their genetic profile and as a result of acquired resistance. One 
category of such chemotherapeutic drugs are microtubule inhibitors, which are acclaimed as 
a promising therapeutic approach against a broad variety of cancer (Abal, et al., 2003; 
Ganansia-Leymarie, et al., 2003). The present study describes the basis of cell death 
mechanisms in Burkitt lymphomas upon microtubule inhibitor treatment, revealing some of 
the major aspects of the molecular mechanism linking apoptosis and mitotic catastrophe.  
 Taxol, which primarily targets the microtubule components of cytoskeleton impeding 
microtubule depolymerization (Wang, et al., 1999), has a broad spectrum of clinical activity 
against human cancers (Huizing, et al., 1995; Rowinsky, et al., 1992). In a first set of 
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experiments, as demonstrated in Figure 8, it was found that taxol induces apoptosis in 
various Burkitt lymphoma cell lines at concentrations ranging from 10 to 100 nM. This 
finding, together with reports from earlier publications, confirms that taxol preferentially 
induces apoptotic and not necrotic cell death at concentrations below 1 µg/ml in a variety of 
cell types, for example, B-lymphoid cells (Essmann, et al., 2000; Wieder, et al., 2001), human 
breast cancer cells (Charles, et al., 2001), and lung cancer cells (Das, et al., 2001). The results 
presented here show that taxol and nocodazole, the reversible spindle toxin that used as a 
control, together with vincristine induce morphological changes in Burkitt lymphoma cells 
leading to cell death in a time- and dose-dependent manner. Contradictory observations 
exist concerning the mode of cell death induced by taxol. Some evidence indicates that this 
drug causes damage leading to mitotic catastrophe – the type of cell death accompanied by 
the appearance of giant, multinucleated cells with non-condensed chromosomes (Castedo, 
et al., 2002; Ricci and Zong, 2006; Roninson, et al., 2001). While others claim that taxol 
induces cell death with typical signs of apoptosis (Bhalla, et al., 1993; Liu, et al., 1994; Yeung, 
et al., 1999), or necrosis (Michalakis, et al., 2005; Yeung, et al., 1999) depending on the dose 
of the drug. However, the reason behind the variation in response to taxol is unclear and it is 
interesting to further elucidate the underlying mechanism. In the present investigation, at 
100 nM concentration of taxol or nocodazole, cells showed distinct phenotypes either 
leading to apoptosis or polyploidy (>4N DNA content) (Figure 9 & Figure 10). Although most 
of the cell lines treated with taxol induced apoptosis, some are resistant. Interestingly, 
Burkitt lymphomas resistant to taxol-induced apoptosis showed enhanced polyploidy; 
whereas cell lines sensititve to apoptosis exhibited limited or no polyploidy. This gives us a 
clear picture of an inverse correlation between apoptosis and polyploidy upon taxol 
treatment. Another microtubule inhibitor, nocodazole, which functions by destabilizing 
microtubules, induces apoptosis similar to that of taxol treatment. This is in line with other 
reports that nocodazole induces apoptosis in a variety of cell types, for instance, in CLL cells 
(Beswick, et al., 2006; Verdoodt, et al., 1999) and Colon carcinoma cells (Zhang, et al., 2002). 
Moreover, a similar pattern of inverse correlation of apoptosis and polyploidy observed 
upon taxol treatment was also observed with nocodazole treatment.  
 As mentioned in many reports, taxol exerts effects mainly through regulation of 
microtubular dynamics that subsequently leads to G2/M arrest, which is usually followed by 
apoptosis or necrosis (Abal, et al., 2003). In concordance with this, it is clear that 
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microtubule inhibitors taxol and nocodazole induces arrest at the G2/M phases of the cell 
cycle in Burkitt lymphoma. More significantly, taxol promotes the accumulation of cyclin B1 
and induces the in vitro histone H1 kinase activity of CDK1, which triggers G2/M transition 
and mitotic arrest preceding apoptosis. This histone H1 kinase activity of CDK1 is considered 
as mitotic marker (Ibrado, et al., 1998). However, there are other reports showing that cells 
undergoing mitosis are positive for MPM2, a well-established mitosis-specific phospho-
epitope and mitotic marker (Andreassen and Margolis, 1994; Davis, et al., 1983). Considering 
MPM2 as a mitotic marker, all the Burkitt lymphoma cell lines studied were positive for 
MPM2, signifying mitotic accumulation upon exposure to taxol or nocodazole (Figure 13). 
Following mitotic arrest, cells undergo apoptosis. However, apoptosis resistant cells show 
persistant mitotic arrest for prolonged time periods and interestingly, a major portion of 
mitotically arrested cells are polyploid, which might be a consequence of endoreplication 
(Figure 14).  
This feature of polyploidization is considered as a hallmark of mitotic catastrophe. 
There are diverse descriptions of mitotic catastrophe from earlier studies. Initially, mitotic 
catastrophe was associated with incomplete DNA synthesis and premature chromosome 
condensation (Ianzini and Mackey, 1998; Mackey, et al., 1988) with features in common with 
apoptosis. Other authors define it as an aberrant form of mitosis associated with the 
formation of multinucleate giant cells that are temporarily viable but reproductively dead 
(King and Cidlowski, 1995; Miranda, et al., 1996). Some others state that, mitotic 
catastrophe is pre-determined in G2 and characterized by an abortive shortcut into 
metaphase arrest (Kondo, 1995; Rhind and Russell, 1998). Mitotic failure often manifests 
with micronucleation (Abend, et al., 1996; Heddle and Carrano, 1977) and nuclear 
segmentation (Dini, et al., 1996) and this in turn is associated with mitosis restitution into 
interphase polyploid cells (Nagl, 1990). Similar results have been described by others where 
giant polyploid cells were seen upon treatment of cancer cells with different stimuli, 
including etoposide (Rello-Varona, et al., 2006), doxorubicin (Eom, et al., 2005), heat shock 
(Nakahata, et al., 2002) and ionizing radiation (Kakizaki, et al., 2006). So far, only limited 
studies have been reported about this mode of cell death induced by taxol (Jordan, et al., 
1996; Michalakis, et al., 2005; Xiao, et al., 2005). However, it is more apparent from our 
results (Figure 8 - Figure 10) that the microtubule inhibitors taxol and nocodazole induce 
polyploidy which might be a consequence of failed apoptosis. There are various reports and 
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predictions about when polyploidy is triggered during the cell cycle. Polyploidy, which 
corresponds to a change to an exact multiple of the haploid number of chromosomes 
(hyperploidy), can be induced via two main routes: rereplication of the DNA in the absence 
of an intervening mitosis or in the absence of a functional spindle or premature exit from 
mitosis to the next G1 phase
 without having completed chromatid migration to the poles 
(Kirsch-Volders, et al., 1998). Inhibition of histone deacetylase activity (Shin, et al., 2003) or 
inhibition of protein kinases in mitotically arrested cells by use of staurosporine triggers 
premature mitotic exit and polyploidy (Hall, et al., 1996). There are other evidences showing 
that loss of APC (anaphase promoting complex) leads to chromosomal instability as a result 
of compromised mitotic spindle checkpoint (Tighe, et al., 2004). Interestingly, data from 
Figure 14B demonstrates that most of the cells stained for MPM2 are polyploid, which 
indicates that the possible trigger for polyploidization originates during mitosis.  
Vincristine, another microtubule inhibitor interfering with microtubule dynamics, has 
been used widely in anticancer therapy for more than 30 years (Gidding, et al., 1999). It has 
a wide range of clinical applications and continues to be a key drug in the combination 
chemotherapy for childhood acute lymphoblastic leukemia (ALL) and non Hodgkin’s 
lymphoma (NHL) [reviewed in (Gidding, et al., 1999)]. Since the mode of action is not well 
established, it is interesting to investigate the mechanism involved in cell death induced by 
vincristine. As shown in Figure 12A, vincristine induces apoptosis to a similar extent in 
Burkitt lymphomas as observed with taxol or nocodazole in apoptosis sensitive cell lines. 
Burkitt lymphomas resistant to taxol or nocodazole were also found to be resistant to 
vincristine treatment; probably the same factors are responsible for the distinct features 
including apoptosis resistance and sensitivity. Additionally, vincristine treated cells also 
showed prolonged mitotic arrest in apoptosis resistant but not in sensitive cell lines. Of note 
and contrary to the effect of taxol or nocodazole, there was no polyploidy induction 
observed in apoptosis resistant cells (Figure 12B). This established that vincristine treatment 
specifically fails to induce polyploidization in apoptosis resistant cell lines. This clearly 
conveys the existence of different signalling mechanisms upon vincristine treatment as 
compared to that of taxol or nocodazole treatment. Conversely, there are opposing 
evidences obtained in sarcoma cells undergoing both DNA fragmentation and polyploidy in 
response to vincristine (Mujagic, et al., 1983). Thus, absence of polyploidy induction in 
Burkitt lymphomas with vincristine treatment is an interesting aspect. However, further 
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validatation of mechanistic details would be benificial in understanding the cancer response 
to microtubule-targeted therapies.  
 The microtubule inhibitors taxol and nocodazole induce two distinct features in 
Burkitt lymphomas, one feature leading to cell death via apoptosis and the other feature 
showing prolonged mitotic arrest and polyploidization. However, the consequence of 
microtubule inhibitors induced mitotic arrest and polyploidy in resistant Burkitt lymphomas 
is unclear. It is probable that apoptosis resistant cells undergo delayed apoptosis or die by 
other means of cell death. Although most of the apoptosis resistant cells are reproductively 
dead with loss of proliferative ability upon taxol, they are viable with intact plasma 
membrane (Figure 15). In addition, the effect of taxol seems to be irreversible, where the 
cells failed to recover after 3 days of drug removal (Figure 16). Nevertheless, it is important 
to consider the possibility that cells may take a longer duration to recover from taxol effect 
or subjected to delayed apoptosis. This might impact on the clonogenic survival and lead to 
better outgrowth of aneuploid subclones. 
 Interestingly, there are other evidences that generation of polyploid gaint cells 
provides a survival mechanism by a complex somatic reduction process involving meiotic-like 
bouquets. This has been reported recently for some Burkitt lymphoma cell lines after high 
doses of irradiation (Dooley, et al., 1991; Illidge, et al., 2000; MacAuley, et al., 1998). Taken 
together, it can be predicted that polyploidization is a means of survival mechanism in 
aggressive Burkitt lymphomas, which is supported by the evidence that aneuploid tumors 
are associated with high-grade invasive tumors and poor prognosis (Giaretti, 1994; Sandberg, 
1977; Segers, et al., 1994; Verdoodt, et al., 1994).  
 According to clinical evidence, vincristine is more effective than taxol or nocodazole 
in treatment of Burkitt lymphomas and the reason behind this is unexplored. Probably, the 
fact that vincristine fails to induce polyploidization probable cancer cell survival mechanism, 
might explain its better performance compared to taxol in treating Burkitt lymphomas.  
So far the findings discussed are presented in a schematic illustration in Figure 41. In 
brief, Burkitt lymphomas undergo mitotic arrest followed by either apoptosis with no 
polyploidy or polyploidy without apoptosis induction in response to microtubule inhibitors. 
Further analysis of apoptosis resistant cells demonstrated persistant mitotic arrest with most 
of them displaying a DNA content of more than 4N. Moreover, they showed a loss of 
proliferative ability and failed to recover for a time period of 72 h after microtubule inhibitor 
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rescue. These phenotypes of prolonged mitotic arrest, polyploidization and loss of 
proliferative ability observed in resistant Burkitt lymphomas in response to microtuble 
inhibitors are characteristics of mitotic catastrophe. 
 
 
Figure 41: Schematic representation of microtubule inhibitor induced cell death in Burkitt lymphomas: 
apoptosis or mitotic catastophe. The initial data indicate that stress induced by microtubule inhibitors in 
Burkitt lymphoma cells stimulated them to either undergo apoptosis without genomic instabilty or to genomic 
instability i.e. polyploidy without apoptosis. These distinct phenotypes seem to be cell type specific. On the 
other hand, the effect of microtubule inhibitors on cell viability is irreversible and at the same time apoptotic 
resistant cells showing hyperploidy fail to induce other ways of cell death like necrosis. 
 
  In the subsequent experiments, biochemical aspects associated with 
apoptosis and mitotic catastrophe were analyzed to understand the rationale behind the 
sensitivity and resistance to apoptosis. Taxol-induced apoptosis is accompanied by caspase-
3, -9 and -8 cleavage in cells sensitive to apoptosis (Figure 17), which is concordant with 
previous studies, demonstrating that taxol-induced apoptosis involves hierarchical activation 
of mitochondria, caspases-3, and -8 (Wieder, et al., 2001). In addition, it is well established 
that taxol-induced cell death depends in part on the activation of caspase-3-like protease 
activities (Essmann, et al., 2000; Suzuki, et al., 1998). Apoptosis induction and caspase-8 
processing by taxol or other drugs such as anthracyclines or nucleoside analogs was 
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suggested to occur via the CD95/Fas receptor/ligand system (Biswas, et al., 2001; Friesen, et 
al., 1999; Fulda, et al., 2001; Fulda, et al., 2001; Nomura, et al., 2000). Thus, caspase-8 
activation could occur via the death-receptor associated DISC (Muzio, et al., 1998). However, 
there is evidence showing that caspase-8 activation may also occur in death receptors 
independent signaling in taxol-induced apoptosis (von Haefen, et al., 2003). In line with this, 
there are previous studies describing that cFLIPL may form death receptor independent 
heterodimers with caspase-8, which leads to weak activation and initial processing of 
caspase-8 (Krueger, et al., 2001). Another possibility of caspase-8 processing can be 
explained at least in part by the fact that probably other proteases, such as serine proteases 
(Huang, et al., 1999) can do the job. Furthermore, inhibition of caspase-8 activity results in 
impaired DNA fragmentation. Nevertheless, neither the pan-caspase nor the caspase-8-
specific inhibitors completely blocked taxol-induced DNA fragmentation (Figure 27 - Figure 
30), indicating that caspase-8 independent mechanisms are also at work. 
However, apoptosis resistant cells failed to exhibit significant activation or processing 
of caspase-3 and -9 (Figure 17 - Figure 18), but showed a reduction in caspase-8 proform 
with sparsely visible cleavage products suggesting slight activation of caspase-8 (Figure 17). 
Further, amplification of caspase-8 activation or processing is not observed in apoptosis 
resistant cell lines, probably due to lack of feedback amplification via caspase-3 activity. This 
is in line with previous reports demonstrating activation of caspase-8 in drug-induced 
apoptosis via the mitochondrial pathway (Belka, et al., 2000; Engels, et al., 2000; 
Wesselborg, et al., 1999). This transduction of signals from caspase-8 to mitochondria 
involves activation of Bax/Bak, which confer an essential gateway for the activation of 
effector caspases in mitochondrially mediated intrinsic apoptosis pathway (Korsmeyer, et al., 
2000). Caspase-8 is activated downstream of caspase-3 during drug-induced apoptosis 
(Daniel, et al., 2001) including cell death activated by taxol, probably through a feedback 
loop that seems to also include autoprocessing of the enzyme (Wieder, et al., 2001). 
 Looking into the regulation of the caspase-8 substrate Bid, a proapoptotic Bcl-2 
family member, a reduced proform of Bid was observed in both sets of cells lines exhibiting 
either apoptosis resistance or sensitivity in response to taxol (Figure 17). This is supported by 
findings from previous studies that, low amounts of activated caspase-8 are sufficient to 
process Bid to its active truncated form tBid, thus transducing apoptotic signals from the 
cytoplasm to the mitochondrial membrane (Gross, et al., 1999; Li, et al., 1998). This further 
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validates the existence of such a feedback loop amplification of caspase-8 activation. 
Additionally, the lack of difference in Bid regulation in apoptosis sensitive and resistance cell 
lines also suggests that, Bid cleavage to tBid has no correlation in imparting apoptosis 
resistance and induction of polyploidy in response to microtubule inhibitors in Burkitt 
lymphomas.  
 There is evidence that bid gene is transcriptionally regulated by p53 and may enhance 
the apoptosis response to specific chemotherapies (Sax, et al., 2002). The importance of 
apoptosis for p53-mediated tumor suppression has been suggested from correlative studies 
linking p53 loss to apoptotic defects during the progression of murine and human tumors 
(Attardi and Jacks, 1999; Bardeesy, et al., 1995), as well as by functional studies 
demonstrating that strictly anti-apoptotic activities can accelerate tumorigenesis in 
transgenic mice (Eischen, et al., 2001; Strasser, et al., 1990; Yin, et al., 1997). Furthermore, 
certain p53 wild type tumors harbor mutations that have been shown to suppress apoptosis 
downstream of p53 (Soengas, et al., 2001), and some tumor-derived p53 mutants are known 
to be defective in inducing apoptosis but not cell-cycle arrest (Aurelio, et al., 2000). In the 
present study, each Burkitt lymphoma cell line has a different p53 status: one cell line has a 
wild type p53, while others have mutated p53 leading to their stabilization. The status of p53 
neither shows any direct correlation on the sensitivity of the cell lines to apoptosis induction 
nor on polyploidy induction (Figure 19). This implies that taxol induced apoptosis is p53 
independent. This is in line with other reports demonstrating that taxol induce apoptosis 
independently of p53 (Woods, et al., 1995). Reduced levels of p53 correlated with increased 
G2/M phase arrest, micronucleation, and p53-independent taxol-induced apoptosis (Wahl, 
et al., 1996). (Giannakakou, et al., 2000) proposed that functional microtubules and the 
dynein motor protein participate in transport of p53 and facilitate its accumulation in the 
nucleus after DNA damage. Disruption of normal microtubule dynamics, whether by 
stabilization with taxol or depolymerization with vincristine, compromises microtubule 
function. Both of these drug treatments impair nuclear accumulation of p53 after DNA 
damage (Michael and Oren, 2003). This information in part can explain the lack of p53 
stabilization in BL2 cells with endogeneous wild type p53 besides reduction in stable mutant 
p53 levels in other cell lines, probably through disruption of microtubule/p53 association 
leading to p53 exposure to proteosomal degradation in response to taxol. Nevertheless, p53 
mutation may add to the advantage of deregulated apoptosis in induction of polyploidy, 
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which is yet to be investigated.  
 As Bid was found to be regulated in response to microtubule targeted drugs in our 
hand, it is interesting to check the downstream targets of Bid. There are evidences showing 
that tBid preferentially activates mitochondria to release cytochrome c in a Bax/Bak-
dependent manner (Korsmeyer, et al., 2000; Zamzami, et al., 2000). Nevertheless, several 
groups have demonstrated that mitochondria can be activated either by Bax or Bak-
dependent mechanisms (Gillissen, et al., 2003; Gillissen, et al., 2007; Hemmati, et al., 2002; 
Radetzki, et al., 2002; von Haefen, et al., 2002; Wendt, et al., 2005). Bak and Bax are 
generally assumed to substitute for each other, since deficiency of both genes is required to 
render cells resistant to a number of proapoptotic agents (Janssen, et al., 2007; Wei, et al., 
2001). Another group has demonstrated, that lack of bax promotes survival of tetraploid 
cells at least as efficiently as the p53 or p21 knockout (Castedo, et al., 2006). In the present 
study, most resistant Burkitt lymphomas lack functional Bax and show weak expression of 
Bak protein whereas sensitive cell lines are Bax/Bak proficient. This implies that probably 
lack of functional Bax/Bak confers resistance against taxol-induced apoptosis and in turn 
leads to induction of polyploidy in Burkitt lymphomas (Figure 20). This also delineates that 
apoptosis induction upon spindle toxin exposure acts as a fail-safe mechanism to prevent 
accumulation of aneuploid cells. This seems to be achievied by p53 independent signalling. 
Similar observations were made here in FDM (factor dependent monocyte) cell lines where 
double knockouts for Bax and Bak failed to induce apoptosis, and, these cells were triggered 
for polyploidization (Figure 24). This indicates that Bax/Bak play a crucial role in imparting 
resistance to apoptosis induction and induction of polyploidy. This is not the case with 
individual knockouts of Bax or Bak proving their functional redundancy in taxol-induced 
apoptosis (Figure 24).  
 Apart from evidences that Bid plays a role in taxol induced cell death, many studies 
have shown that cells undergo taxol-induced cell death when the mitochondrial apoptosis 
pathway is activated (Torres and Horwitz, 1998; von Haefen, et al., 2003; Woods, et al., 
1995). The regulators of this mitochondrial apoptosis pathway are the BH3-only proteins 
(Bouillet and Strasser, 2002; Willis and Adams, 2005). Specifically, the BH3-only protein Bim 
has been shown to play a major role in taxol-induced cell death (Li, et al., 2005; Li, et al., 
2007; O'Connor, et al., 1998; Sunters, et al., 2003; Tan, et al., 2005). Depletion of Bim in in 
vitro cell culture models (Li, et al., 2005; Li, et al., 2007; Sunters, et al., 2003) as well as, in in 
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vivo bim−/− mouse models, delays taxol-mediated apoptosis (Tan, et al., 2005). Bim is also 
known to play an important role in cell death caused by growth factor deprivation in various 
cell types including neuronal and hematopoietic cells (Dijkers, et al., 2000; Putcha, et al., 
2001). However, there is also contrary report demonstrating that Bim is not absolutely 
required for taxol-induced cytotoxicity (Czernick, et al., 2009). According to the present 
findings, an essential role of Bim in taxol induced cell death is debatable. Moreover, 
expression of Bim is highly variable in Burkitt lymphomas with several cell lines being void 
Bim expression. Another BH3-only protein, Puma, was also shown to be unregulated in 
apoptosis induced by taxol (Wang, et al., 2007). The present study shows that the pro-
apoptotic BH3-only proteins like Bim, Puma, Noxa and Nbk seem to have no role in taxol 
induced apoptosis in Burkitt lymphomas except for Bid. Instead they are downregulated 
upon taxol treatment, which might be the cell’s counter action against cell death induction 
(Figure 21). However, the mechanism behind this is unclear and further studies are 
necessary to understand the mechanism and implications of their downregulation. The 
genetic knockout of Bim, Puma, Noxa or Bid, respectively in FDM cells, failed to inhibit 
apoptosis or to induce polyploidy upon taxol treatment (Figure 26). This supports in part the 
observations made with Burkitt lymphoma cells and also implies the possibility of BH3-only 
proteins being functionally redundant. 
 Mcl-1, an anti-apoptotic protein is highly expressed in hematopoietic cells and in 
leukemias (Andersen, et al., 2005; Chetoui, et al., 2008; Petlickovski, et al., 2005; Sorensen, 
et al., 2006). Mcl-1 protects against apoptosis and silencing it by a shRNA approach 
sensitizes HeLa cells to TRAIL-induced apoptosis (Clohessy, et al., 2006) and malignant 
melanoma cells to Fas-mediated apoptosis (Chetoui, et al., 2008). Genetic studies with the 
use of a conditional knockout approach also revealed that Mcl-1 is required both in early 
lymphoid development and in the maintenance of mature B and T lymphocytes, which are 
rapidly lost when Mcl-1 is deleted (Opferman, et al., 2003). There is evidence for 
predominant expression of Bcl-xL by malignant cells in various types of malignant 
lymphomas (Xerri, et al., 1996). Additional studies have demonstrated that expression of Bcl-
xL has been largely
 associated with their drug resistance (Heere-Ress, et al., 2002; Jansen, et 
al., 1998; Jansen, et al., 2000). Overexpression of Bcl-xL inhibits taxol-mediated apoptosis 
(Ibrado, et al., 1997; von Haefen, et al., 2003). There are other evidences showing that taxol 
downregulates the expression of Bcl-xL and Mcl-1 (Jazirehi and Bonavida, 2004). Yet, it is 
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interesting to study how this signalling is carried out on a comparative basis in Burkitt 
lymphomas and in relation to apoptosis and mitotic catastrophe. The Burkitt lymphoma  cell 
lines used in the present study express Bcl-xL and Mcl-1; only Mcl-1 expression was 
decreased in all the cell lines studied after taxol treatment (Figure 22), suggesting that 
regulation of this protein in different Burkitt lymphomas seems to be similar. However, Bcl-xL 
demonstrated downregulation upon taxol exposure only in some cell lines implying the 
distinct regulation and cell type specificity (Figure 22). There are several mechanisms 
associated with Mcl-1 regulation. Mcl-1 is phosphorylated at Ser121 and Thr163 by JNK in 
response to stimulation with H2O2, and transfection of unphosphorylatable Mcl-1 resulted in 
an enhanced anti- apoptotic activity in response to stimulation with H2O2 (Inoshita, et al., 
2002). Other evidences demonstrated that ERK activation was necessary for the increase in 
Mcl-1, as inhibition of ERK phosphorylation prevented the increase in Mcl-1 expression and 
caused rapid cell death by apoptosis (Townsend, et al., 1998). Nevertheless, okadaic acid and 
taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites in BL41-3 
cells (De Biasio, et al., 2007; Domina, et al., 2004). Nocodazole induced phosphorylation of 
Mcl-1 at ser-64 prominently in the G2/M phase of the cell cycle, which would diminish the 
anti-apoptotic function of Mcl-1 (Kobayashi, et al., 2007). Mcl-1 is readily downregulated in 
response to certain death stimuli. The short half-life of Mcl-1 is attributed to constitutive 
polyubiquitination and subsequent degradation of Mcl-1 by the proteasome, which is a 
prerequisite for induction of apoptosis after UV irradiation (Nijhawan et al., 2003). 
Polyubiquitination of Mcl-1 is catalyzed, e.g., by Mule/ARF-BP1, a novel E3 ubiquitin ligase 
that binds to Mcl-1 via a BH3 domain and marks Mcl-1 for proteasomal degradation (Zhong, 
et al., 2005) and -TrCP (Ding, et al., 2007). Mcl-1 was shown as a new substrate for caspases 
during induction of apoptosis (Herrant, et al., 2004; Weng, et al., 2005). Conversely, Burkitt 
lymphomas that are resistant to apoptosis induced by taxol also showed Mcl-1 
downregulation but failed to activate caspases (Figure 22 and Figure 18). The inhibition of 
the mitochondrial death pathway by Mcl-1 could proceed through several mechanisms. In 
this context, it was recently shown that Mcl-1 can interact with tBid and inhibits its ability to 
activate the mitochondrial death pathway downstream of death receptors (Clohessy, et al., 
2006). In summary, these results suggests that Mcl-1 is regulated possibly through ERK or 
JNK signalling, either leading to a loss of interaction with tBid, thereby activating Bax and/or 
Bak or by unleashing the direct sequestration of Bax and Bak for further activation.  
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 The only evidence, which distinguished here between apoptosis sensitivity and 
resistance, is based on the availabilty of Bax/Bak protein. Yet, it is not clear whether Bax and 
Bax proficiency or the downstream effector molecules act as a connecting link between 
apoptosis and mitotic catastophe. There is evidence that p53, Bax or p21 KO cells showed 
reduced cell death and increased hyperploid viability. Besides, pan-caspase inhibitor failed to 
enhance the polyploidy in nocodazole treated HCT116 cells. Nevertheless, tetraploid cells 
exhibited an enhanced rate of spontaneous apoptosis that could be suppressed by inhibition 
of p53 or by knockdown of proapoptotic p53 target genes such as puma/bbc3, gadd45a and 
ferredoxin reductase (Castedo, et al., 2006). In line with this, we earlier mentioned the 
probable role of Bax in polyploidy induction. Besides, inhibition of caspase activity leads to 
reduced apoptosis in Burkitt lymphomas treated with microtubule inhibitors, which 
conversely showed enhanced polyploidy (Figure 27 -Figure 28).  
 However, this inverse correlation between reduced apoptosis and enhanced polyploidy 
upon pan-caspase inhibition is observed only in response to taxol, nocodazole but not to 
vincristine treatment (Figure 29). These results confirm the earlier evidence that vincristine 
has a different mechanism of cell death induction, where it, as shown here, prevents mitotic 
catastrophe. Hematological malignancies, specifically Burkitt lymphomas, are known to 
respond even better than solid tumors to vincristine than taxol treatment that is not a drug 
of choice in clinical lymphoma therapy. Cancers are usually associated with genomic 
instability, which may favor the generation of more aggressive tumor cells with a reduced 
propensity for undergoing apoptosis, Thus, absence of genomic instability in vincristine 
therapy in spite of failed apoptosis would probably justify its efficiency as a better treatment 
option. The fact that vincristine impedes development of aneuploidy appears to be linked to 






Figure 42: Model illustrating cell death induced by microtubule inhibitors in Burkitt lymphoma cells based on 
results from this study and litrature. Mcl-1 down-regulation and Bid cleavage lead to the release of Bax and 
Bak for further triggering of apoptosis signaling cascade through caspase 9, 3 and 8 activation following DNA 
fragmentation. Conversely lack of Bax and Bak leads to polyploidy showing no sign of apoptosis. In addition 




Collectively, the data supports a model shown in Figure 42 in which, depending on 
the proficiency of Bax/ Bak, Burkitt lymphomas induced apoptosis or mitotic catastrophe in 
response to microtubule inhibitors. Although they induce distinct responses, they showed 
commonality in downregulation of Mcl-1 and cleavage of Bid. Apoptosis sensitive cells 
display a hierarichal activation of caspase-8, -9 and -3 leading to execution of apoptosis. 
Amplification of caspase-8 activation is known to occur in a feedback loop besides 
autoprocessing (Wieder, et al., 2001). However, the trigger for polyploidization seems to 
happen downstream of Bax/ Bak. Inhibition of pancaspase activity lead to enhanced 
polyploidy in apoptotic sensitive cell lines. Nonetheless, vincristine failed to induce 
polyploidy despite inhibition of caspase activity. 
 Interestingly, there are other studies showing caspase-dependent cleavage of mitotic 
checkpoint proteins, Bub1 and BubR1 leading to cell death, in response to microtubule 
inhibitor exposure. Mutation of caspase cleavage sites in BubR1 leads to prolonged mitotic 
arrest and increased aneuploidy (Baek, et al., 2005; Kim, et al., 2005). Overexpression of 
BubR1 predicted tumor recurrence and disease progression in bladder carcinomas 
(Yamamoto, et al., 2007). In line with these finding, CDC25A phosphatase, a cell cycle 
regulator acting at the G2/M transition is also cleaved by caspases generating a catalytically 
active C-terminal fragment. This catalytically active C-terminal fragment reduced the 
inhibitory phosphorylation of the CDC25A substrate cyclin-dependent kinase 2 (CDK2) on 
Tyr15 in non-genotoxic apoptotic induction (Mazars, et al., 2009). These data, taken 
together, infere that caspases play a crucial role not only in the execution of apoptosis but 
also have a pivotal role in cell cycle check point control and prevention of aneuploidy. 
 Microtubule-specific drugs elicit the spindle checkpoint through mechanisms that 
monitor correct spindle formation and tension. In normal cells, this control system preserves 
genomic integrity by ensuring, that the correct number of chromosomes is distributed to 
daughter cells. The spindle checkpoint blocks progression into anaphase until all 
chromosomes have completely aligned at the metaphase plate (Kops, et al., 2005). Various 
spindle checkpoint proteins, BubR1, Bub1, Bub3, Mad1, Mad2, and Plk1 are proposed as 
components of a sensorial system that monitors lack of tension or attachment between the 
kinetochore and microtubules of the mitotic spindle (Hardwick, 2005). Thereby, playing a 
multifunctional role in mitotic progression (Weaver, et al., 2003). There are convincing 
evidences from cell culture experiments and animal models that targeted inhibition of genes 
103 
 
involved in controlling cell proliferation and apoptosis combined with various anticancer 
drugs is a promising approach for cancer therapy (Kim, et al., 2004; Kim, et al., 2004; Lee, et 
al., 2004; Sonnemann, et al., 2004; Zhang, et al., 2003). 
 PLK1 has gained attention in recent years, because it has multiple functions during the 
cell cycle and is known to be overexpressed in approx. 80% of human tumors of diverse 
origins. Overexpression of PLK1 promotes neoplastic transformation of human cells (Park, et 
al., 2009; Strebhardt and Ullrich, 2006). Elevated levels of PLK1 expression correlate with 
poor prognosis for a wide range of human cancers, such as non-small-cell lung cancer, 
oropharyngeal carcinoma, esophageal carcinoma, melanoma, colorectal cancer, 
hepatoblastoma, and non-Hodgkin lymphoma (Strebhardt and Ullrich, 2006). PLK1 
knockdown studies in cancer cells revealed increases in G2/M arrested cells up to 5-fold 
compared with controls followed by apoptosis induction (Spankuch, et al., 2006). Numerous 
investigations have now established that PLK1 is a prime target candidate for drug 
development in proliferative diseases such as cancer (Eckerdt, et al., 2005). 
 Although there were many studies involving PLK1 knock down in various cancer cells, 
its functional mechanism is not well understood. Therefore, Burkitt lymphoma cells with 
conditional overexpression of Polo box domain of PLK1 (PLK1-PBD), kinase domain (PLK1-KD) 
and PLK1, respectively were created to understand its relevance in cell death induction and 
mechanisms involved. The Polo box domain of PLK1 confers molecular alterations of PLK1 
inhibition by tethering away endogenous PLK1 from its original subcellular localization sites 
and substrates. Because this approach has successfully been used to validate the PBD 
function (Hanisch, et al., 2006), we also relied in our studies on this mode of PLK1 
interference. The ectopic expression of PLK1 or PLK1-KD or PLK1-PBD did not demonstrate 
enhanced apoptosis compared to control (Figure 32). In concordance to earlier reports 
mentioned (Spankuch, et al., 2006), cell cycle analysis demonstrated acumulation of PLK1-
PBD overexpressing cells in the G2/M phase of the cell cycle, which was limited in PLK1 and 
PLK1-KD overexpressing cells (Figure 33). There are evidences describing PLK1 regulation in 
G2 phase of cell cycle upon genotoxic stress, but its role in eliciting G2 checkpoint arrest is 
not clear (Bassermann, et al., 2008). MPM2 staining (Figure 29) showed that, only a portion 
of the G2/M phase population is in the M-phase implying that, PLK1 deregulation triggers 
checkpoint activation not only at M-phase but also at the G2-phase of cell cycle. Though 
PLK1-PBD overexpression failed to induce high rates of apoptosis in Burkitt lymphoma cell 
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lines, it resulted in an antiproliferative effect and induction of necrosis in Burkitt lymphomas 
(Figure 37). These results are in part supported by earlier evidences that Plk1-PBD only 
triggers, a growth delay in RKO cells and a growth delay plus the occurrence of an increased 
number of binucleated cells in the PC-3 cell line without induction of cell death. Besides, 
inhibition of PLK1 by PLK1 kinase inhibitor resulted in mitotic accumulation followed by 
apoptosis in these cell lines. Nonetheless, the authors also showed that the cellular 
phenotype observed after ectopic expression of the PBD in U2OS and HeLa cells contrasts 
the effects observed in RKO and PC-3 cells, where cells demonstrated significant mitotic 
accumulation accompanied with subsequent onset of programmed cell death (Fink, et al., 
2007). Evidently, most studies related to PLK1 functions are conducted in U2OS and HeLa 
cells (Hanisch, et al., 2006; Kang, et al., 2006; Lee, et al., 1998; Lowery, et al., 2005). 
 In the present study, the Burkitt lymphoma cells examined showed similar features of 
an antiproliferative effect, induction of G2/M arrest and slight induction of apoptosis upon 
functional abrogation of PLK1 with PBD overexpression (Figure 35). Among the Burkitt 
lymphomas investigated, DG75 and CA46 cell lines showed less apoptosis induction 
compared to the BL41 cell line. Interestingly, only DG75 and CA46 cell lines showed 
induction of polyploidy, displaying the inverse relationship between induction of apoptosis 
and polyploidy (Figure 36). This can be attributed to the loss of functional Bax and a weak 
expression of Bak, which might enhance their affinity for induction of polyploidy in 
consequence of their failure to die by apoptosis. Thus, BL41 cells failed to develop 
polyploidy, which can be explained by their Bax/Bak proficiency (Figure 35). In subsequent 
experiments with PLK1-PBD overexpression, cervical carcinoma HeLa cells underwent 
apoptosis in a caspase dependent manner (Figure 38), which is in concordant to previous 
reports of (Fink, et al., 2007). Inhibition of caspases in addition to functional abrogation of 
PLK1 in apoptosis sensitive HeLa cells leads to reduced apoptosis. Additional treatment of 
PLK1 overexpressing cells with microtubule inhibitors showed similar levels of apoptosis 
inhibition upon inhibition of caspases indicating that both PLK1 interference and taxanes 
trigger caspase dependent death pathways. Nevertheless, only cells with functional 
abrogation of PLK1 displayed enhanced polyploidy irrespective of taxol treatment upon 
caspase inhibition (Figure 39). Further, in line with other’s (Hanisch, et al., 2006), 
immunofluorescence studies in HeLa and BJAB cells showed that the PBD induce checkpoint-
dependent mitotic arrest characterized by aberrant spindle formation leading to monopolar, 
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multipolar or bipolar spindles with lagging chromosomes. Consequently these events lead to 
the chromosomal instability followed by the cell death. While in the case of failed apoptosis, 
these events would result in polyploidization. Taken together, it is evident that the PLK1 
inhibition and taxol work in the same pathway. Caspases play a pivotal role in cell cycle 
checkpoint induced apoptosis and act as a connecting link between apoptosis and mitotic 
catastrophe. These data further strengthen the inverse relationship between induction of 
apoptosis and polyploidy. 
 Sensitivity to taxol was previously shown to correlate with decreased BubR1 protein 
expression in human cancer cell lines, including those from breast and ovarian cancer 
(Ditchfield, et al., 2003; Lee, et al., 2004). This observation is consistent with an earlier report 
of increased drug sensitivity after knockdown of BubR1 (Ditchfield, et al., 2003). Thus, drug-
sensitive cells were found to lack one or more components of the mitotic spindle checkpoint 
signalling machinery. Making the spindle checkpoint less robust would possibly make cancer 
cells more sensitive to drugs that disrupt microtubule dynamics. Thus, it might be that 
dominant negative inhibition of PLK1 at the kinetochores may stabilize microtubule 
attachment to kinetochores and contributes to an imbalance of the spindle checkpoint, 
causing increased sensitivity to microtubule drugs such as taxol, vincristine and nocodazole. 
In concordance with this, a combination of PLK1 knockdown through antisense inhibitors 
against PLK1 and taxol treatment have been shown to cause synergistic effects in breast 
cancer cells (Spankuch, et al., 2006). In the present study, deregulation of PLK1 function and 
microtubule inhibitor treatment failed, however, to show synergistic effects in induction of 
apoptosis, which might be attributed to cell type specificity (Figure 38 - Figure 39). Mitotic 
spindle inhibitors and / or abrogation of mitotic checkpoint regulator PLK1 probably have the 







Figure 43: Model illustrating cell death induced by abrogation of cell cycle checkpoint regulator PLK1 in 
Burkitt lymphoma cells based on results from this study. Displacing the endogeneous PLK1 by PBD 
overexpression leads to the cell cyle arrest at both G2 and mitotic phase. Further depending on Bax and Bak 
proficiency and caspase activity, cells either undergo mitotic catastophe or cell death via necrosis or apoptosis 
depending on the differences in cell type.  
 
 In conclusion, this study yields various interesting results giving broad insight in to the 
biology of Burkitt lymphomas and their response to abrogation of mitotic spindle dynamics. 
These findings provide clear experimental evidence of an inverse correlation between 
apoptosis and mitotic catastrophe in various Burkitt lymphomas in response to microtubule 
inhibitors. Microtubule inhibitor taxol-induced apoptosis proceeds via a caspases-8/-3-driven 
mitochondrial amplification loop and Mcl-1, Bid, Bax and Bax as upstream regulators. Failed 
apoptotic signal transduction due to Bax/ Bak deficiency or effector caspase inhibition leads 
to polploidy with more than 4N DNA content. However, this is not the consequence of 
vincristine treatment, which failed to induce polyploidy in the absence of Bax/Bak and 
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caspase activity. Abrogation of PLK1 function induces checkpoint activation further leading 
to cell death in a caspase dependent manner and lack of caspase activity leads to genomic 
instability. Our data clearly delineate that intrinsic resistance and genomic instabilty of 
Burkitt lymphomas against mitotic spindle inhibitors or abrogation of mitotic cell cycle 
checkpoint regulator PLK1 may be linked to the status of Bax/Bak and caspase activity but 
not the p53 pathway. These results provide novel insights for better disease prognosis by 
considering targets to induce Bax/Bak independent caspase activation in addition to 
microtubule inhibitors. As a perspective, it would also be of great importance to identify 
novel caspase substrates and proteins associated in triggering endoreduplication leading to 
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Human cervical epithelial cell line  




5.1.2 Genetically modified cell lines 
Transfectants Description 
BJAB-Mock BJAB cells harboring pRTS1 vector with tet-inducible promoter 
BJAB-PLK1 BJAB cells harboring PLK1 ORF with tet-inducible promoter 
BJAB-PBD BJAB cells harboring Polo-box-domain with tet-inducible promoter 
BJAB-KD BJAB cells harboring Kinase domain with tet-inducible promoter 
BL41-Mock BL41 cells harboring pRTS1 vector with tet-inducible promoter 
BL41-PLK1 BL41 cells harboring PLK1 ORF with tet-inducible promoter 
BL41-PBD BL41 cells harboring Polo-box-domain with tet-inducible promoter 
BL41-KD BL41 cells harboring Kinase domain with tet-inducible promoter 
CA46-Mock CA46 cells harboring pRTS1 vector with tet-inducible promoter 
CA46-PLK1 CA46 cells harboring PLK1 ORF with tet-inducible promoter 
CA46-PBD CA46 cells harboring Polo-box-domain with tet-inducible promoter 
CA46-KD CA46 cells harboring Kinase domain with tet-inducible promoter 
DG75-Mock DG75 cells harboring pRTS1 vector with tet-inducible promoter 
DG75-PLK1 DG75 cells harboring PLK1 ORF with tet-inducible promoter 
DG75-PBD DG75 cells harboring Polo-box-domain with tet-inducible promoter 
DG75-KD DG75 cells harboring Kinase domain with tet-inducible promoter 
HeLa-Mock HeLa cells harboring pRTS1 vector with tet-inducible promoter 
HeLa-PLK1  HeLa cells harboring PLK1 ORF with tet-inducible promoter 
HeLa-PBD HeLa cells harboring Polo-box-domain with tet-inducible promoter 
HeLa-KD HeLa cells harboring Kinase domain with tet-inducible promoter 
5.1.3 Cell culture media 
Cell culture media including RPMI and DMEM were from (GIBCO BRL) 
5.1.4 Buffers and solutions  
Agarose gel electrophoresis 
 
50X TAE buffer (Stock solution) 
242 g    Tris base 
57.1 ml   glacial acetic acid 




SDS PAGE sample lysis buffer  
0.606 g   Tris –Amino hydroxide 
9.242 g   Saccharose 
1 ml   TritonX100 
2 Pellets   Protease Inhibitor 
Made up the volume 100ml with H2O after adjusting the pH to 7.5 
 
5X SDS gel loading buffer: 
300mM   Tris-Cl (pH 6.8) 
3%     ß-Mercaptoethanol 
50%     Glycerin 
0.1% w/v  Bromophenolblue 
2% w/v   SDS 
 
1X SDS PAGE running buffer 
25 mM   Tris 
0.1% w/v   SDS 
200 mM   Glycin 
Adjusted pH to 8.3 
 
Western blot transfer buffer 
10%    Methanol 
10 mM   CAPS (pH 11) 
10X Ponceau S stain 
2 g    Ponceau S 
30 g   Trichloroacetetic acid 
30 g   Sulfosalicylic acid 
Made up the volume to 100 ml with H2O 
 
10 X PBST 
10 X    PBS 
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2.5 ml   Tween-20 
 
Blocking buffer 
7-10% Casein-blocking reagent from Roche (#11921673001) in 1X PBST 
 
Western blot stripping buffer  
62.5 mM   Tris/ HCl pH 6.7  
100 mM  β-Mercaptoethanol  
2%    SDS  
 
Protein marker 
ColorBurst™ Electrophoresis Marker (Sigma, #C1992) 
 
1X PBSTF 
10 ml    10X PBS 
10 ml    FBS 
50 µl    Tween-20 
 
Pepsin 
0.05 g   Pepsin 
5 ml    2M HCl 
Made up the volume to 100 ml with H2O 
 
Borax buffer 
0.1 M    Sodium tetraborate (pH 8.5) 
 
Freezing medium 
20%    DMSO 
80%    FBS  
 
LB Broth (Agar) 
10 g    Bacto-typtone 
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5 g    Bacto-yeast extract 
10 g    NaCl 
20 g    Agar (for plates only) 
Made up the volume to 1l with H2O after pH was adjusted to 7.0 with 5N NaOH and 
sterilized by autoclaving. 
5.1.5 Fine chemicals 
Chemical Company and catalog number 
Taxol (Paclitaxel) Bristrol-Myers Squibb GmbH, #7375335 
Nocodazole  Sigma, # M1404 
Vincristinsulfat GRY-Pharma GmbH, # 7555221 
Hoechst 33342 Sigma, # B2261 
5.1.6 Kits used in this study 
Kit Company and catalog number 
Western pico supersignal (ECL) Pierce, # 0034078 
BCA
TM
 Protein assay Kit  Pierce, # 23225 
QIAquick Gel Extraction Kit  Qiagen # 28704 
QIAquick PCR Purification Kit  Qiagen # 28104 
PureLink™ Quick Plasmid Miniprep Kit  Invitrogen, # K210011 
PureLink™ HiPure Plasmid Maxiprep Kit  Invitrogen, # K2100-02 
Green FLICA Caspase 9 Assay Kit  Immunochemistry, # 912 
Green FLICA Caspases 3&7 Detection kit  Immunochemistry, # 93 
5.1.7 Antibodies 
Table 4: List of the primary antibodies employed in this study 
Antigen Species Dilution for 
Western Blot 




Mouse 1:1000 Upstate, # 05-368 
Bak Rabbit 1:1000 Sigmaaldrich, # 5897 
Bax Rabbit 1:1000 Upstate, # 06-499 
Bcl-x Rabbit 1:1000 BD pharmingen, # 610211 
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Bid Rabbit 1:1000 Cell Signalling, # 2002 
Bim Rabbit 1:500 Cell Signalling, # 2819 
Caspase-3 Rabbit 1:1000 R & D, # AF835 
Caspase-8 Mouse 1:1000 Alexis, # ALX-804-242 
Caspase-9 Goat 1:200 R & D, # AF8301 
C-Myc (9e10) Mouse 1:500 Santa cruz, # SC40 
C-Myc (A-14) Rabbit 1:1000 Santa cruz, # SC789 
Mcl-1 Rabbit 1:1000 Santa cruz, # SC20679 
NBK (N-19) Goat 1:1000 Santa cruz, # SC1710 
Noxa(N-15) Goat 1:1000 Santa cruz, # SC26917 
p53 Mouse 1:500 BD pharmingen, # 554293 
PLK1 Mouse 1:1000 Zymed, # 31-7100 
Puma(N-19) Goat 1:1000 Santa cruz, # SC19187 
β-actin Rabbit 1:1000 Sigma, # A2066 
 









Company and catalog number 
Goat Anti Mouse IgG(H+L) 1:1000 - Southern Biotech, # 1031-05 
Goat Anti Rabbit IgG(H+L) 1:1000 - Southern Biotech, # 4050-05-147 
Rabbit Anti Goat IgG(H+L) 1:1000 - Southern Biotech, # 6160-05 
FlTC Goat Anti Mouse 
IgG(H+L) 
 1:200 Jackson immuno research, # 115-095-062 
5.1.8 Primers 
Forward Primer SfiI:  5’ GGC CTC ACT GGC CAA GCT GGC TAG CGT TT 3’  
Reverse Primer SfiI: 5’ GGC CTC ACT GGC CCT CTA GAC TCG AGC 3’ 
5.1.9 Plasmids and expression constructs 
Plasmid Name Description 
pcDNA3.1(+/-)  Invitrogen 
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pGEM T Promega, Wisconsin, USA 
pRTS1 Georg W. Bornkamm et al. 
pBSK-PLK1 Full length PLK1 cDNA cloned in to pBluescript II SK(+/-) vector (provided 
by Eric. A. Nigg) 
pcDNA 3.1/mycC-PBD wt Polo Box domain of PLK1 cloned in to pcDNA3.1(-) vector (provided by 
Eric. A. Nigg) 
pGEM T_SfiI(+/-) Shuttle vector contruct was generated by PCR amplification of multiple 
cloning site of pCDNA3.1(+) using primers flanked with SfiI site, followed 
by insertion of PCR product in to pGEM T Vector  
pcDNA 3.1_PLK1 Full length PLK1 from pBSK-PLK1 vector was subcloned in to pcDNA 
3.1(+) expression vector at EcoR V and Not I sites  
pGEM T_SfiI+_PLK1 Full length PLK1 from pBSK-PLK1 vector was subcloned in to pGEM T 
SfiI(+) expression vector at HindIII and XbaI sites  
pGEM T_SfiI+_PBD PBD from pcDNA 3.1/mycC-PBD wt vector was subcloned in to pGEM T 
SfiI(+) expression vector at HindIII and XbaI sites  
pGEM T_SfiI+_KD KD from pcDNA 3.1/mycC-KD vector was subcloned in to pGEM T_ SfiI(+) 
expression vector at HindIII and XbaI sites  
pRTS1_PLK1 Full length PLK1 from pGEM T_Sfi I(+)_PLK1 was subcloned in to pRTS1 
expression plasmid at SfiI site  
pRTS1_PBD PBD from pGEM T_SfiI(+)_PBD was subcloned in to pRTS1 expression 
plasmid at SfiI site  
pRTS1_KD KD from pGEM T_SfiI(+)_KD was subcloned in to pRTS1 expression 
plasmid at SfiI site  
5.1.10 Enzymes 
Restriction endonucleases used in this study for molecular cloning were from 
NEB 
NotI AflII HindIII NheI EcoRI BstXI ApaLI XbaI 
EcoRV KpnI XhoI NdeI BamHI SfiI BglII  
 
Other DNA modifying enzymes 
Name of enzyme Company and catalog number 
GoTaq
®
 DNA Polymerase (5 U/µl) Promega, Mannheim, # 9PIM300 
Crimson
TM
 Taq DNA Polymerase (5 U/µl) NEB, Frankfurt am Main, # M0324 




5.2.1 Cell biology methods 
5.2.1.1 Culturing of mammalian cells 
All mammalian cell lines were maintained at 37°C and 95% humidity in the presence of 5% 
CO2. Confluent cultures were subcultured at a density of 1 × 10
5 cells/ml. 
Human Burkitt lymphoma cell lines (BL) and mouse factor dependent monocytes (FDM) 
were cultivated in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine 
serum, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.56 g/l L-glutamine. For FDM cells, 
10% IL3 was additionally added to the culture media. 
HeLa cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) with high-glucose 
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 0.1 g/ml 
streptomycin (all from Gibco, Karlsruhe, Germany). Tet-inducible BL cells and HeLa cells were 
cultured in media with or without 1 µg/ml doxycyclin. 
5.2.1.2 Freezing and thawing procedure 
Freezing: Log phase cells were pelleted by centrifugation at 300g for 5 min, washed with 1X 
PBS and resuspended in culture medium and freezing medium in the ratio 1:1 and preserved 
in cryovial at -80°C for short term storage and in liquid nitrogen for long term storage. 
Thawing: Frozen cells were thawed, transferred in to pre-warmed culture medium, pelleted 
and resuspended in fresh medium in a tissue culture flask. 
5.2.1.3 Microtubule inhibitor treatment 
Suspension cells were diluted to 4 × 105 cells/ml one day prior to starting an experiment. 
Cells were seeded with the density of 1 × 105 cells/ml with the desired concentrations of the 
respective cytostatic drugs. In standard experiments taxol, vincristine and nocodazole were 
used at a concentration of 100 nM. 
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5.2.1.4 Transient transfection of BL cells 
Plasmids encoding PLK1, PBD and KD were kindly provided by Prof. E. Nigg, and used for 
further cloning into pRTS-1 plasmid. In general, 6 × 105 B cells were transfected with 10 µg of 
pRTS-1 DNA by electroporation and expanded in 500 µg/ml or 600 µg/ml hygromycin B for 
CA46, BL41 or BJAB cells, respectively for at least 2 weeks. Selection was performed either in 
the presence or in the absence of doxycycline. Since a sub-population of non transfectants 
were hygromycine B resistant and outgrew the transfectants, cells were partially induced for 
12 - 16 h with 1 µl/ml doxycycline and eGFP positive cells were FACS sorted. These cells were 
used for further experiments. 
5.2.1.5 Stable transfection and establishment of single cell clones  
Lipofection was carried out as described later in 5.2.1.13.2 and the cells were allowed to 
recover in 10 ml growth medium for two days at 37°C and 5% CO2. Cells were counted and 
plated into 96-well plates in 100 µl at a density of 0.6 viable cells per well. After 5–6 days, 
100 µl growth medium was added containing 250 µg/ml hygromycin B for HeLa cells. 
Replacing 50 µl of the cell supernatant with fresh selection medium weekly, the hygromycin 
B concentration was slowly increased to a final concentration of 300 µg/ml. Within the next 
2 - 4 weeks, hygromycin B resistant cells grewout. The outgrowing cells were regarded as 
single cell clones, which were confirmed by observing portion of cells for eGFP expression by 
flow cytometry after induction with doxycycline for 24 h. When an appropriate cell density 
was reached, cells were expanded successively into 48 and 24 well plates, and finally into 75 
ml tissue culture flasks and maintained in culture under hygromycin B selection in the 
absence of doxycycline. 
5.2.1.6 Measurement of cell death 
5.2.1.6.1 Propidium iodide uptake 
For the determination of cell death, 3 × 104 cells per well were seeded in 96 well microtiter 
plates and treated for different time periods with microtubule inhibitor. Cell death was 
assessed by the uptake of propidium iodide (PI) (2 µg/ml) in phosphate-buffered saline (PBS) 
into nonfixed cells and by subsequent flow cytometric analysis using the FSC-FL3 profile. 
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Analysis was performed on a FACScalibur (Becton Dickinson; Heidelberg, Germany) using 
CellQuest analysis software. 
5.2.1.6.2 Trypan blue exclusion 
Cells were harvested at 300g for 5 min and pellet was resuspended in 1X PBS. 10 µl of cells 
were incubated with 90 µl 0.4% trypan blue solution for 5 min. 10 µl of stained cells was 
added in a Neubauer counting chamber and counted for the number of viable (unstained) 
and dead (stained) cells. Average number of unstained cells in each quadrant was calculated, 
and multiplied by 1 × 105 to determine cells/ml. Blue cells were assumed as dead. At least 
100 cells were counted.  
5.2.1.7 XTT cell proliferation and viability assay 
The cell viability was determined by XTT assay using a Cell Proliferation Kit II (Roche 
Molecular Biochemicals) according to the manufacturer’s protocol. In brief, cells were 
seeded at a concentration of 4 × 103 cells/well in 100 µl of cultured media into microplates 
(tissue culture grade, 96 wells, flat bottom). Cells were incubated for 3 days with respective 
cytostatic drug treatment at 37°C and 5% CO2. To this 50 µl of XTT labeling mixture was 
added and incubated for 4 - 24 h at 37°C and 5% CO2. Spectrophotometrical absorbance of 
the samples was measured using a microplate (ELISA) reader at 450 nm keeping reference 
wavelength at 620 nm. In each treatment group, triplicates wells were measured for cell 
viability. 
5.2.1.8 DNA fragmentation and cell cycle analysis 
Cells were collected by centrifugation at 300 g for 5 min, washed with 1X PBS at 4°C, and 
fixed with PBS/2% (vol/vol) formaldehyde on ice for 30 min. After fixation, cells were 
incubated with ice-cold ethanol/PBS (2:1, vol/vol) for 15 min, pelleted, and resuspended in 
1X PBS containing 40 µg/ml RNase A. After incubation for 30 min at 37°C, cells were pelleted 
again and finally resuspended in PBS containing 50 µg/ml propidium iodide. Nuclear DNA 
fragmentation and polyploidy were determined by flow cytometric quantification of 
hypodiploid DNA and hyperploidy DNA content. Data were collected and analyzed using a 
FACScan (Becton Dickinson) equipped with the CELLQuest software. Data are given in 
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percentage hypodiploidy (subG1) and percentage hyperploidy (>4N DNA content), which 
reflects the number of apoptotic cells and polyploid cells, respectively. 
5.2.1.9 Quantitative DNA cell cycle analysis and cell proliferation assays  
Cells were collected by centrifugation at 300 g for 5 min, washed with 1X PBS at 4° C, and 
fixed with ice-cold ethanol/PBS (2:1, vol/vol) for 15 min. Fixed cells were pelleted, and 
resuspended in 200 µl of pepsin (0.4 mg/ml in 0.1 M HCl). After incubation for 30 minutes at 
room temperature, cells were pelleted again and resuspended in 200 µl of 2 M HCl. After 
incubation for 30 min at 37ºC, cells were pelleted and resuspended in 200 µl of borax buffer 
for 5 min. Cells were pelleted again, washed and finally resuspended in PBS containing 50 
µg/ml propidium iodide. Data were collected using a FACScan (Becton Dickinson) equipped 
with the CELLQuest software and analyzed using Modfit LT software, the most robust and 
simultaneously easy-to-use software tool for DNA -ploidy /proliferation analysis.  
5.2.1.10 Determination of the mitotic index 
Cells were collected and resuspended in 70% ethanol overnight at −20°C. Cells were 
pelleted, washed with 1X PBST and incubated with a phospho-Ser/Thr-Pro MPM2 
monoclonal antibody diluted in 1X PBST for 1 h at 4ºC. Further cells were washed and 
labeled with a FITC-conjugated anti-mouse secondary antibody for 1 h at room temperature 
in the dark. Cells were then washed twice with 1X PBST and resuspended in a propidium 
iodide (PI) solution consisting of 50 μg/ml PI and 50 μg/ml RNase A for 15 min. Cells were 
then sorted and analyzed using FACScan (Becton Dickinson) equipped with the CELLQuest 
software. 
5.2.1.11 Caspase activation assay 
Active caspases were detected using FLICA Apoptosis Detection Kits for Caspase-3/7 and 
Caspase-9 (Immunochemistry Technology, LLC, Bloomington, MN) according to the 
manufacturer's instructions. This kit employs carboxyfluorescein-labeled fluoromethyl 
ketone peptide inhibitors of caspases-3/7 (FAM-DEVD-FMK) and -9 (FAM-LEHD-FMK), which 
are cell-permeable and non-cytotoxic fluorochrome inhibitors. These labeled peptide 
inhibitors covalently bind to a reactive cysteine residue on the large subunit of the active 
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caspase heterodimer, inhibiting enzymatic activity and producing green fluorescence. Thus, 
the green fluorescent signal directly corresponds to the amount of active caspases present in 
the cell at the time the reagent was added.  
In brief, cells cultured in the presence and absence of chemostatic drug for 48 h were 
harvested, washed in 1X PBS and resuspended in FLICA working solution and allowed to 
incubate for 1 h at 37ºC, 5% CO2 in fully humified atmosphere in dark with occational gentle 
swirlling. Thereafter, cells were washed with 1X PBS and resuspended in 200 µl PBS before 
determining the fluorescence or Caspase activation with a FACScan flow cytometer. 
5.2.1.12 Caspase inhibition assay 
Q-VD-OPh (N-(2-Quinolyl)valyl-aspartyl-(2,6-difluorophenoxy)methyl Ketone) is a cell-
permeable, irreversible, broad-spectrum caspase inhibitor (Calbiochem). Z-IETD-FMK (Z-
IE(OMe)TD(OMe)-FMK) is a potent, cell-permeable, and irreversible inhibitor of caspase-8 
(Calbiochem). For inhibiton of pan-caspase activity or caspase-8 activity, cells were 
incubated with 10 mM Q-VD-OPh or 20 mM Z-IETD-FMK respectively 2 h prior to treatment 
with microtubule inhibitors. These cells were further analyzed for apoptosis after 72 h. 
5.2.1.13 Transient Transfection 
5.2.1.13.1 Electroporation 
5 × 106 cells in log phase were washed with 1X PBS and resuspended in 400 µl of RPMI media 
without FBS and pencilline/streptomycine. To this 10 µg of plasmid DNA was added and 
incubated for 5 min at room temperature. DNA/cell suspension was transferred to an 
electroporation cuvette (with 0.4 cm interelectrode distance) and electroporated (BioRad 
gene pulser) at 250 V and 960 µF for 12 sec. The mixture in the cuvette was left for 10 min at 
room temperature before transfering the cells to T75 flask containing culture media with 
10% FBS. 
5.2.1.13.2 Lipofection 
Plasmid trasfection was carried out using Lipofectamine 2000 reagent according to the 
manufacturers (Invitrogen) instructions.  
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5.2.2 Molecular biology methods 
5.2.2.1 Construction of shuttle vector pGEM-T_SfiI 
Multiple cloning sites from pcDNA3.1+ were PCR amplified using forward and reverse 
primers flanked with SfiI recognition sites. Primer sequences are reported in materials as 
Forward Primer SfiI and Reverse primer SfiI. The amplified product was analyzed on 1% 
agarose gel and purified using PCR gel elution kit (Qiagen). The 135 bp DNA fragment 
obtained was cloned into pGEM-T Easy vector. Plasmid and insert orientation were 
confirmed by restriction digestion. Plasmid was named as pGEM-T_SfiI+ (Figure 44) or as 
pGEM-T_SfiI- depending on the orientation of the insert. 
5.2.2.2 Construction of pGEM T_SfiI+_PLK1 
Full length ORF of PLK1 gene (2119 bp) from the bluescript II sk(+/-)-PLK1 (gifted by Prof. E. 
Nigg) was excised with HindIII-XbaI and subcloned into HindIII-XbaI sites of pGEM-T_SfiI(+) 
vector. Similarily, Polo Box Domain of PLK1 gene (831 bp) and Kinase Domain of PLK1 (1056 
bp) from parent plasmid pcDNA3.1/mycC-PBD wt and pcDNA3.1/mycC-aa1-352, respectively 
(gifted by Prof. E Nigg) were excised with HindIII-XbaI and subcloned into the HindIII-XbaI 
sites of pGEM-T_SfiI(+) vector (Figure 44). Plasmids with PLK1, PBD or KD were confirmed by 







Figure 44: Subcloning of PLK1 (Polo like kinase 1), PBD (polo box domain of PLK1), and KD (Kinase domain of 
PLK1) in to shuttle vector pGEM-T SfiI+. PLK1 excised from pBluescript II SK(+/-) and PBD, KD fragments from 
pcDNA3.1 3x myc-C plasmids, respectively with HindIII/ XbaI REases and were cloned into pGEM-T_SfiI(+) 
shuttle vector having same flanking ends. 
5.2.2.3 Construction of pRTS-1_PLK1, pRTS-1_PBD and pRTS-1_KD 
Full length PLK1, Polo Box Domain of PLK1 gene and Kinase Domain of PLK1 from shuttle 
vector pGEM-T_SfiI_PLK1, pGEM-T_SfiI_PLK1-PBD and pGEM-T_SfiI_PLK1-KD, respectively 
were excised with SfiI and cloned into pRTS-1. Plasmids with right orientation of the insert 






Figure 45: Subcloning of PLK1, PBD and KD in inducible mammalian expression vector pRTS-1. PLK1, PBD and 
KD fragments excised from pGEM-T_SfiI_PLK1, pGEM-T_SfiI_PBD, pGEM-T_SfiI_KD respectively with SfiI 
flanking ends were ligated to pRTS-1 plasmid at SfiI RE sites and clones were verified for proper orientation of 
inserted fragment.  
5.2.2.4 Bacterial Culture and storage conditions 
The E. coli cultures were routinely grown at 37ºC on Luria-Bertani (LB) agar or in LB broth, 
containing ampicillin (100 µg/ml) or kanamycine (30 µg/ml) 
For long-term storage, a fresh overnight culture was prepared: Bacteria were streaked on to 
agar plate of the respective selective medium, and incubated overnight at 37ºC. Several 
colonies were transferred separately in to 10 ml falcon tubes containing 2 ml liquid media, 
and incubated for 14 - 16 h at 37ºC with shaking at 180-200 rpm. Then 800 µl of the bacterial 
culture were transferred into a storage tube and sterile glycerol was added to a final 
concentration of 20%. The vials were snap-frozen in liquid nitrogen, and stored at -80ºC until 
use. To recover a bacterial culture, a small proportion of the frozen glycerol stock was 
streaked onto an LB agar plate, containing the appropriate antibiotic. The plate was 
incubated overnight at 37ºC. These colonies were used as a working stock. The plates were 
sealed with parafilm and stored at 4ºC for up to four weeks. Alternatively, a small portion of 
the frozen glycerol stocks was transferred into 2 ml of the LB broth containing the 
appropriate antibiotic, and incubated overnight at 37ºC with shaking at 180-200 rpm. 
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5.2.2.5 Agarose gel electrophoresis 
The gels were prepared by melting 1% (w/v) agarose in 1 x TBE buffer and adding 25 µl/l 
ethidium bromide. Each DNA sample was mixed with 1/6 volume of 6 x DNA loading buffer. 
Gels were run in 1X TBE buffer at a constant voltage of 100 V, imaged under UV-light and 
digitized for documentation.  
5.2.2.6 Mini-preparation of plasmid DNA 
For mini-preparation of plasmid DNA from bacteria, a QIAprep Spin Miniprep kit from 
Qiagen was used. For isolation of ~10 µg of Plasmid DNA, 2 ml overnight culture of E. coli 
DH5  in LB medium was prepared. Plasmid DNA was isolated according to the 
manufacturer’s recommendations. DNA was eluted in 30 µl of the elution buffer and stored 
at -20°C.  
5.2.2.7 Large-Scale preparation of plasmid DNA 
For the large-scale plasmid isolation a QIAGEN Plasmid Midi and Maxi Kits were used. 
Plasmid DNA was isolated according to the supplier’s manual, 200 ml of E. coli DH5  
overnight culture was used for each experiment. 
5.2.2.8 Measurement of DNA concentration 
Concentration of DNA was measured using a UV-Spectrophotometer (Pharmacia Biotech) at 
the wavelength of 260 nm. The amount of DNA was calculated based on the optical density 
(OD) value (OD 260 = 1 corresponds to 50 µg/ml double-stranded DNA). 
5.2.2.9 Enzymatic manipulation and analysis of DNA 
Digestion of DNA with restriction endonucleases 
Digestion of the DNA with restriction endonucleases was performed according to the 
recommendations of the manufacturer. For the digestion of 5-10 µg of DNA, 10 U of enzyme 
was added with an appropriate buffer to the DNA in a final volume of 15 µl.  
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5.2.2.10 Vector dephosphorylation 
To avoid self-ligation of restriction digested vector DNA, 5’-overhanging phosphate groups 
were cleaved off by adding 1 unit calf intestine alkaline phosphatase per 1 µg DNA and 
incubating for 1 h at 37°C. 
5.2.2.11 DNA ligation 
For the ligation of cDNA or PCR amplified DNA fragments into a plasmid vector T4 DNA ligase 
(New England Biolabs) was used. For ligation, 50-100 ng of the digested plasmid DNA was 
used. The amount of insert was calculated according to a molar ratio 3:1 (Insert:Vector). The 
reaction was incubated overnight at 16°C. 
5.2.2.12 Polymerase chain reaction (PCR) 
PCR is used to amplify specific regions of a DNA strand (the DNA target). This can be a single 
gene, a part of a gene, or a non-coding sequence. For amplification of DNA fragments by 
PCR, 50 µl reaction mixtures containing 10-50 ng plasmid DNA template, 10 pmol of forward 
primer, 10 pmol of reverse primer, 100 nmol dNTPs and 2.5 units Taq DNA polymerase in 1 x 
reaction buffer were prepared on ice. The PCR was carried out after an initial denaturation 
step of 30 sec at 95°C with 30 cycles comprising the following steps: 1) denaturation for 30 
sec at 95° C, 2) annealing for 30 sec at 55°C (adjusted for each primer) and 3) elongation for 
1.5 min per kb of fragment-length at 68°C. The final elongation step was extended by 10 min 
at 72°C.  
5.2.2.13 Purification of PCR-amplified DNA fragments 
PCR amplified DNA was either purified using the QIAquick PCR Purification Kit according to 
instructions or from 1% agarose gels with the QIAquick Gel Extraction Kit. 
5.2.2.14 Transformation of E. coli 
Competent E.coli DH5 ent cells were thawed on 
ice and mixed gently. For each transformation, 40 µl of competent cells were transferred 
into a microcentrifuge tube and 20-50 ng of plasmid DNA or 1-3 µl of ligation mixture was 
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added, swirled gently and incubated on ice for 30 min. Tube with bacteria were heat-pulsed 
in a 42°C water bath for 45 to 90 sec. Then the tube was incubated on ice for 2 min and 900 
µl of the LB medium pre warmed to 37°C was added and incubated at 37°C for 1 h with 
shaking at 180-200 rpm. 100 µl of transformation mixture was plated on the LB agar plates 
with appropriate antibiotic using a sterile spreader and incubated overnight at 37°C.  
5.2.3 Immunoblotting 
5.2.3.1 Preparation of SDS PAGE gels 
According to the apparent molecular weight of the proteins in question, gels containing 
different concentrations of acrylamide were used. The composition of different gels is given 
in table below. Separation was performed at 180 V until the methylene blue front had left 
































8% 2.0 2.5 5.3 100 8 100 
10% 2.5 2.5 4.7 100 4 100 
12% 3.0 2.5 4.3 100 4 100 
14% 3.5 2.5 3.7 100 4 100 
16% 4.0 2.5 3.3 100 4 100 
5.2.3.2 Composition of polyacrylamide gels  
For one-dimensional gel electrophoresis acrylamide gels with the above given volumes of 
stock solutions were prepared. 10% aqueous APS was prepared freshly and the acrylamide 
stock solution contained acrylamide/ bisacrylamide in a ratio of 29:1. 
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5.2.3.3 Sample preparation for SDS PAGE  
Cells were harvested at 300 g for 5 min and washed twice in an appropriate volume of 1X 
PBS. Lysis buffer was added and incubated for 30 min on ice. Debris was spun down at 16000 
g for 15 min and the supernatant was collected as sample.  
5.2.3.4 Determination of protein concentration 
Protein concentration was determined using the bicinchonic assay kit by Pierce essentially 
according to the manufacture’s protocol. 2 μl of sample was diluted in 200 μl of BCA solution 
in an ELISA plate (flat bottom) and incubated at room temperature for 30 min in the dark.  
Absorbance was measured using an ELISA reader at 620 nm. BSA was used as standard and 
the protein concentration was calculated on the basis of the derived standard curve.  
5.2.3.5 Electrophoresis and immunoblotting of proteins  
Proteins were separated under reducing conditions for 1 h at 180 V in 10-14% gels 
depending on the molecular weight of the respective protein and then blotted for 1 h at 1 
mA/cm2 onto the nitrocellulose membranes (Millipore) using blotting buffer and BioRad 
semi dry blotting apparatus (Transblot SD cell). Membranes were stained with Ponceau Red 
to verify homogenous protein transfer and destained in H2O.  
Membranes were blocked for 1 h in blocking solution and then incubated overnight with 
primary antibody. Excess primary antibody was removed, washed thrice, each for 5 min in 1X 
PBST and incubated with the peroxidase coupled secondary antibody for 1 h at room 
temperature. Excess antibody was washed off twice for 7 min each with 1X PBST and bound 
antibody was detected by enhanced chemiluminescence detection method (ECL kit, Pierce). 
Blots were sometimes stripped and probed with other antibodies.  
5.2.3.6 Stripping of nitrocelulose membrane blots 
Membranes were washed with 1X PBST for 5-10 min. Then about 50 ml of stripping solution 
was added and incubated in a shaking waterbath at 50°C for 30 min. The blots were then 
washed with 1X PBST and incubated with 7% blocking buffer in 1X PBST. 
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5.2.4 Immunofluorescence microscopy 
Cells were grown on coverslips and fixed in 4% formaldehyde for 30 min, and permeabilized 
with 0.2% Triton X-100 + PBS for 10 min at room temperature.  Afterwards cells were 
washed and incubated for 30 min at room temperature in blocking solution (PBS+ 1% bovine 
serum albumin). Mouse monoclonal anti-β-tubulin (1:1000; Sigma) antibody was used for 
staining -tubulin. Cells were incubated with primary antibody for 2 h at room temperature 
in a humidified chamber, followed by three washes in PBS. Subsequently, cells were 
incubated with Alexa Fluor 594–conjugated chicken anti–mouse IgG [Invitrogen] secondary 
antibody for 1 h at room temperature. For staining DNA, cells were incubated in PBS + 4,6-
diamidino-2-phenylindole (DAPI; 1mg/ml) for 5 min. Cells were washed and mounted in 
fluorescence mounting medium (Dako). For sub-cellular localization pattern analysis, cells 
were inspected with a microscope (Axiovert 200; Carl Zeiss, Inc.) equipped with a 63x/1.4 
and 100x objective lens (Plan-Apochromat; Carl Zeiss, Inc.) and a digital camera (ORCA ER; 
Hamamatsu Photonics). Images were acquired by Openlab software (Improvision) and 
vertical slices (0.2-µm separation) were deconvoluted with Openlab 5.0.2 nearest–neighbor 
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AIF apoptosis inducing factor 
APS Ammonium persulphate 
ATCC American Type Culture Collection 
BSA Bovine serum albumin 
CAPS 3-cyclohexylamino-1-propanesulfonic acid 
CARD Caspase activation and recruitment domain 
Caspase cysteinyl aspartate-specific protease 
CO2 Carbon dioxide 
cyt c Cytochrome c 
dATP deoxyadenosin triphosphate 
DED Death effector domain 
DISC Death inducing signaling complex 
DMSO dimethylsulfoxide 
DNA Deoxyribonucleic acid 
e.g For example (latin:'exempli gratia') 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
FACS fluorescence activated cell sorting 
FBS Fetal bovine serum 
FITC Fluorescein isothiocyanate 
g Gram 
g Gravity 
GM Growth medium 
h Hour 
H2O Water 
HEPES N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
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HRP Horse radish peroxidase 
i.e. That is (latin: 'id est') 
IF Immunofluorescence 
Ig Immunoglobulin 
KDa Kilo Dalton 








NCCD The Nomenclature Committee on Cell Death 
nM Nanomolar 
PBS Phosphate buffered saline 
PBD Polo Box Domain of PLK1 
PCD Programmed cell death 
PLK1 Polo Like Kinase 1 
PS Phosphotidyl serine 
pH Negative decadic logarithm of the hydrogen ion concentration 
(latin: 'potentia hydrogenii') 
PI Propidium Iodid 
PVDF Polyvinylidene fluoride 
RPMI Roswell Park Memorial Institute 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
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